Vol. 15 Issue 5 (2022)

VSKM 2022 N 5

PDF download Download the whole Issue

ORIGINAL RESEARCH

Features of the course of the new coronavirus infection COVID – 19 among employees of medical organizations of the Republic of Bashkortostan and compensation for damage to victims Bakirov AB (Russia, Ufa), Valeeva ET (Russia, Ufa), Shaikhlislamova ER (Russia, Ufa), Latypov MM (Russia, Ufa), Galimova RR (Russia, Ufa), Gazizova NR (Russia, Ufa), Galiullina DM (Russia, Ufa), Mironova GR (Russia, Ufa) P. 7-15

Effectiveness of dasabuvir / ombitasvir / paritaprevir / ritonavir in hemodialysis patients with hepatitis C virus infection Galeeva NV (Russia, Kazan), Podryadnova TV (Russia, Kazan), Mamedova AН (Russia, Kazan), Nafeeva DN (Russia, Kazan) P. 16-21

The effect of hepatoprotectors on the state of the liver in post covid-19 patients Daminova LT (Uzbekistan, Tashkent), Adilova DSh (Uzbekistan, Tashkent) P. 22-26

Medical and social characteristics of geriatric patients in medical organizations of Mongolia Dashlhundev S (Russia, Moscow), Shulaev AV (Russia, Moscow), Konovalov OE (Russia, Moscow) P. 27-31

Рrevalence of the diagnosis of «obesity» among law enforcement officers Ishkineev FI (Russia, Kazan), Ishkineeva FF (Russia, Kazan), Saveleva ZV (Russia, Kazan), Khusainova LK (Russia, Kazan) P. 32-37

Risk factors development of periodontitis in patients in the postcovid period Kazakova LN (Russia, Saratov), Kuligin AV (Russia, Saratov), Edikhanova KI (Russia, Saratov), Tereshchuk OS (Russia, Saratov), Egorova AV (Russia, Saratov), Mahonova EV (Russia, Saratov) P. 38-43

Clinical and genetic aspects of regress of left ventricular myocardial hypertrophyMulerova TA (Russia, Kemerovo), Morozova NI (Russia, Kemerovo), Bazdyrev ED (Russia, Kemerovo), Tsygankova DP (Russia, Kemerovo), Agienko AS (Russia, Kemerovo), Indukaeva EV (Russia, Kemerovo), Nahratova OV (Russia, Kemerovo) P. 44-51

To the question about evaluation of the state of periodontal tissues in the area of fixed implant-supported prostheses made by cad/cam technology Nikitina LI (Russia, Cheboksary), Mukchamedzhanova LR (Russia, Cheboksary), Egorov MA (Russia, Cheboksary), Gromova AS (Russia, Cheboksary) P. 52-57

Assessing of proprioceptive function in patients after the anterior cruciate ligament repair Romanov DA (Russia, Moscow), Garkavi AV (Russia, Moscow), Drogin AR (Russia, Moscow), Shishova AA (Russia, Moscow), Kneller LO (Russia, Moscow), Molchanov IS (Russia, Moscow) P. 58-65

Effectiveness of intravenous administration of iron (III) sucrose complex hydroxide in patients with chronic heart failure with preserved ejection fraction and iron deficiency Smirnova MP (Russia, Yaroslavl), Chizhov PA (Russia, Yaroslavl), Baranov AA (Russia, Yaroslavl) P. 66-72

Сomputer simulation of atherosclerotic process influence in the internal carotid artery on the hemodynamics of brachiocephal arteries and the circle of willisian Tsvetkova NV (Russia, Pskov), Sluchanko EI (Russia, Pskov) P. 73-80

MSCT of osteomyelitis of the upper jaw in patients who had COVID-19 Yunusova LT (Uzbekistan, Tashkent), Ikramov GO (Uzbekistan, Tashkent), Khalmanov BA (Uzbekistan, Tashkent), Suvonov KJ (Uzbekistan, Tashkent) P. 81-85

Prognostic value of genetic polymorphisms of matrix metalloproteinases in patients with chronic heart failure with preserved ejection fraction associated with obstructive sleep apnea syndrome Yakovlev AV (Russia, Novosibirsk), Teplyakov AT (Russia, Tomsk), Mayanskaya SD (Russia, Kazan), Grakova EV (Russia, Tomsk), Shilov SN (Russia, Novosibirsk), Kopyeva KV (Russia, Tomsk), Efremov IA (Russia, Novosibirsk)  P. 86-92

REVIEWS

Long-term impacts of tonsillectomy in children Boiko NV (Russia, Rostov-on-Don), Stagnieva IV (Russia, Rostov-on-Don), Kim AS (Russia, Rostov-on-Don), Gukasyan EL (Russia, Rostov-on-Don), Zatulivetrova DO (Russia, Rostov-on-Don), Stateshnaya DA (Russia, Rostov-on-Don) P. 93-99

Reproductive health of the Russian population as a key factor of demographic dynamics Kadyrov ZA (Russia, Moscow), Faniev MV (Russia, Moscow), Prokopiev YV (Russia, Kazan), Faustova KV (Russia, Kazan), Sevryukov FA (Russia, Nizhny Novgorod), Vodolazhsky DI (Russia, Simferopol), Krupin VN (Russia, Rostov-on-Don) P. 100-106

Drug-induced liver injury - modern view on the correct problem Molostova AF (Russia, Kazan), Khabirova GI (Russia, Kazan), Kharisova YI (Russia, Kazan), Salimova LM (Russia, Kazan) P. 107-115

Clinical outcomes of COVID-19 in people living with HIV Ovsyannikov NV (Russia, Omsk), Bilevich OA (Russia, Omsk), Pyannikova VA (Russia, Omsk) P. 116-121

EXPERIENCE EXCHANGE

Risk assessment of the severe course of COVID-19 and cases of irrational prescribing of medications Chereshneva ND (Russia, Yoshkar-Ola) P. 122-128

HEALTHCARE ORGANIZATION

Application of fuzzy mathematics to manage medical and social decisions during a pandemic Lyapin VA (Russia, Omsk), Marenko VA (Russia, Novosibirsk), Nesterova KI (Russia, Omsk), Nesterova AA (Russia,  Moscow), Mirakyan RG (Russia, Moscow), Yelokhova YuA (Russia, Omsk) P. 129-136

___

ORIGINAL RESEARCH

UDC: 616.9:314.42:616-051:347.51(470.57)

DOI:10.20969/VSKM.2022.15(5).7-15

PDF download FEATURES OF THE COURSE OF A NEW CORONAVIRUS INFECTION COVID-19 AMONG EMPLOYEES OF MEDICAL ORGANIZATIONS OF THE REPUBLIC OF BASHKORTOSTAN AND COMPENSATION FOR DAMAGE TO VICTIMS

BAKIROV AHAT B., ORCID ID: 0000-0003-3510-2595, Author ID: 124541, SPIN-код: 4024-3660; D. Med. Sci., Professor, Academician of the Academy of Sciences of the Republic of Bashkortostan, Director of the Ufa Research Institute of Occupational Medicine and Human Ecology, Head of the Department of Internal Medicine and Occupational Diseases, Bashkir State Medical University, 450106, Russia, Ufa, Stepan Kuvykina Str., 94, е-mail: fbun@uniimtech.ru

VALEEVA ELVIRA T., ORCID ID: 000-0002-9146-5625, Author ID: 158750, SPIN-код: 6778-8590; D. Med. Sci., Chief Researcher of the Department of Occupational Medicine of the Ufa Research Institute of Occupational Medicine and Human Ecology, Associate Professor of the Department of Internal Medicine and Occupational Diseases, Bashkir State Medical University, 450106, Russia, Ufa, Stepan Kuvykina Str., 94, e-mail: oozr@mail.ru

SHAIKHLISLAMOVA ELMIRA R., ORCID ID: 0000-0002-6127-7703, Author ID: 538386, SPIN-код: 1041-3862; C. Med. Sci., Deputy Director for Scientific and Organizational and Methodological Work of the Ufa Research Institute of Occupational Medicine and Human Ecology, Associate Professor of the Department of Internal Medicine and Occupational Diseases, Bashkir State Medical University, 450106, Russia, Ufa, Stepan Kuvykina Str., 94, e-mail: shajkh.ehlmira@yandex.ru

LATYPOV MARAT M., ORCID ID: 0000-0002-7762-1310, Author ID: 591979; Cand. Economy Sciences, Manager of the Regional Branch of the Social Insurance Fund of the Russian Federation in the Republic of Bashkortostan, 450103, Russia, Ufa, Sochinskaya Str., 15, e-mail: info@ro2.fss.ru

GALIMOVA RASIMA R., ORCID ID: 0000-0002-4658-545X, Author ID: 294139, SPIN-код: 6388-0203; C. Med. Sci., Senior Researcher, Department of Occupational Medicine, Ufa Scientific Research Institute of Occupational Medicine and Human Ecology, 450106, Russia, Ufa, Stepan Kuvykina Str., 94, e-mail: oozr@mail.ru

GAZIZOVA NAILYA R., ORCID ID: 0000-0001-7831-4702, Author ID: 904835, SPIN-код: 1007-3366; Deputy Chief Physician of the clinic for the medical part, Ufa Scientific Research Institute of Occupational Medicine and Human Ecology, 450106, Russia, Ufa, Stepan Kuvykina Str., 94, e-mail: nelli.ga012@gmail.com

GALIULLINA DINARA M., ORCID ID: 0000-0002-6659-3983, Author ID: 964166, SPIN-код: 8669-3512; Head of the Therapeutic Occupational Pathology Department, Ufa Scientific Research Institute of Occupational Medicine and Human Ecology, 450106, Russia, Ufa, Stepan Kuvykina Str., 94, e-mail: dinara.galiullina.81@mail.ru

MIRONOVA GULNARA R., ORCID ID: 0000-0002-9873-7611; Head of the Consultative and Outpatient Clinic Department of the Clinic of the Ufa Research Institute of Occupational Medicine and Human Ecology, 450106, Russia, Ufa, Stepan Kuvykina Str., 94, e-mail: gulnara3083@gmail.com

Abstract. Introduction. The morbidity and mortality of medical workers from COVID – 19 in the process of production activity remains one of the most serious problems of healthcare and, in particular, occupational medicine, as it causes the loss of qualified personnel. Aim. The purpose of the study is to study the peculiarities of morbidity and mortality of employees of medical organizations of the Republic of Bashkortostan and the volume of lump-sum insurance payments due to infection with a coronavirus infection. Material and methods. A retrospective analysis of 46 fatal cases of employees of medical organizations with a confirmed diagnosis of a new coronavirus infection for 2020 and 9 months of 2021 was applied, according to the data of the Rospotrebnadzor Department for the Republic of Bashkortostan. Statistical processing of the material was carried out using the Statistica 10.0 program. Results and discussion. It is shown that the majority of COVID – 19 patients of medical organizations sought medical help late and were admitted to the hospital already in a serious and extremely serious condition. Clinical, laboratory, instrumental studies have revealed a significant severity of the viral-infectious process with hypercoagulation phenomena, impaired function of almost all organs and systems. The cause of death of all employees was a new coronavirus infection COVID – 19 identified by laboratory research methods with severe pulmonary pathology, multiple organ failure. Conclusion. The main features of COVID – 19 in workers of medical organizations that led to death were an extremely severe, progressive course with impaired function of all organs and systems with late access to medical care. The loss of qualified personnel against the backdrop of a shortage of medical workers in the context of the COVID – 19 pandemic requires the development of large-scale medical and preventive measures. sanitary and hygienic measures to prevent infection with infectious agents.

Key words: employees of medical organizations, new coronavirus infection, examination of the connection of the disease with the profession, acute occupational disease, mortality.

For reference: Bakirov AB, Valeeva ET, Shaikhlislamova ER, Latypov MM, Galimova RR, Gazizova NR, Galiullina DM, Mironova GR. Features of the course of the new coronavirus infection COVID – 19 among employees of medical organizations of the Republic of Bashkortostan and compensation for damage to victims. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):7-15. DOI: 10.20969/VSKM.2022.15(5).7-15.

References

  1. Coronavirus disease (COVID-19) pandemic [Electronic resource]. https://www.who.int/emergencies/diseases/ novel-coronavirus-2019 (дата обращения: 28.09.2021)

  2. Tan Z, Khoo DWS, Zeng LA, et al. Protecting health care workers in the front line: Innovation in COVID-19 pandemic. J Glob Health. 2020; 10(1): 010357. DOI: 10.7189/jogh.10.010357

  3. COVID – 19: protecting health-care workers. Lancet. 2020; 395: 922. DOI: 10.1016/S0140-6736(20)30644-9

  4. Бухтияров И.В. Эпидемиологические и клинико-экспертные проблемы профессиональной инфекционной заболеваемости работников при оказании медицинской помощи в условиях пандемии COVID – 19 // Медицина труда и промышленная экология. – 2021. – No 61(1). – С. 4-12. [Buhtijarov IV. Jepidemiologicheskie i kliniko-jekspertnye problemy professional’noj infekcionnoj zabolevaemosti rabotnikov pri okazanii medicinskoj pomoshhi v uslovijah pandemii COVID – 19 [Epidemiological and clinical-expert problems of occupational infectious morbidity of workers in the provision of medical care in the conditions of the COVID – 19 pandemic]. Medicina truda i promyshlennaja jekologija [Occupational Health and Industrial Ecology]. 2021; 61(1): 4-12. (in Russ.)]. DOI:10.31089/1026-9428-2021-61-1-4-12

  5. Атьков О.Ю., Горохова В.Ф , Пфаф С.Г. Коронавирусная инфекция – новая проблема в профессиональной заболеваемости медицинских работников // Медицина труда и промышленная экология. – 2021. – No61(1). – С. 40-48. [At’kov OJu, Gorohova SG, Pfaf VF. Koronavirusnaja infekcija – novaja problema v professional’noj zabolevaemosti medicinskih rabotnikov [Coronavirus infection is a new problem in the occupational morbidity of medical workers]. Medicina truda i promyshlennaja jekologija [Occupational Health and Industrial Ecology]. 2021; 61(1): 40-48. (in Russ.)]. DOI: 10.31089/1026-9428-2021-61-1-40-48

  6. Валеева Э.Т., Шайхлисламова Э.Р., Бакиров А.Б., Ахметшина В.Т. COVID – 19 как причина изменения структуры профессиональной заболеваемости в Республике // Санитарный врач. – 2021. – No5(208). – С. 33-40. [Valeeva Je T, Shajhlislamova Je R, Bakirov A B, Ahmetshina VT COVID – 19 kak prichina izmenenija struktury professional’noj zabolevaemosti v Respublike Bashkortostan [COVID – 19 as a reason for changing the structure of occupational morbidity in the Republic of Bashkortostan]. Sanitarnyj vrach [Sanitary doctor]. 2021; 05(208):33-40. (in Russ.)]. DOI:10.33920/med-08-2105-04

  7.  Rekatsina M, Paladini A, Moka E, et al. Healthcare at the time of COVID-19: A review of the current situation with emphasis on anesthesia providers. Best Pract Res Clin Anaesthesiol. 2020; 34(3):539-551. DOI: 10.1016/j. bpa.2020.07.002

  8.  Kalantari H, Tabrizi AHH, Foroohi F. Determination of COVID-19 prevalence with regards to age range of patients referring to the hospitals located in western Tehran, Iran. Gene Rep. 2020; 21:100910. DOI: 10.1016/j. genrep.2020.100910

  9.  Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARSCoV-2 in Singapore. JAMA. 2020; 323 (15):1488-1494. DOI: 10.1001/jama.2020.3204

  10. World Health Organization (2‎ 020).‎ Coronavirus disease 2019 (C‎ OVID-19):‎ situation report, 51. World Health Organization. https://apps.who.int/iris/ handle/10665/331475.

  11.  Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID – 19) outbreak. J Autoimmun. 2020; 109: 102433. DOI: 10.1016/j.jaut.2020.102433

  12.  Barycka K, Torlinski T, Filipiak KJ, et al. Risk of self-contamination among healthcare workers in the COVID-19 pandemic. Am J Emerg Med. 2021 Aug; 46:751-752. DOI: 10.1016/j.ajem.2020.09.055

  13.  Miyamae Y, Hayashi T, Yonezawa H, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Tokyo, Japan. Int J Infect Dis. 2020; 97:293-295. DOI: 10.1016/j.ijid.2020.06.020

  14.  Qi L, Yang Y, Jiang D, et al. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. Int J Infect Dis. 2020; 96:531-537. DOI: 10.1016/j.ijid.2020.05.045

  15.  Eyre DW, Lumley SF, O’Donnell D, et al. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. Elife. 2020; 9: e60675. DOI: 10.7554/eLife.60675

  16.  Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020;5(9): e475–83–e483. DOI: 10.1016/S2468-2667(20)30164-X

  17. Bielicki JA, Duval X, Gobat N, et al. Monitoring approaches for health-care workers during the COVID-19 pandemic. Lancet Infect Dis. 2020;20(10): e261–e267. DOI: 10.1016/S1473-3099(20)30458-8

  18. Belingheri M, Paladino ME, Riva MA. Beyond the assistance: additional exposure situations to COVID-19 for healthcare workers. J Hosp Infect. 2020;105(2):353. DOI: 10.1016/j.jhin.2020.03.033

  19. Celebi G, Piskin N, Celik Beklevic A, et al. Specific risk factors for SARS-CoV-2 transmission among health care workers in a university hospital. Am J Infect Control. 2020; 48(10):1225–1230. DOI: 10.1016/j. ajic.2020.07.039

  20. Baud D, Qi X, Nielsen-Saines K, et al. Real estimates of mortality following COVID – 19 infection. Lancet Infect Dis. 2020;20(7):773. DOI: 10.1016/S1473-3099(20)30195-X

  21. Bongiovanni M, Marra AM, De Lauretis A, et al. Natural history of COVID-19 infection in healthcare workers in Northern Italy. J Hosp Infect. 2020; 106(4):709-712. DOI: 10.1016/j.jhin.2020.08.027

  22. Levene LS, Coles B, Davies MJ, et al. COVID-19 cumulative mortality rates for frontline healthcare staff in England. Br J Gen Pract. 2020; 70(696): 327-328. DOI: 10.3399/bjgp20X710837

  23. Suarez-Garcıa I, Lopez Mjm de A, Vicente AS, Abascal PL. SARS-CoV-2 infection among healthcare workers in a hospital in Madrid, Spain. J Hosp Infect. 2020;106(2):357– 363. DOI: 10.1016/j.jhin.2020.07.020

  24. Barranco R, Ventura F. COVID – 19 and infection in health-care workers: An emerging problem. Med Leg J. 2020; 88(2):65-66. DOI: 10.1177/0025817220923694

  25. Khunti K, Adisesh A, Burton C, et al. The efficacy of PPE for COVID-19-type respiratory illnesses in primary and community care staff. Br J Gen Pract. 2020; 70(697): 413-416. DOI: 10.3399/bjgp20X710969

  26. Chen Y, Tong X, Wang J, et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020; 81(3):420-426. DOI: 10.1016/j.jinf.2020.05.067

  27. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using Open SAFELY. Nature. 2020; 584 (7821): 430-436. DOI: 10.1038/s41586-020-2521

  28. Motta I, Centis R, D’Ambrosio L, et al. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020;26(4):233-40. DOI: 10.1016/j.pulmoe.2020.05.002

 

UDC:616.36-002.2; 616.61-78

DOI: 10.20969/VSKM.2022.15(5).16-21

PDF download EFFECTIVENESS OF DASABUVIR / OMBITASVIR / PARITAPREVIR / RITONAVIR IN HEMODIALYSIS PATIENTS WITH HEPATITIS C VIRUS INFECTION

GALEEVA NELLI V., ORCID ID: 0000-0001-5080-6529, SPIN-код: 8921-4689, Author ID: 293975, Assistant Professor, Infectious Diseases Department, Kazan State Medical University, 420012, Russia, Kazan, Butlerova Str., 49, e-mail: nelli_04@mail.ru

PODRYADNOVА TAT’YANA V., ORCID ID: 0000-0002-3386-8768; Infectiologist, Republic Clinical Infectious Diseases Hospital, Kazan, 423231, Russia, Kazan, Prospekt Pobedy Str., 83, e-mail: podryadnova@gmail.com

MAMEDOVA AIDA H., ORCID ID: 0000-0001-9107-2998 student of the Faculty of General Medicine, Kazan State Medical University, 420012, Russia, Kazan, Butlerova Str., 49, e-mail: osnebaa@mail.ru

NAFEEVA DINARA N., ORCID ID: 0000-0002-6852-1780, student of the Faculty of General Medicine, Kazan State Medical University, 420012, Russia, Kazan, Butlerova Str., 49, e-mail: dnafeeva@mail.ru

Abstract. Introduction. Hepatitis C virus is very common in patients on maintenance hemodialysis, resulting in high morbidity and mortality. Currently, new direct antiviral agents lead to a cure of Hepatitis C virus among most patients with a very good safety profile, which has allowed their use in the treatment of patients with Chronic Kidney Disease as well. Aim. To analyze the practical experience of using dasabuvir/ ombitasvir/ paritaprevir/ ritonavir in patients with chronic hepatitis C with history of chronic kidney disease. Material and methods. Treatment with dasabuvir/ ombitasvir/ paritaprevir/ ritonavir was carried out in 11 patients on hemodialysis with chronic hepatitis C. The virologic response was evaluated in 4 and 8 weeks at the end of the treatment, as well as sustained virologic response in 12 and 24 weeks after the start of treatment. Tolerability and safety of the drugs were also evaluated. Laboratory parameters and adverse reactions during treatment were analyzed. Results and discussion. Treatment using dasabuvir/ ombitasvir/ paritaprevir/ ritonavir was tolerated satisfactorily by all patients. There were no undesirable events. All patients completed the treatment cycle with a 100% rapid virologic response and 100% sustained virological response. No serious adverse reactions were registered. Upon follow-up, the hepatitis C virus was again detected in one patient, but of a different genotype. Conclusion. Treatment using dasabuvir/ ombitasvir/ paritaprevir/ ritonavir is effective for patients with chronic hepatitis C of the first genotype of the virus on the background of chronic kidney disease with program hemodialysis. Patients with chronic kidney disease are at high risk of infection and reinfection with parenteral viral hepatitis.

Key words: chronic hepatitis C, direct-acting antivirals, hemodialysis.

For reference: Galeeva NV, Podryadnova TV, Mamedova AН, Nafeeva DN. Effectiveness of dasabuvir / ombitasvir / paritaprevir / ritonavir in hemodialysis patients with hepatitis C virus infection. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):16-21 DOI: 10/20969/VSKM. 2022.15(5).16-21.

References

1. Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant. 1996; 11 (4):36-38. DOI:10.1093/ndt/11.supp 4.36

2. Collier S, Davenport A. Reducing the risk of infection in end-stage kidney failure patients treated by dialysis. Nephrol Dial Transplant. 2014; 29 (12): 2158-2161. DOI:10.1093/ndt/gfu321

3. Нечаев В.В., Команденко М.С., Радченко В.Г., Ряснянский В.Ю. Вирусные гепатиты у больных, подвергающихся диализу: руководство для врачей // Санкт-Петербург: СпецЛит, 2011. – 159 с. [Nechaev VV, Komandenko MS, Radchenko VG, Ryasnyanskij VYU. Virusnye gepatity u bol’nyh, podvergayushchihsya dializu: rukovodstvo dlya vrachej [Viral hepatitis in patients undergoing dialysis: a guide for doctors]. Sankt-Peterburg: SpecLit. [Saint Petersburg: SpecLit]. 2011; 159 р. (In Russ.)].

4. Fabrizi F, Donato FM, Messa P. Association Between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Ann Hepatol. 2018; 17 (3):364-391. DOI: 10/5604 / 01/3001/0011/7382

5. Михайлов М.И., Мамедов М.К., Дадашева А.Э. Характеристика инфекций, вызванных вирусами гепатитов В и С у больных хронической почечной недостаточностью, находящихся на программном гемодиализе // Вестник РУДН, серия Медицина. - 2013. – Т. 24, вып. 1. – С. 46-50. [Mihajlov MI, Mamedov MK, Dadasheva AE. Harakteristika infekcij, vyzvannyh virusami gepatitov V i S u bol’nyh hronicheskoj pochechnoj nedostatochnost’yu, nahodyashchihsya na programmnom gemodialize [Harakteristika infekcij, vyzvannyh virusami gepatitov V i S u bol’nyh hronicheskoj pochechnoj nedostatochnost’yu, nahodyashchihsya or programmnom gemodialize]. Vestnik RUDN, seriya Medicina [Bulletin of the RUDN, Medicine series]. 2013; 24 (1): 46-50. (In Russ.)].

6. Чупрасов В.Б. Программный гемодиализ: монография // Санкт-Петербург: Фолиант, 2004. – 252 с. [CHuprasov VB. Programmnyj gemodializ [Programmatic hemodialysis]. Sankt-Peterburg: Foliant [St. Petersburg: Folio]. 2004: 252р. (In Russ.)]. 

7. Frisk P, Aggefors K, Cars T, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018; 74 (7): 971-978. DOI: 10/1007/s00228-018-2456

8. Iliescu EL, Mercan-Stanciu A, Toma L. Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrol. 2020; 21(1): 21. DOI: 10/1186/s12882-020-1687-1

9. Suda G, Furusyo N, Toyoda H, et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol. 2018; 53(1):119-128. DOI: 10.1007/s00535-017-1353

10. Nevola R, Rinaldi L, Zeni L, et al. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open. 2020; 4(4):713-721. DOI: 10.1002/jgh3.12324

11. Бурневич Э.З., Никулкина Е.Н., Щаницына С.Е. Омбитасвир + паритапривир / ритонавир и дасабувир + рибаверин – оптимальная противовирусная терапия хронического гепатита С препаратами прямого действия // Клиническая фармакология и терапия. – 2015. – Т. 24, вып. 2. – С. 13-20. [Burnevich EZ, Nikulkina EN, SHCHanicyna SE. Ombitasvir + paritaprivir / ritonavir i dasabuvir + ribaverin – optimal’naya protivovirusnaya terapiya hronicheskogo gepatita S preparatami pryamogo dejstviya [Ombitasvir + paritaprivir / ritonavir and dasabuvir + ribaverine - optimal antiviral therapy of chronic hepatitis With direct-acting drugs]. Klinicheskaya farmakologiya i terapiya [Clinical pharmacology and therapy]. 2015; 24(2):13-20. (In Russ.)].

12. Знойко О.О. Практические аспекты применения первой безинтерфероновой схемы лечения хронического гепатита С в России – 3D-терапия (паритапревир/ритонавир + омбитасвир + дасабувир) // Инфекционные болезни: новости, мнения, обучение. – 2015. – No 3. – С. 96–103. [Znojko OO. Prakticheskie aspekty primeneniya pervoj bezinterferonovoj skhemy lecheniya hronicheskogo gepatita S v Rossii – 3D-terapiya (paritaprevir/ritonavir + ombitasvir + dasabuvir) [Practical aspects of the application of the first interferon-free treatment regimen for chronic hepatitis C in Russia - 3D therapy (paritaprevir/ritonavir + ombitasvir + dasabuvir)]. Infekcionnye bolezni: novosti, mneniya, obuchenie [Infectious diseases: news, opinions, training].2015; (3):96-103. (In Russ.)].

13. Muñoz-Gómez R, Rincón D, Ahumada A, et al. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J Viral Hepat. 2017; 24 (6): 464-471. DOI: 10.1111/jvh.12664

14. Yaraş S, Üçbilek E, Özdoğan O, et al. Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey. Turk J Gastroenterol. 2019; 30 (4): 331-335. DOI: 10.5152/tjg.2018.18269

15. Ponziani FR, Siciliano M, Lionetti R, et al. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. Am J Kidney Dis. 2017; 70 (2): 297-300. DOI: 10.1053/j.ajkd.2017.01.037

16. Крюков Е.В., Черкашин Д.В., Салухов В.В. и др. Внепеченочные проявления хронического вирусного гепатита С // Вестник Российской военно-медицинской академии. - 2022. - Т. 24, вып. 2. - С. 341–352. [Kryukov EV, CHerkashin DV, Saluhov VV, i dr. Vnepechenochnye proyavleniya hronicheskogo virusnogo gepatita C [Extrahepatic manifestations of chronic viral hepatitis C]. Vestnik Rossijskoj voennomedicinskoj akademii [Bulletin of the Russian Military Medical Academy]. 2022; 24 (2): 341-352. (In Russ.)]. DOI: 10.17816/brmma103982

17. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012; 19 (9): 601-607. DOI: 10.1111/j.1365-2893.2012.01633

18. Li C, Liang J, Xiang H, et al. Effectiveness of directacting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine (Baltimore). 2020; 99(48): e23384. DOI:10.1097/MD.0000000000023384

19. Roth D, Bloom RD, Molnar MZ, et al. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis. 2020; 75(5): 665-683. DOI: 10.1053/j.ajkd.2019

20. Gordon CE, Balk EM, Francis JM. Summary of the 2018 Kidney Disease Improving Global Outcomes (KDIGO) Guideline on hepatitis C in chronic kidney disease. Semin Dial. 2019; 32(2):187-195. DOI: 10.1111/sdi.12768

21. Lee BS, Song MJ, Kwon JH, et al. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis. Gut Liver. 2019; 13(2):191-196. DOI: 10.5009/gnl18240

22. Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis. 2001; 38(5):1009-1015. DOI: 10.1053/ajkd.2001

23. Kalantar-Zadeh K, Miller LD, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis. 2005; 46(2): 290-300. DOI: 10.1053/j.ajkd.2005.05.006

24. Saifan C, El-Charabaty E, Kleiner M, El-Sayegh S. Effect of hepatitis C virus infection on erythropoiesis in patients on hemodialysis. Int J Nephrol Renovasc Dis. 2013; 6:121-124. DOI: 10.2147/IJNRD.S44656

25. Alsaran KA, Sabry AA, Alghareeb AH, Al Sadoon G. Effect of hepatitis C virus on hemoglobin and hematocrit levels in saudi hemodialysis patients. Ren Fail. 2009; 31(5):349-54. DOI: 10.1080/08860220902835855

26. Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998; 54(4):1337-43. DOI: 10.1046/j.1523-1755.1998.00084

27. Yuen D, Richardson RM, Fenton SS, et al. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. ASAIO J. 2005; 51(3): 236-241. DOI: 10.1097/01.mat.0000160578.43422.60

 

UDC:616.98-036-07-08:616.36-008.64

DOI:10.20969/VSKM.2022.15(5).22-26

PDF download THE EFFECT OF HEPATOPROTECTORS ON THE STATE OF THE LIVER IN POST COVID-19 PATIENTS

DAMINOVA LOLA T., ORCID ID: 0000-0003-2344-3544, Dr. Med. Sci, Professor of the Department of Internal Medicine Topics No.2, Tashkent State Dental Institute, Uzbekistan, 100047, Tashkent, Yashnabad district, 103 Taraqqyot Street, tel. +99-871-230-20-73, e-mail: lola.daminova@yandex.ru

ADILOVA DURDONA SH., ORCID ID: 0000-0002-5243-1473, Doctoral student of the Department of Internal Diseases, Nephrology and Hemodialysis, Tashkent Pediatric Medical Institute, Uzbekistan, 100140, Tashkent, Yunusabad district, Bogishamol Street, 223, tel. +99-871-262-33-20, e-mail: adilovadurdona7@gmail.com

Abstract. Introduction. In previous studies, it was found that MERS-CoV and SARS-CoV cause damage to parenchymal organs, including liver damage in patients with COVID-19. Virus-induced influence on hepatocytes and cholangiocytes is considered one of the possible factors of liver failure. Direct viral damage to the liver can be detected in the infectious period, inflammatory and toxic damage can develop both in the acute period and in the post-infectious phase against the background of the rehabilitation period. Aim. The aim of the study was to study the effect of various hepatoprotectors on the functional state of the liver in patients in the early rehabilitation period of COVID-19. Material and methods. 243 post COVID-19 patients were under observation, depending on the therapy, the patients were divided into 4 groups: group 0 – group (n=60) – therapy without hepatoprotectors; ursodeoxycholic acid group (n=61) – ursodeoxycholic acid was included in therapy; glycyrrhizic acid and phospholipids group (n=63) – glycyrrhizic acid and phospholipids in the form of Phosphogliv tablets are included in therapy; group ademeteonin (n=59) – ademeteonin is included in therapy. The control examination was carried out a month later. The control group consisted of 20 healthy individuals. To assess the functional state of the liver in the blood of patients, the enzymes alanine aminotransferase, aspartate aminotransferase, gamma-glutamylaminotransferase, lactate dehydrogenase, alkaline phosphatase, total and direct bilirubin, albumin was determined. Conclusion. In patients in the early rehabilitation period of COVID-19, there are increase in the levels of enzymes alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase and bilirubin in the blood, which indicates functional liver disorders. The use of hepatoprotectors makes it possible to increase the positive effect of rehabilitation on the severity of markers of cytolytic and cholestatic syndromes. Ursodeoxycholic acid has the most pronounced effect on normalization of alanine aminotransferase, total and direct bilirubin levels.

Key words: hepatoprotectors, COVID-19, ursodeoxycholic acid, glycyrrhizic acid, phospholipids.

For reference: Daminova LT, Adilova DSh. The effect of hepatoprotectors on the state of the liver in post covid-19 patients. Bulletin of Modern Clinical Medicine. 2022.15(5):22-26. DOI: 10.20969/VSKM.2022.15(5).22-26.

References

1. Ильченко Л.Ю., Никитин И.Г., Федоров И.Г. COVID-19 и поражение печени. Архивъ внутренней медицины [Ilchenko LYu, Nikitin IG, Fedorov IG. COVID-19 i porajenie pecheni [ COVID-19 and liver damage]. Arxiv vnutrenney mediciny [Archive of Internal Medicine]. 2020; 10(3): 188-197. (In Russ.)]. DOI: 10.20514/2226-6704-2020-10-3-188-197

2. Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10224):507-13. DOI: 10.1016/ S0140-6736(20)30211-7

3. Xu L, Liu J, Lu M. et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998-1004. DOI: 10.1111/liv.14435

4. El Ouali S, Romero-Marrero C, Regueiro M. Hepatic manifestations of COVID-19. Cleve Clin J Med. 2020. DOI: 10.3949/ccjm.87a.ccc061

5. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, Poucke SV, Liu WY, Zheng MH. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J ClinTranslHepatol. 2020; 8:18–24. DOI:10.14218/JCTH.2020.00018

6. Li X,Xu S,Yu M,Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy ClinImmunol. 2020). 146: 110–8. DOI: 10.1016/j.jaci.2020.04.006

7. Webb GJ, Marjot T, Cook JA, Aloman C, Armstrong MJ, Brenner EJ, Catana MA, Cargill T, Dhanasekaran R, García-Juárez I, Hagström H, Kennedy JM, Marshall A, Masson S, Mercer CJ, Perumalswami PV, Ruiz I, Thaker S, Ufere NN, Barnes E, Barritt AS 4th, Moon AM. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. LancetGastroenterolHepatol. 2020; 5: 1008–1016. DOI: 10.1016/s2468-1253(20)30271-5

8. Galanopoulos M, Gkeros F, Doukatas A, Karianakis G, Pontas C, Tsoukalas N, Viazis N, Liatsos C, Mantzaris GJ. COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020; 26: 4579–4588. DOI: 10.3748/wjg. v26.i31.4579

9. ZhaoB,NiC,GaoR,WangY,YangL,WeiJ,LvT,Liang J,ZhangQ,XuW,XieY,WangX,YuanZ,ZhangR,LinX. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020; 11: 771–775. DOI: 10.1007/s13238-020-00718-6

10. Wang Y, Shi L, Wang Y, Yang H. An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients. Am J Emerg Med. (2021); 40: 208–209. DOI: 10.1016/j.ajem.2020.05.063

 

UDC: 616-058-053.9(517)

DOI:10.20969/VSKM.2022.15(5).27-31

PDF download MEDICAL AND SOCIAL CHARACTERISTICS OF GERIATRIC PATIENTS IN MEDICAL ORGANIZATIONS OF MONGOLIA

DASHLHUNDEV SAMBUUDOR J., ORCID ID: 0000-0002-8251-2266; postgraduate student of the Department of Public Health, Health Care and Hygiene of the Medical Institute of Russian University of Peoples’ Friendship, Russia, Moscow, st. Miklukho-Maklaya, 10, bldg. 2, e-mail: dashlkhundevsambuudorj@gmail.com

SHULAEV ALEXEY V., ORCID ID: 0000-0002-2073-2538; Scopus Author ID 57313158200, SPIN-код: 3229-1913, AuthorID: 210271, D. Med. Sci, professor, vice-Rector for Clinical Work, Head of the Department of General Hygiene of Kazan State Medical University, Russia, Kazan, st. Butlerova, 49, e-mail: alexs_shu@mail.ru

KONOVALOV OLEG EV., ORCID ID: 0000-0003-1974-9882; Scopus Author ID 7006781195; SPIN-код: 5181-8547, AuthorID: 250753, D. Med. Sci, professor of the Department of Public Health, Health Care and Hygiene of the Russian University of Peoples’ Friendship, Russia, Moscow, st. Miklukho-Maklaya, 10, bldg. 2, e-mail: konovalov_oe@mail.ru

Abstract. Introduction. Improving care for the elderly and senile requires an assessment of not only their health status, but also their social well-being, as well as their lifestyle, including their attitude to their health. Aim. To study the medical and social characteristics, including lifestyle features, of geriatric patients who admitted to the medical organizations in Mongolia. Material and methods. With the help of a specially designed questionnaire, a sociological survey was conducted of 726 respondents older than working age, who applied to aimak or soum hospitals, to the gerontological center of Ulaanbaatar or geriatric rooms of district medical centers in Mongolia. We studied the medical and social characteristics of elderly and senile people, their subjective assessment and attitude to their own health, as well as medical activity.Results and discussion. Respondents of elderly and senile age believed that their health is mainly influenced by lifestyle, quality of medical care, family relations and financial situation. Despite the fact that almost all respondents had several chronic diseases, they showed insufficient medical activity. At the same time, many rarely and irregularly sought medical help, did not always follow the preventive recommendations they received, did nothing to maintain and improve their health, smoked and drank alcohol. In addition, the degree of mobility, self-service and physical activity of the respondents indicated a rather low socio-psychological adaptation. Conclusion. The results obtained will make it possible to correct the main directions for further implementation of measures for the health protection of the elderly and senile in Mongolia in modern conditions.

Key words: population of Mongolia, age older than working age, sociological survey, medical and social characteristics.

For reference: Dashlhundev S, Shulaev AV, Konovalov OE. Medical and social characteristics of geriatric patients in medical organizations of Mongolia. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):27-31. DOI: 10.20969/VSKM.2022.15(5).27-31.

References

 1. Сененко А.Ш., Короткова А.В., Воробьев Р.В., Ниценко Д.И. Современные подходы к организации помощи лицам пожилого и старческого возраста: обзор международного опыта // Менеджер здравоохранения. – 2018. – No 8. – С. 52-60. [Senenko ASh, Korotkova AV, Vorob’ev RV, Nicenko DI. Sovremennye podhody k organizacii pomoshhi licam pozhilogo i starcheskogo vozrasta: obzor mezhdunarodnogo opyta [Modern approaches to organization of care to personsof elderly and senile age: a review of international experience]. Menedzher zdravoohranenija [Manager zdravoohranenia]. 2018; 8: 52-60. (in Russ.)]. https:// www.elibrary.ru/item.asp?id=36284182

2. Галкин К.А. Социальная политика активного долголетия в России и государствах всеобщего благосостояния Европы: опыт сравнительного анализа // Экономические и социальные перемены: факты, тенденции, прогноз. – 2022. – Т. 15, No 2. – С. 239-252. [Galkin KA. Social’naja politika aktivnogo dolgoletija v Rossii i gosudarstvah vseobshhego blagosostojanija Evropy: opyt sravnitel’nogo analiza [Social policy of active aging in Russia and European welfare states: Comparative analysis]. Jekonomicheskie i social’nye peremeny: fakty, tendencii, prognoz [Economic and Social Changes: Facts, Trends, Forecast]. 2022; 15(2): 239-252. (in Russ).]. DOI 10.15838/esc.2022.2.80.15.

3. Кочетков С.С. Социальная практика повышения социальной активности пожилых людей // E-Scio. – 2022. – Т. 66, No 3. – С. 727-731. [Kochetkov SS. Social’naja praktika povyshenija social’noj aktivnosti pozhilyh ljudej [Social practice of increasing social activity of the elderly]. E-Scio. 2022; 66(3): 727-731. (in Russ.)]. https://cyberleninka.ru/article/n/sotsialnaya-praktika- povysheniya-sotsialnoy-aktivnosti-pozhilyh-lyudey

4. Родионова В.И., Швачкина Л.А., Санков И.Д., Биланик М.Ю. Пожилые люди как объект исследования социальной работы // Глобализация социально-экономических процессов в условиях цифровизации и устойчивой трансформации бизнес-среды: сборник материалов Международной научно-практической конференции, Ставрополь, 14–15 февраля 2022 года. – Ставрополь: Издательство «АГРУС», 2022. – С. 573-577. [Rodionova VI, Shvachkina LA, Sankov ID, Bilanik MJu. Pozhilye ljudi kak ob’ekt issledovanija social’noj raboty. Globalizacija social’nojekonomicheskih processov v uslovijah cifrovizacii i ustojchivoj transformacii biznes-sredy: sbornik materialov Mezhdunarodnoj nauchno-prakticheskoj konferencii, Stavropol’, 14–15 fevralja 2022 goda [Older people as an object of research on social work//Globalization of socio-economic processes in the context of digitalization and sustainable transformation of the business environment: a collection of materials from the International Scientific and Practical Conference, Stavropol, February 14-15, 2022]. Stavropol’: Izdatel’stvo “AGRUS” [Stavropol Territory: Publisher “AGRUS”]. 2022: 573-577. (in Russ.)].

5. Izekenova AK, Rakhmatullina АT, Izekenova AK, Tolegenova АS. Is there any need for gender oriented employment policy for the elderly? Вестник университета «Туран». 2022; 1(93): 103-111. DOI 10.46914/1562-2959-2022-1-1-103-111

6. Banerjee D, Javed A, Rao GP, Javed A, Saha G, Pradhan SN. The WPA-IPS-SPF-AFPA Joint Panel Discussion Organized by the IPA: Voices from South Asia Regarding Older People’s Mental Health Advocacy and Services. Consortium Psychiatricum. 2022; 3(1): 92-97. DOI 10.17816/CP147

7. Haz-Gomez FE, Manzanera-Roman S. Egovernment and digital gap among the elderly in Spain. 2022; 44-47.

8. Левендеева Л.Ю. Пожилой человек в современном обществе - его положение и проблемы // Апгрейд молодёжных инициатив: Обновление - 2025: материалы VII Всероссийской научно–практической конференции с международным участием, Москва, 29–30 октября 2021 года. – Ульяновск: ИП Кеньшенская Виктория Валерьевна (издательство «Зебра»), 2021. – С. 37-40. [Levendeeva LJu. Pozhiloj chelovek v sovremennom obshhestve - ego polozhenie i problemy. Apgrejd molodjozhnyh iniciativ: Obnovlenie - 2025: materialy VII Vserossijskoj nauchno–prakticheskoj konferencii s mezhdunarodnym uchastiem, Moskva, 29–30 oktjabrja 2021 goda [An elderly person in modern society - his situation and problems // Upgrade of youth initiatives: Update - 2025: materials of the VII All-Russian Scientific and Practical Conference with international participation, Moscow, October 29-30, 2021]. Ul’janovsk: IP Ken’shenskaja Viktorija Valer’evna (izdatel’stvo “Zebra”) [Ulyanovsk: individual entrepreneur Kenshenskaya Victoria Valerievna (Zebra publishing house)]. 2021; 37-40. (in Russ.)].

9. Шибалков И.П., Недоспасова О.П. Удовлетворенность качеством жизни в российских регионах в контексте реализации ресурсного потенциала пожилых // Институциональная трансформация экономики: человек и социум (ИТЭ-ЧС 2021): Материалы VII Международной научной конференции, Томск, 21–23 октября 2021 года. – Томск: Национальный исследовательский Томский государственный университет, 2021. – С. 214-215. [Shibalkov IP, Nedospasova OP. Udovletvorennost’ kachestvom zhizni v rossijskih regionah v kontekste realizacii resursnogo potenciala pozhilyh // Institucional’naja transformacija jekonomiki: chelovek i socium (ITJe-ChS 2021): Materialy VII Mezhdunarodnoj nauchnoj konferencii, Tomsk, 21–23 oktjabrja 2021 goda [Satisfaction with the quality of life in Russian regions in the context of the realization of the resource potential of the elderly. Institutional transformation of the economy: person and society (ITE-ES 2021): Materials of the VII International Scientific Conference, Tomsk, October 21-23]. Tomsk: Nacional’nyj issledovatel’skij Tomskij gosudarstvennyj universitet [Tomsk: National Research Tomsk State University]. 2021; 214-215. (in Russ).]. DOI 10.17223/978-5-907442-40-5-2021-144

10. Илларионова В.Л. Социально-психологические аспекты исследования старости // Актуальные вопросы психологии развития и образования: Сборник материалов IV Всероссийской научно-практической конференции, Санкт-Петербург, 28–29 сентября 2021 года. – Санкт-Петербург: Ленинградский государственный университет имени А.С. Пушкина, 2022. – С. 79-86. [Illarionova VL. Social’no-psihologicheskie aspekty issledovanija starosti. Aktual’nye voprosy psihologii razvitija i obrazovanija: Sbornik materialov IV Vserossijskoj nauchno-prakticheskoj konferencii, Sankt-Peterburg, 28–29 sentjabrja 2021 goda [Social and psychological aspects of the study of old age. Actual issues of psychology of development and education: Collection of materials of the IV All-Russian Scientific and Practical Conference, St. Petersburg, September 28-29, 2021]. Sankt-Peterburg: Leningradskij gosudarstvennyj universitet imeni A.S. Pushkina [St. Petersburg: Pushkin Leningrad State University]. 2022; 79-86. (in Russ).].

11. Золин И.Е. Перспективы развития занятости пожилых людей в современном российском обществе // Персонал старшего возраста как человеческий капитал современного общества: условия, возможности, ограничения: Сборник материалов дискуссионной площадки VI Всероссийского социологического конгресса, Санкт-Петербург, 09 декабря 2021 года. – Нижний Новгород: Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского, 2022. – С. 67-74. [Zolin IE. Perspektivy razvitija zanjatosti pozhilyh ljudej v sovremennom rossijskom obshhestve. Personal starshego vozrasta kak chelovecheskij kapital sovremennogo obshhestva: uslovija, vozmozhnosti, ogranichenija: Sbornik materialov diskussionnoj ploshhadki VI Vserossijskogo sociologicheskogo kongressa, Sankt-Peterburg, 09 dekabrja 2021 goda [Prospects for the development of employment of older people in modern Russian society//Older personnel as the human capital of modern society: conditions, opportunities, restrictions: Collection of materials from the discussion platform of the VI All-Russian Sociological Congress, St. Petersburg, December 09, 2021]. Nizhnij Novgorod: Nacional’nyj issledovatel’skij Nizhegorodskij gosudarstvennyj universitet im. N.I. Lobachevskogo [Nizhny Novgorod: National Research Nizhny Novgorod Lobachevsky State University]. 2022; 67-74. (in Russ).]. https://pure.spbu.ru/ws/portalfiles/portal/92929992/ _._._.pdf

 

UDC:616.12.03.008

DOI:10.20969/VSKM.2022.15(5).32-37

PDF download PREVALENCE OF THE DIAGNOSIS OF «OBESITY» AMONG LAW ENFORCEMENT OFFICERS

ISHKINEEV FARID I., ORCID ID: 0000-0001-8551-1253, Head of Medical Unit of Military Medical Commission of the Ministry of Internal Affairs of Russia in Tatarstan Republic, 420111, Russia, Kazan, Lobachevskogo street, 13, e-mail: fishkineev@mvd.ru

ISHKINEEVA FARIDA F., ORCID ID: 0000-0002-2372-8198; SPIN-code: 7589-4300; AuthorID: 333377, C. Soc. Sci., Associate Professor, Department of General and Ethnic Sociology, Institute of Social and Philosophic Sciences and Mass Communications, Kazan Federal University, 420008, Russia, Kazan, Kremlyovskaya street, 18, e-mail: farida1967@mail.ru

SAVELEVA ZHANNA V., ORCID ID: 0000-0003-1465-0664, SPIN-code: 6808-3803; AuthorID: 545572; D. Soc. Sci., Associate Professor, Department of General and Ethnic Sociology of Kazan Federal University, 420008, Russia, Kazan, Kremlyovskaya street, 18, e-mail: gedier@mail.ru

KHUSAINOVA LILIA K., general practitioner of the Military Medical Commission of the Medical and Sanitary Unit of the Ministry of Internal Affairs of Russia in the Republic of Tatarstan, Kazan, Russia, Lobachevsky str. 13

Abstract. Introduction. The issue of the prevalence of the disease among law enforcement officers is of particular relevance and urgency in connection with the problems of professional performance. At the same time, this socio-professional group was not in the focus of researchers’ attention in the context of the prevalence of the disease. Aim.Identification of the dynamics of the prevalence of obesity among law enforcement officers of the Republic of Tatarstan.Material and methods. A statistical analysis of the conclusions issued by the military medical commission of the medical and sanitary unit of the Ministry of Internal Affairs of the Russian Federation in the Republic of Tatarstan for the control 1970, 1980, 1990, 2000, 2010, 2020 years with an interval of ten years, for the presence of a diagnosis - «obesity», by the method of summarizing and grouping data. The number of persons included in the study in 1970 amounted to 1922 people, in 1980 - 2928, in 1990 - 4530, in 2000 - 5061, in 2010 - 4617, in 2020 – 4109 people. All respondents are divided into 3 groups: those who are examined upon entering the service, those who are examined upon moving through the service, those who are examined before the upcoming dismissal. Results and discussion.The results of examinations of candidates and employees of the Department of Internal Affairs showed a steady trend towards an increase in the diagnosis of «obesity» among them. This trend is associated with risks not only in relation to the threat of reduced working capacity, but also with an increase in concomitant diseases, disability and mortality of both employees of the Department of Internal Affairs and the population as a whole. In addition, it poses a serious problem for the health care system. Conclusion. Obesity is a serious problem both for the preservation of professional ability to work and the prevention of concomitant diseases among employees of internal affairs bodies, and for the health care system in terms of the need to revise social policy, in particular, to organize work on the prevention and treatment of the disease.

Keywords: obesity, overweight, law enforcement officer, population, prevention, military medical examination.

For reference: Ishkineev FI, Ishkineeva FF, Saveleva ZV, Khusainova LK. Рrevalence of the diagnosis of «obesity» among law enforcement officers. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):32-37. DOI: 10.20969/ VSKM.2022.15(5).32-37.

References

1. Драпкина О.М., Ким О.Т., Дадаева В.А. История ожи-рения: от символа плодородия до глобальной проблемы общественного здравоохранения // Профилактическая медицина. – 2021. – Т.24, вып. 1. – С. 98–103. [Drapkina OM, Kim OT, Dadaeva VA. Istoriya  ozhireniya: ot simvola plodorodiya do globalnoi problemi obsh’estvennogo zdravoohraneniya [A history of obesity: from a fertility symbol to a global public health problem]. Profilakticheskaya medicina [The Russian Journal of Preventive Medicine]. 2021; 24(1): 98–10. (In Russ.)]. DOI: 10.17116/profmed20212401198

2. Лескова И.В., Ершова Е.В., Никитина Е.А., и др. Ожирение в России: современный взгляд под углом социальных проблем // Ожирение и метаболизм. – 2019. – Т.16, вып. 1. – С. 20-26. [Leskova IV, Ershova EV, Nikitina EA, еt al. Ozhirenie v Rossii: sovremennii vzglyad pod uglom socialnih problem [Obesity in Russia: modern view in the light of a social problems]. Ozhirenie i metabolizm [Оbesity and metabolism]. 2019; 16 (1): 20-26. (In Russ.)]. DOI: 10.14341/omet9988

3. Obesity and overweight. World Health Organization. https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight

4. Physical activity strategy for the WHO European Region 2016–2025. WHO. 2015.

5. Григорьева М. Эпидемия избыточного веса в России // Демоскоп. – 2012. No 529 – 530. http://www.demoscope. ru/weekly/2012/0529/tema03.php [Grigoreva M. Epidemiya izbitochno vesa v Rossii [Overweight epidemic in Russia]. Demoskop [Demoscope]. 2012; 529–530. (In Russ.)].

6. Григорьева М.А. Социально-экономические причины и последствия распространения избыточной массы тела в России // Профилактическая медицина. – 2014. - No 5. – С.34-41. [Grigoreva MA. Socialno-ekonomicheskie prichini i posledstviya rasprostraneniya izbitochnoi massi tela v Rossii [The socioeconomic causes and consequences of the prevalence of overweight in Russia]. Profilakticheskaya medicina [Preventive Medicine]. 2014; 5: 34-41. (In Russ.)]. DOI: 10.17116/ profmed20212409130

7. Росстат изучил рацион россиян / Федеральная служба государственной статистики. [Rosstat izuchil racion rossiyan / Federalnaya sluzhba gosudarstvennoi statistiki [Rosstat studied the diet of Russians / Federal State Statistics Service]. https://rosstat.gov.ru/folder/313/ document/70761 (In Russ.)].

8. Гайсёнок О.В., Александрова А.А., Савина Н.М. Выявление распространенности ожирения и оценка его взаимосвязи с сердечно-сосудистым риском по данным скрининговых программ обследования населения // Социальные аспекты здоровья населения. 2020. No 2 (66). [Gaisenok OV, Alexandrova AA, Savina NM. Viyavlenie rasprostranennosti ozhireniya i ocenka ego vzaimosvyazi s serdechno-sosudistim riskom po dannim skriningovih programm obsledovaniya naseleniya [Prevalence of obesity and its relationship with cardiovascular risk according to data of population screening programs]. Socialnie aspekti zdorovya naseleniya [Social aspects of population health]. 2020; 66 (2): 1. Available from: http://vestnik.mednet.ru/content/ view/1145/30/lang,ru/(In Russ.)]. DOI: 10.21045/2071-5021-2020-66-2-1

9. Бочаров Е.П., Янгирова Э.Х., Фролова О.А. Вероятностный риск здоровью женщин, связанный с недостаточным потреблением пищевых веществ // Актуальные вопросы профилактической медицины и обеспечения санитарно-эпидемиологического благополучия населения: сборник тезисов VIII Межрегиональной научно-практической конференции – Казань: КГМУ, 2021 – С.13-15. [Bocharov EP, YAngirova ЕN, Frolova OA. Veroyatnostnii risk zdorovyu zhensh’in, svyazannii s nedostatochnim potrebleniem pish’evih vesh’estv [Probable risk to women’s health associated with insufficient nutritional intake]. Aktualnie voprosi profilakticheskoi medicini i obespecheniya sanitarno-epidemiologicheskogo blagopoluchiya naseleniya: sbornik tezisov VIII Mezhregionalnoi nauchno-prakticheskoi konferencii [Topical issues of preventive medicine and ensuring the sanitary and epidemiological welfare of the population: a collection of abstracts of the VIII Interregional scientific and practical conference]. Kazan: KGMU, 2021. 13-15. (In Russ.)]. DOI: 10.14341/OMET201613-8

10. Всемирная организация здравоохранения. [Vsemirnaya organizaciya zdravoohraneniya [World Health Organization]. Available from: https://www.who.int/ ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019. (In Russ.)].

11. Разина А.О., Ачкасов Е.Е., Руденко С.Д. Ожирение: современный взгляд на проблему // Ожирение и ме-таболизм. – 2016. – Т. 13, вып. 1. – С. 3-8. [Razina AO, Achkasov EE, Runenko SD. Ozhirenie: sovremennii vzglyad na problemu [Obesity: the modern approach to the problem]. Ozhirenie i metabolism [Оbesity and metabolism]. 2016; 13(1): 3-8. (In Russ.)]. DOI: 10.14341/ omet201613-8

12. Максимова Т.М. Современное состояние, тенденции и перспективные оценки здоровья населения. – М.: Пер Се, 2002. – 192 с. [Maksimova TM. Sovremennoe sostoyanie, tendencii i perspektivnie ocenki zdorovya naseleniya [Current state, trends and prospective assessments of public health] Moskva: Per Se [Moscow: Per Se]. 2002; 192 p. (In Russ.)].

13. Шальнова С.А., Деев А.Д., Баланова Ю.А., и др. Масса тела и ее вклад в смертность от сердечно-сосудистых заболеваний и всех причин среди российского населения // Кардиоваскулярная терапия и профилактика. – 2014. – Т.3, вып. 1. – С. 44-48. [SHalnova SA, Deev AD, Balanova YA, еt al. Massa tela i ee vklad v smertnost ot serdechno-sosudistih zabolevanii i vseh prichin sredi rossiiskogo naseleniya [Body weight and its impact on all-cause and cardiovascular mortality in Russia] Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2014; 13(1): 44-48 (In Russ.)]. DOI: 10.15829/1728-8800-2014-1-44-48

14. Статистика о ведущих причинах смертности и инвалидности в‎ о всем мире за период 2000–2019 гг.‎ / Всемирная организация здравоохранения. [Statistika o vedush’ih prichinah smertnosti i invalidnosti v‎ o vsem mire za period 2000–2019 gg.‎ [Statistics on the leading causes of death and disability w‎ orldwide for the period 2000–2019]‎.Vsemirnayaorganizaciyazdravoohraneniya [World Health Organization] (In Russ.)]. https://www. who.int/ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019

15. Соловьев А.Г., Богдасаров Е.Г., Ичитовкина Е.Г. Структура и уровни заболеваемости психическими расстройствами сотрудников органов внутренних дел // Практическая медицина. – 2019. – Том 17, вып. 3. – С. 73-78. [Solovev AG, Bogdasarov YV, Ichitovkina EG. Struktura i urovni zabolevaemosti psihicheskimi rasstroistvami sotrudnikov organov vnutrennih del [Structure and levels of mental disorders morbidity of the employees of the internal affairs bodies]. Prakticheskaya medicina [Practical Medicine]. 2019; 17 (3): 73-78 (In Russ.)]. DOI: 10.32000/2072-1757-2019-3-73-78

16. Давхале Р.А., Потапова М.В., Амиров Н.Б. Распространенность артериальной гипертензии среди сотрудников правоохранительных органов (обзор литературы) Вестник современной клинической медицины. – 2013. – Т.6, вып. 2. – С. 66-72. [Davhale RA, Potapova MV, Amirov NB. Rasprostranennost arterialnoi gipertenzii sredi sotrudnikov pravoohranitelnih organov (obzor literaturi) [Prevalence аrтеrial hipertension among the employees of law-enforcement bodies (review of the literature)]. Vestnik sovremennoi klinicheskoi medicini [The Bulletin of Contemporary Clinical Medicine]. 2013; 6 (2): 66-72. (In Russ.)]. http://vskmjournal.org/images/Files/Issues_ Archive/2013/Issue_2/VSKM_2013_N_2.pdf

17. Хисамиев Р.Ш., Амиров Н.Б., Гинятуллина Л.Р. и др. Сравнительный анализ заболеваемости артериальной гипертензией и распространенности факторов риска среди сотрудников органов внутренних дел Казанского гарнизона // Вестник современной клинической медицины. – 2016. – Т. 9, вып. 6. – С.89-95. [Hisamiev RSH, Amirov NB, Ginyatullina LR, еt al. Sravnitelnii analiz zabolevaemosti arterialnoi gipertenziei i rasprostranennosti faktorov riska sredi sotrudnikov organov vnutrennih del Kazanskogo garnizona [Comparative analysis of the incidence of hypertension and of the prevalence of risk factors among internal affairs bodies of Kazan garrison]. Vestnik sovremennoi klinicheskoi medicine [The Bulletin of Contemporary Clinical Medicine]. 2016; 9 (6): 89-95. (In Russ.)]. DOI: 10.20969/VSKM.2016.9(6).89-95

18. Ганишев А.В. Влияние военно-врачебной комиссии на совершенствование лечебно-диагностической работы // Медицинский вестник МВД – 2015. – Т. LXXVIII, No5. – С.2-4. [Ganishev AV. Vliyanie voenno-vracebnoy komiccii na sovershenstvovanie lechebno-diagnosticheskoy raboti [The influence of the military medical commission on the improvement of medical and diagnostic work]. Medicinckiy vestnik MVD [Medical Bulletin of the Ministry of Internal Affairs]. 2015; LXXVIII (5): 2-4. (In Russ.)]. https://elibrary. ru/download/elibrary_24105883_66354043.pdf

 

UDC:616.314.17-002-035.2-06:616.98:578.834.1(045)

DOI:10.20969/VSKM.2022.15(5).38-43

PDF download RISK FACTORS DEVELOPMENT OF PERIODONTITIS IN PATIENTS IN THE POSTCOVID PERIOD

KULIGIN ALEXANDER V., ORCID ID: 0000-0001-5705-215Х, Dr. Sci. Med., professor, The Head of Department of Emergency medicine, Anesthesiology, Resuscitation and Simulation technologies in medicine, Saratov State Medical University, 4100012, Russia, Saratov, B. Kazachya street, 112, tel.: 8-937-636-72-32, e mail: avkuligin@yandex.ru

KAZAKOVA LARISA N., ORCID ID: 0000-0001-8060-1348; C. Med. Sci., associate professor, Department of Pediatric Dentistry and Orthodontics, Saratov State Medical University, 4100012, Russia, Saratov, B. Kazachya street, 112, tel.: 8-905-321-06-11, e-mail: avkuligin@yandex.ru

EDIKHANOVA KAMILA I., ORCID ID: 0000-0003-2901-0133; student of the dentistry faculty, Saratov State Medical University, Russia, 410012, Saratov, B. Kazachya street, 112, tel.: 8-927-118-35-51, e-mail: edi.kami@mail.ru

TERESHCHUK OKSANA S., ORCID ID: 0000-0002-4917-797X, Assistant Professor, Department of Emergency medicine, Anesthesiology, Resuscitation and Simulation technologies in medicine, Saratov State Medical University, 4100012, Russia, Saratov, B. Kazachya street, 112, e-mail: kleo.ok@yandex.ru

EGOROVA ANASTASIYA V., ORCID ID: 0000-0001-7097-7763; C. Med. Sci., Associate professor, Department of Pediatric Dentistry and Orthodontics, Saratov State Medical University, 4100012, Russia, Saratov, B. Kazachya street, 112, tel.: 8-905-321-06-11, e-mail: nastia02@mail.ru

MAHONOVA EKATERINA V., ORCID ID: 0000-0001-5249-8582; Assistant Professor, Department of Pediatric Dentistry and Orthodontics, Saratov State Medical University, 4100012, Russia, Saratov, B. Kazachya street, 112, tel.: 8-905-384-40-03, e-mail: mahonova.ev@mail.ru

Abstract. Introduction. According to independent epidemiological research of World Health Organization (WHO) intact periodontitis occurs only among 2-10% of the population, while inflammatory periodontal diseases are detected in 90-95% of cases. The awareness of risk factors and their impact on periodontal diseases in somatic pathology allows not only to reduce the aggressiveness of disease development with the help of preventive measures, but also to predict possibilities of the main disease development. Aim. To identify the nature of periodontal microvasculature disorders among patients during post-covid period. Material and methods. We performed laboratory hematological examination, arterial blood oxygen level estimation, Doppler microcirculation study of periodontal tissues in patients diagnosed with B 34.2 «Coronavirus infection unspecified» COVID-19 of medium severity in hospital and in outpatient clinic after recovery. We conducted a questionnaire survey of patients «Subjective characteristic of the general state at the time of the disease outbreak», «Subjective characteristic of the state of the oral cavity in the aftercare period». Results and discussion. The Covid infection is associated with changes in the blood coagulation in conditions of persistent hypoxia, which is confirmed by all the stated methods of research. Complaints of varying degrees of severity about poor general well-being and changes in the oral cavity were noted in 100% of cases. No clinical manifestations of inflammation of periodontal tissues causing concern were found in patients in the post-occlusive period during the initial examination, but Doppler examination showed significant microcirculatory disorders. Conclusion. Laser Doppler flowmetry as an additional method of investigation reveals persistent microcirculatory disorders of periodontal tissues on the basis of extensive vascular endothelial damage in patients post COVID-19 which are not clinically manifested at this stage.

Key words: periodontitis, COVID-19, hemostasis, microcirculation, oxygenation.

For references: Kazakova LN, Kuligin AV, Edikhanova KI, Tereshchuk OS, Egorova AV, Mahonova EV. Risk factors development of periodontitis in patients in the postcovid period. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):38-43. DOI: 10.20969/VSKM.2022.15(5).38-43.

References

1. Жулев Е.Н., Кочубейник А.В., Круглова Н.В. Диагностические критерии при планировании ортопедического лечения пациентов с воспалительными заболеваниями пародонта // Проблемы стоматологии. - 2019. - No 15 (2). - С. 102-105. [Zhulev EN, Kochubejnik AV, Kruglova NV. Diagnosticheskie kriterii pri planirovanii ortopedicheskogo lecheniya pacientov s vospalitelnymi zabolevaniyami parodonta [Diagnostic criteria for planning orthopedic treatment of patients with inflammatory periodontal diseases]. Problemy stomatologii [Problems of dentistry]. 2019; 15 (2): 102-105. (in Russ.)]. DOI 10.18481/2077-7566-2019- 15-2-102-105

2. Кочубейник А.В., Круглова Н.В. Особенности консервативной терапии при комплексном лечении воспалительных заболеваний пародонта // Dental Forum. - 2015. - No 4. - С. 45. [Kochubejnik AV, Kruglova NV. Osobennosti konservativnoj terapii pri kompleksnom lechenii vospalitelnyh zabolevanij parodonta [Features of conservative therapy in the complex treatment of inflammatory periodontal diseases]. Dental Forum [Dental Forum]. 2015; 4: 45. (in Russ.)].

3. Кильмухаметова Ю. Х. Заболевания пародонта на фоне соматических патологий // Молодой ученый. — 2017. — No 26 (160). — С. 57-62. [Kilmuhametova YuH. Zabolevaniya parodonta na fone somaticheskih patologij [Periodontal disease against the background of somatic pathologies]. Molodoj uchenyj [The young scientist]. 2017; 26 (160): 57-62. (in Russ.)]. https://moluch.ru/ archive/160/44921

4. Муниев Б.Х. Клинико-функциональные особенности поражения тканей пародонта у больных ишемической болезнью сердца: автореф. дис. на соискание научн. степени кандидата мед. наук: спец. 14.00.21 — «Стоматология» / Б.Х. Муниев — М., 2005. — С.18. [Muniev BH. Kliniko-funkcionalnye osobennosti porazheniya tkanej parodonta u bolnyh ishemicheskoj boleznyu serdca [Features of periodontal tissue damage in patients with coronary heart disease]. Avtoreferat dissertacii na soiskanie uchenoy stepeni kandidata medicinskih nauk: spez. 14.00.21 «Stomatologiya» [PhD thesis abstract: spes: 14.00.21 «Dentistry».]. M. 2005: 18. (in Russ.)].

5. Полторак Н.А. Взаимосвязь воспалительных заболеваний пародонта с ишемической болезнью сердца: автореф. дис. На соискание научн. степени кандидата мед. наук: спец. 14.00.21 — «Стоматология» / Н.А. Полторак. — М., 2007.— 21 с. [Poltorak NA. Vzaimosvyaz vospalitelnyh zabolevanij parodonta s ishemicheskoj boleznyu serdca [Inflammatory periodontal disease with coronary heart disease]. Avtoreferat dissertacii na soiskanie uchenoy stepeni kandidata medicinskih nauk: spez. 14.00.21 «Stomatologiya» [PhD thesis abstract: spes: 14.00.21 «Dentistry».]. M., 2007: 21. (in Russ.)].

6. Елисеева А.Ф., Цимбалистов А.В., Шторина Г.Б. Клиническая оценка состояния пародонта на фоне ишемической болезни сердца и без нее // Институт стоматологии. 2011. No 3. С.70-71. [Eliseeva AF, Cimbalistov AV, Shtorina GB. Klinicheskaya ocenka sostoyaniya parodonta na fone ishemicheskoj bolezni serdca i bez nee [Clinical assessment of periodontal condition against the background of coronary heart disease and without it]. Institut stomatologii [Institute of Dentistry]. 2011; 3: 70-71. (in Russ.)].

7. Шевченко Е.А., Успенская О.А., Загребин Е.А., Спиридонова С.А. Нарушение гемостаза как причина пародонтита у больных сахарным диабетом II типа // Пародонтология. 2021.- No3.- С. 240-244. [Shevchenko EA, Uspenskaya OA, Zagrebin EA, Spiridonova SA. Narushenie gemostaza kak prichina parodontita u bolnyh saharnym diabetom II tipa [Impaired hemostasis as a cause of periodontitis in patients with type II diabetes mellitus]. Parodontologiya [Periodontology]. 2021;3: 240-244 (in Russ.)]. DOI 10.33925/1683-3759-2021-26-3-240-244

8. Погодина А.В., Валявская О.В., Колесникова Л.Р. и др. Артериальная гипертензия и пародонтит: ключевые аспекты коморбидности // Артериальная гипертензия. 2019. 25. No6. С. 682-692. [Pogodina AV, Valyavskaya OV,KolesnikovaLR.Arterialnayagipertenziyaiparodontit: klyuchevye aspekty komorbidnosti [Arterial hypertension and periodontitis: key aspects of comorbidity]. Arterialnaya gipertenziya [Arterial hypertension]. 2019; 25: 682-692 (in Russ.)]. DOI: 10.18705/1607-419X-2019-25-6-682-692

9. Ferrari M, et al. Hypoxemia in COVID-19: cerebral oximetry should be explored as a warning indicator for mechanically ventilated adults with COVID-19. Respir Res. 2020; 132 (1): 74-81. DOI: 10.1186/s12931-020-01462-5

10. Казакова Л.Н., Терещук О.С., Фирсова И.В., Толстых О.А. Влияние уровня оксигенации на физиологические параметры тканей полости рта // Dental Forum. 2021.- No4 (83) - С.38. [Kazakova LN, Tereshchuk OS, Firsova IV, Tolstyh OA. Vliyanie urovnya oksigenacii na fiziologicheskie parametry tkanej polosti rta [Influence of the level of oxygenation on the physiological parameters of oral tissues]. Dental Forum [Dental Forum]. 2021; 4 (83):38. (in Russ.)].

 

UDC:616.12-007.61

DOI:10.20969/VSKM.2022.15(5).44-51

PDF download CLINICAL AND GENETIC ASPECTS OF REGRESS OF LEFT VENTRICULAR MYOCARDIAL HYPERTROPHY. RESULTS OF A PROSPECTIVE STUDY IN MOUNTAIN SHORIA

MULEROVA TATIANA A., ORCID ID: 0000-0002-0657-4668; D. Med. Sci, lead researcher at the laboratory of cardiovascular disease epidemiology, Research Institute for Complex Issues of Cardiovascular Diseases, Russia, 650002, Kemerovo, Sosnoviy Blvd., 6, e-mail: mulerova-77@mail.ru

MOROZOVA NATALIA I., ORCID ID: 0000-0001-9463-4183; candidate for a degree, Research Institute for Complex Issues of Cardiovascular Diseases, Russia, 650002, Kemerovo, Sosnoviy Blvd., 6; tel.: +7-913-298-49-81, e-mail: morozova-30.10@yandex.ru

BAZDYREV EVGENIY D., ORCID ID: 0000-0002-3023-6239, Scopus Author ID: 19337085800; D. Med. Sci, head of cardiovascular disease epidemiology laboratory, Research Institute for Complex Issues of Cardiovascular Diseases, Russia, 650002, Kemerovo, Sosnoviy Blvd., 6; tel.: 8-384-264-42-40, e-mail: edb624@mail.ru

TSYGANKOVA DARYA P., ORCID ID: 0000-0001-6136-0518, Scopus Author ID: 57194717730; C. Med Sci., researcher at the laboratory of cardiovascular disease epidemiology, Research Institute for Complex Issues of Cardiovascular Diseases, Russia, 650002, Kemerovo, Sosnoviy Blvd., 6; tel.: 8-384-234-53-91, e-mail: darjapavlovna2014@mail.ru

AGIENKO ALENA S., ORCID ID: 0000-0001-5521-4653; research laboratory assistant at the laboratory of cardiovascular disease epidemiology, Research Institute for Complex Issues of Cardiovascular Diseases, Russia, 650002, Kemerovo, Sosnoviy Blvd., 6; tel.: 8-384-234-53-91, e-mail: agienko_alena@mail.ru

INDUKAEVA ELENA V., ORCID ID: 0000-0002-6911-6568, Scopus Author ID: 55229341200, Researcher ID: I-2340-2017; C. Med. Sci., senior researcher at the laboratory of cardiovascular disease epidemiology, Research Institute for Complex Issues of Cardiovascular Diseases, Russia, 650002, Kemerovo, Sosnoviy Blvd., 6; tel.: 8-384-234-53-91, e-mail: indelen@mail.ru

NAHRATOVA OLGA V., ORCID ID: 0000-0002-2778-6926; junior researcher at the laboratory of cardiovascular disease epidemiology, Research Institute for Complex Issues of Cardiovascular Diseases, Russia, 650002, Kemerovo, Sosnoviy Blvd., 6; tel.: 8-384-234-53-91, e-mail: nahratovao.v@yandex.ru

Abstract. Introduction. Left ventricular hypertrophy is an independent predictor of adverse outcomes in patients with arterial hypertension. Aim. To evaluate clinical and genetic factors, as well as the effectiveness of antihypertensive drugs classes in terms of regression of left ventricular hypertrophy in the indigenous population of Mountain Shoria within 5-year prospective observations. Material and methods. The study was based on the results of a 5-year observation of the indigenous population of Mountain Shoria. The study included 901 people aged 18 and over. At the one-stage stage (from 2013 to 2017), an anamnesis and complaints were collected, a clinical examination by a cardiologist, anthropometry, a biochemical blood test was performed, and genetic testing of polymorphisms of arterial hypertension candidate genes (ACE (I/D, rs 4340), AGT (c.803T>C, rs699), AGTR1 (А1166С, rs5186), ADRB1 (с.145A>G, Ser49Gly, rs1801252), ADRA2B (I/D, rs28365031), MTHFR (С677Т, rs1801133), eNOS (VNTR 4b/4a)), performed electrocardiography, echocardiography. The prospective stage included 263 patients with hypertension without previous antihypertensive therapy. Blood pressure figures were monitored and corrected annually, and left ventricular hypertrophy dynamics was assessed 5 years after inclusion in the study. Statistical processing of the results of the study was carried out using the program "Statistica 10.0".Results and discussion. In the Shors cohort, left ventricular hypertrophy regression was associated with a lower degree of arterial hypertension (odds ratio 1.39) and with the achievement of target blood pressure levels (odds ratio 1.71), as well as with the addition of a diuretic, indapamide retard, to renin-angiotensin-aldosterone system blockers (odds ratio 2.65). In the present study, an association was found between carriage of the D/D genotype of the ACE gene (odds ratio 0.43) and 4a/4a of the eNOS gene (odds ratio 0.35) with negative dynamics in relation to myocardial mass of the left ventricle. With respect to genotype I/I of the ADRA2B gene (odds ratio 2.00) and 4b/4b of the eNOS gene (odds ratio 2.93), an associative relationship with regression of left ventricular hypertrophy was demonstrated. Conclusion. The results obtained once again prove the promise of using genetic approaches for the early diagnosis of left ventricular hypertrophy.

Key words: left ventricular hypertrophy, prospective observation, polymorphism of candidate genes, ethnos.

For reference: Mulerova TA, Morozova NI, Bazdyrev ED, Tsygankova DP, Agienko AS, Indukaeva EV, Nahratova OV. Clinical and genetic aspects of regress of left ventricular myocardial hypertrophy. Results of a prospective study in Mountain Shoria. The Bulletin of Contemporary Clinical Medicine.2022.15(5):44-51. DOI: 10.20969/VSKM.2022.15(5).44-51.

References

1. Барсуков А.В., Зобнина М.П., Таланцева М.С. Гипертрофия левого желудочка и прогноз: данные пятилетнего ретроспективного наблюдения за пациентами с эссенциальной артериальной гипертензией // Артериальная гипертензия. – 2012. – Т. 18, вып. 5. – С.385-398. [Barsukov AV, Zobnina MР, Talanzeva MS. Gipertrofiya levogo zheludochka i prognoz: dannye pyatiletnego retrospektivnogo nablyudeniya za pacientami s essencial’noj arterial’noj gipertenziej [Left ventricular hypertrophy and outcomes: A five-year retrospective analysis of patients with essential hypertension]. Arterial’naya gipertenziya [Arterial Hypertension]. 2012; 5 (18): 385-398. (In Russ.)]. DOI: 10.18705/1607-419X-2012-18-5-385-397

2. Остроумова О.Д., Кочетков А.И., Лопухина М.В., Павлеева Е.Е. Гиперсимпатикотония в развитии гипертрофии миокарда левого желудочка и возможности бета-блокаторов для регресса // Российский кардиологический журнал. – 2018. – Т. 23, вып. 9. –С.77–88. [Ostroumova OD, Kochetkov AI, Lopuhina MV, Pavleeva EE. Gipersimpatikotoniya v razvitii gipertrofii miokarda levogo zheludochka i vozmozhnosti beta-blokatorov dlya regressa [High sympathetic tone in development of the left ventricle hypertrophy and beta-blockers for regression]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2018; 23 (9): 77-88. (In Russ.)]. DOI: 10.15829/1560-4071-2018-9-77-88

3. Кочетков А.И., Борисова Е.В., Остроумова О.Д., и др. Влияние фиксированной комбинации амлодипин/валсартан на гипертрофию и деформационные характеристики миокарда у пациентов среднего возраста с эссенциальной артериальной гипертонией // Рациональная Фармакотерапия в Кардиологии. – 2019. – Т. 15, вып. 3. – С.305-314. [Kochetkov AI, Borisova EV, Ostroumova OD, et al. Vliyanie fiksirovannoj kombinacii amlodipin/valsartan na gipertrofiyu i deformacionnye harakteristiki miokarda u pacientov srednego vozrasta s essencial’noj arterial’noj gipertoniej [Effect of the singlepill amlodipine/valsartan combination on hypertrophy and myocardial deformation characteristics in middle-aged patients with essential arterial hypertension]. Racional’naya Farmakoterapiya v Kardiologii [Rational Pharmacotherapy in Cardiology]. 2019; 15 (3): 305-314. (In Russ.)]. DOI: 10.20996/1819-6446-2019-15-3-305-314

4. Салахов Р.Р., Голубенко М.В., Павлюкова Е.Н., и др. Опыт молекулярно-генетической диагностики гипертрофической кардиомиопатии с использованием нанопорового секвенирования ДНК // Российский кардиологический журнал. – 2021. – Т. 26, вып. 10. – С.4673. [Salakhov RR, Golubenko MV, Pavlukova EN, et al. Opyt molekulyarno-geneticheskoj diagnostiki gipertroficheskoj kardiomiopatii s ispol’zovaniem nanoporovogo sekvenirovaniya DNK [Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2021; 26 (10): 4673. (In Russ.)]. DOI: 10.15829/1560-4071-2021-4673

5. Мирзаев К.Б., Федоринов Д.С., Иващенко Д.В., Сычев Д.А. Мультиэтнический анализ кардиологических фармакогенетических маркеров генов цитохрома Р450 и мембранных транспортеров в российской популяции // Рациональная Фармакотерапия в Кардиологии. – 2019. – Т. 15, вып. 3. – С.393-406. [Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. Mul’tietnicheskij analiz kardiologicheskih farmakogeneticheskih markerov genov citohroma R450 i membrannyh transporterov v rossijskoj populyacii [Multi-Ethnic analysis of cardiac pharmacogenetics markers of cytochrome p450 and membrane transporters genes in the Russian population]. Racional’naya Farmakoterapiya v Kardiologii [Rational Pharmacotherapy in Cardiology]. 2019; 15 (3): 393-406. (In Russ.)]. DOI: 10.20996/1819-6446-2019-15-3-393-406

6. Мулерова Т.А., Цыганкова Д.П., Чигисова А.Н., Огарков М.Ю. Роль факторов риска и генетического полиморфизма в оценке эффективности комбинированной антигипертензивной терапии в малочисленной популяции шорцев // Профилактическая медицина. – 2021. – Т. 24, вып. 2. – С.52-61. [Mulerova TA, Tsygankova DP, Chigisova AN, Ogarkov MYu. Rol’ faktorov riska i geneticheskogo polimorfizma v ocenke effektivnosti kombinirovannoj antigipertenzivnoj terapii v malochislennoj populyacii shorcev [The role of risk factors and genetic polymorphism in assessing the effectiveness of combined antihypertensive therapy in a small population of shor people]. Profilakticheskaya medicina [Preventive Medicine]. 2021; 24 (2): 52–61. (In Russ.)]. DOI: 10.17116/profmed20212402152

7. Михалина Е.В., Мулерова Т.А., Поликутина О.М., Огарков М.Ю. Особенности распространенности ишемической болезни сердца в коренной малочисленной популяции Горной Шории (результаты эпидемиологических исследований в 1998-2001 и 2013-2017 годы) // Комплексные проблемы сердечно-сосудистых заболеваний. – 2019. – Т. 8, вып. 4S. – С.15-21. [Mihalina EV, Mulerova TA, Polikutina OM, Ogarkov MYu. Osobennosti rasprostranennosti ishemicheskoj bolezni serdca v korennoj malochislennoj populyacii Gornoj Shorii (rezul’taty epidemiologicheskih issledovanij v 1998-2001 i 2013-2017 gody) [Prevalence of coronary artery disease in the indigenous population of Gornaya Shoria (the results of epidemiological studies in 1998-2001 and 2013-2017)]. Kompleksnye problemy serdechno-sosudistyh zabolevanij [Complex Issues of Cardiovascular Diseases]. 2019; 8 (4S): 15-21. (In Russ.)]. DOI: 10.17802/2306-1278-2019-8-4S-15-21

8. Остроумова О.Д., Кочетков А.И., Лопухина М.В. Сравнительный анализ эффективности фиксированных комбинаций амлодипин/лизиноприл и бисопролол/ гидрохлоротиазид у пациентов с гипертонической болезнью в сочетании с ожирением и избыточной массой тела // Рациональная фармакотерапия в кардиологии. – 2017. – Т. 13, вып. 4. – С.443-453. [Ostroumova OD, Kochetkov AI, Lopuhina MV. Sravnitel’nyj analiz effektivnosti fiksirovannyh kombinacij amlodipin/lizinopril i bisoprolol/gidrohlorotiazid u pacientov s gipertonicheskoj bolezn’yu v sochetanii s ozhireniem i izbytochnoj massoj tela [Comparative analysis of the efficacy of fixed-dose combinations of amlodipine/lisinopril and bisoprolol/ hydrochlorthiazide in patients with essential arterial hypertension combined with obesity and overweight]. Racional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2017; 13 (4): 443-453. (In Russ.)]. DOI: 10.20996/1819-6446-2017-13-4-443-453

9. Kwiecinski J, Lennen RJ, Gray GA, et al. Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy. J Cardiovasc Magn Reson. 2020; 22 (1): 57. DOI:10.1186/s12968-020-00655-7

10. Tadic M, Cuspidi C. The effect of antihypertensive therapy on left ventricular longitudinal strain: missing part of the puzzle. J Cardiovasc Transl Res. 2021; 14 (1): 125-128. DOI: 10.1007/s12265-020-09970-x

11. Кочетков А.И. Тиазидные и тиазидоподобные диуретики в лечении артериальной гипертонии: есть ли различия? // Рациональная Фармакотерапия в Кардиологии. – 2020. – Т. 16, вып. 6. – С.994-1001. [Kochetkov AI. Tiazidnye i tiazidopodobnye diuretiki v lechenii arterial’noj gipertonii: est’ li razlichiya? [Thiazide and thiazide-like diuretics in the treatment of arterial hypertension: are there any differences?]. Racional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2020; 16 (6): 994-1001. (In Russ.)].] DOI: 10.20996/1819-6446-2020-11-09

12. Недогода С.В. Диуретики при артериальной гипертензии: ангелы и демоны // Российский кардиологический журнал. – 2013. – Т. 3, вып. 101. С.62-66. [Nedogoda SV. Diuretiki pri arterial’noj gipertenzii: angely i demony [Diuretics in arterial hypertension: angels and demons]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2013; 3 (101): 62-66. (In Russ.)]. DOI: 10.15829/1560-4071-2013-3-62-66

13. Gosse P, Sheridan DJ, Dubourg O, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5mg versus enalapril 20 mg: the LIVE study. J. Hypertens. 2000; 18 (10): 1465– 1475. DOI: 10.1097/00004872-200018100-00015

14. Roush GC, Abdelfattah R, Song S, et al. Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. J Hypertens. 2018; 36 (6): 1247-1255. DOI: 10.1097/HJH.0000000000001691

15. Gallego-Delgado J, Connolly SB, Lázaro A, et al. Transcriptome of hypertension-induced left ventricular hypertrophy and its regression by antihypertensive therapies. Hypertens Res. 2009; 32 (5): 347-57. DOI: 10.1038/hr.2009.27

16. Kurland L, Melhus H, Karlsson Ju, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens. 2002; 20 (4): 657-663. DOI: 10.1097/00004872-200204000-00023

17. Моисеев В.С., Котовская Ю.В., Кабалава Ж.Д., и др. Клинико-генетические аспекты гипотензивного ответа и регрессии гипертрофии левого желудочка у больных артериальной гипертензией // Терапевтический архив. – 2002. – Т. 74, вып. 10. – С. 30-7. [Moiseev VS, Kotovskaia IuV, Kobalava ZhD, et al. Kliniko-geneticheskie aspekty gipotenzivnogo otveta i regressii gipertrofii levogo zheludochka u bol’nyh arterial’noj gipertenziej [Clinico-genetic aspects of the hypotensive response and regression of left ventricular hypertrophy in arterial hypertension patients]. Terapevticheskij arhiv [Therapeutic Arkhive]. 2002; 74 (10): 30-7. (In Russ.)].

18. He H, Li LM, Cao WH, et al. A study of the relationships between angiotensin-converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril. Ann Hum Biol. 2005; 32 (1): 30-43. DOI: 10.1080/03014460400027458

19. Каримова И.А., Елисеева М.Р., Каримова Б.Ш., и др. Антиремоделирующая активность небиволола у больных гипертонической болезнью с различными типами полиморфизма 4a/4b гена эндотелиальной NO-синтазы // Кардиология. – 2004. – Т. 44, вып. 8. – С.67-71. [Karimova IA, Eliseeva MR, Karimova BSh, et al. Antiremodeliruyushchaya aktivnost’ nebivolola u bol’nyh gipertonicheskoj bolezn’yu s razlichnymi tipami polimorfizma 4a/4b gena endotelial’noj NO-sintazy [Antiremodeling activity of Nebivolol in patients with essential hypertension and various types of 4a/4b polymorphisms of endothelial NO synthase gene]. Kardiologiya [Cardiology]. 2004; 44 (8): 67-71. (In Russ.)].

 

UDC:616.314.17-008.1+616.314-089.843

DOI:10.20969/VSKM.2022.15(5).52-57

PDF download TO THE QUESTION ABOUT EVALUATION OF THE STATE OF PERIODONTAL TISSUES IN THE AREA OF FIXED IMPLANT-SUPPORTED PROSTHESES MADE BY CAD/CAM TECHNOLOGY

NIKITINA LOUISE I., ORCID ID: 0000-0003-4893-0314, Author ID: 861704; C. Med. Sci., associate professor, the Head of the Department of Dental Diseases and New Technologies, Chuvash State University named after I.N. Ulyanov, 428015, Russia, Cheboksary, 15 Moskovsky Ave, tel.: +7-903-359-38-29, e-mail: prop.stom.zab@mail.ru

MUKHAMEDZHANOVA LYUBOV R., ORCID ID: 0000-0003-0752-6497, Author ID: 797430; D. Med. Sci., professor, professor of the Department of Dental Diseases and New Technologies, Chuvash State University named after I.N. Ulyanov, 428015, Russia, Cheboksary, 15 Moskovsky Ave, tel.: +7-927-436-81-21, e-mail: prop.stom.zab@mail.ru

EGOROV MIKHAIL A., Author ID: 1075838; C. Med. Sci., assistant professor of the Department of Dental Diseases and New Technologies, Chuvash State University named after I.N. Ulyanov, 428015, Russia, Cheboksary, 15 Moskovsky Ave, tel.: +7-927-420-62-07, e-mail: prop.stom.zab@mail.ru

GROMOVA ANNA S., ORCID ID: 0000-0002-5554-7068; psychologist, Department of Dental Diseases and New Technologies, Chuvash State University named after I.N. Ulyanov, 428015, Russia, Cheboksary, 15 Moskovsky Ave, tel.: +7-937-013-88-66, e-mail: prop.stom.zab@mail.ru

Abstract. Introduction. This article presents the results of a comparative assessment of the periodontal condition of implant-supported zirconia dioxide dental prostheses (with all-zirconia abutments). Aim. The aim of this research is to study the condition of periodontal tissues in the area of CAD-CAM technology driven implant-supported fixed dental prostheses. Material and methods. 40 patients aged from 25 to 70 years (22 men and 18 women, the main group) were examined and their prostheses were made with computer technology for modeling. Patients had zirconia dioxide crowns from three different manufacturers (Nobel Biocare, Astra Tech and Straumann) dental implants in this group. The service life of CAD/CAM implant-supported dental prostheses was 9.8±2.4 years. Two comparison groups of patients were formed. Group I: 40 patients of comparable gender and age structure with tooth-supported fixed metal-ceramic dental prostheses. The average service life of dental prostheses: 9.5±2.7 years. Comparison group II: 40 patients of similar gender and age structure with tooth-supported fixed zirconia dioxide dental prostheses. The average service life of dental prostheses: 9,6±1,8 years. Statistical analysis was carried out with application of the hypothesis of homogeneity of the values of the Green-Vermilon, Mulleman-Cowell indices and Svrakov's iodine number by groups. The hypothesis was tested with the Kruskal-Wallis test and the Wilcoxon criterion. Results and discussion. Clinical results of periodontal tissues condition showed significant differences in the hygienic state of the oral cavity (Green-Wermilion index), the severity of inflammatory phenomena (Svrakov iodine number), gingival bleeding (Mulleman-Cowell index), the expression of the stippling phenomenon in patients using zirconia dioxide dental prostheses with both implant- and tooth-supported. Longterm restoration of the prostheses and their aesthetic appearance were observed in the study. The gingival parts of the zirconia dioxide ceramic prostheses were completely satisfactory for the patients and caused no medical complications during the entire period of use. Conclusion. The values of the periodontal condition indicators were the best in the groups of patients using implant-supported and tooth-supported zirconia dioxide prostheses, as evidenced by the values of the Green-Wermillon, Mulleman-Cowell and Svrakov iodine indixes, which differed significantly from similar parameters in the group of patients using tooth-supported metal-ceramic prostheses.

Keywords: prosthetics, dental implants, implant abutments, metal-ceramic crowns, zirconia dioxide crowns, computer modeling, CAD/CAM system.

For reference: Nikitina LI, Mukchamedzhanova LR, Egorov MA, Gromova AS. To the question about evaluation of the state of periodontal tissues in the area of fixed implant-supported prostheses made by cad/cam technology. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):52-57. DOI: 10/20969/VSKM.2022.15(5).52-57.

References

1. Черевко Н. М. Оценка титановых имплантатов с шейкой из оксида циркония in vivo // Проблемы стоматологии. − 2007. − No2. − С. 72. [Cherevko NM. Ocenka titanovyh implantatov s shejkoj iz oksida cirkonija in vivo [Evaluation of titanium implants with a neck of zirconium oxide in vivo]. Problemy stomatologii [Problems of Dentistry]. 2007; 2: 72. (In Russ.)].

2. Вольф Г.Ф., Ратейцхак Э.М., Ратейцхак К.Х. Пародонтология: цветной атлас: пособие: руководство; пер. с нем.: О. Н. Лукинская; под ред. Г. М. Барера. Москва: МЕДпресс-информ, 2014. – 548 с. [Vol’f GF, Ratejchak JeM, Ratejchak KH. Parodontologiya: cvetnoj atlas: posobie: rukovodstvo; per. s nem.: O. N. Lukinskaya; pod red. G. M. Barera. [Periodontology: сolour atlas: handbook; transl. from German: O. N. Lukinskaya; ed. by G. M. Barer]. Moskva: MEDpress-inform [Moskow: MEDpress-inform]. 2014; 548 p. (In Russ.)].

3. Никитина Л.И. Дентальная имплантация при первичной адентии: оценка состояния регионарного кровотока // Современная стоматология: сборник научных трудов, посвященный 125-летию основателя кафедры ортопедической стоматологии КГМУ профессора Исаака Михайловича Оксмана. – Казань: Изд-во КГМУ, 2017. – С. 312–323. [Nikitina LI. Dental’naja implantacija pri pervichnoj adentii: ocenka sostojanija regionarnogo krovotoka [Dental implantation in primary adentia: assessment of regional blood flow]. Sovremennaja stomatologija: sbornik nauchnyh trudov, posvjashhennyj 125-letiju osnovatelja kafedry ortopedicheskoj stomatologii KGMU professora Isaaka Mihajlovicha Oksmana [Modern dentistry. A collection of scientific works dedicated to the 125th anniversary of the founder of the Department of Prosthodontics of KSMU, Professor Isaac Mikhailovich Oxman.]. Kazan’: Izd-vo KGMU [Kazan: KGMU Publ.]. 2017; 312–323. (In Russ.)].

4. Никольский В.Д., Журули Г.Н., Цаликова Н.А. Выбор конструкции протезов при протезировании на зубных имплантатах при полной адентии // Стоматология для всех. – 2015. – No4. – С. 48-52. [Nikol’skij VD, Zhuruli GN, Calikova NA. Vybor konstrukcii protezov pri protezirovanii na zubnyh implantatah pri polnoj adentii [Choice of implant-supported dentures design with full adentia]. Stomatologija dlja vseh [Dentistry for all]. 2015; 4: 48–52. (In Russ.)].

5. Barone A, Marconcini S, Giammarinaro E, et al. Clinical outcomes of implants placed in extraction sockets and immediately restored: a 7-year single-cohort prospective study. Clinical Implant Dentistry and Related Research. 2016; 18 (6): 1103–1112. DOI: 10.1111/cid.12393

6. Параскевич В.Л. Дентальная имплантология. Основы теории и практики. Минск: ООО «Юнипресс», 2002. – 368 с. [Paraskevich VL. Dental’naja implantologija. Osnovy teorii i praktiki [Dental implantology. The foundations of the theory and practice]. Minsk: OOO «Junipress» [Minsk: OOO «Junipress»]. 2002. 368 p. (In Russ.)].

7. Дыгов Э.А. Клиническая характеристика состояния тканей пародонта в области дентальных имплантатов после протезирования несъемными металлокерамическими конструкциями // Современные проблемы науки и образования. – 2016. – No 2. – С. 57–61 [Dygov EA. Klinicheskaya harakteristika sostoyaniya tkanej parodonta v oblasti dental’nyh implantatov posle protezirovaniya nes”emnymi metallokeramicheskimi konstrukciyami [Clinical characteristics of periodontal tissues in the area of dental implants after fixed metal-ceramic restorations]. Sovremennye problemy nauki i obrazovaniya [Contemporary issues in science and education]. 2016; 2: 57–61. (In Russ.)]. https://www.science-education.ru/pdf/2016/2/24164.pdf

8. Никитина Л.И. Использование дентальных имплантатов пациентам с первичной адентией // Актуальные вопросы стоматологии детского возраста: сб. науч. статей III Всерос. науч.-практ. конф. (Казань, 7 февраля 2020 г.). Казань: Изд-во КГМУ, 2020. – С. 130– 133. [Nikitina LI. Ispol’zovanie dental’nyh implantatov pacientam s pervichnoj adentiej [Dental implant placement for patiants with primery adentia]. Aktual’nye voprosy stomatologii detskogo vozrasta: sb. nauch. statej III Vseros. nauch.-prakt. konf. (Kazan’, 7 fevralja 2020 g.). [A collection of scientific articles of 3rd Russ. Sci. and Pr. Conf. «Current issues of pediatric dentistry» (Kazan, February 7, 2020)]. Kazan’: Izd-vo KGMU [Kazan: KGMU Publ.]. 2020; 130–133. (In Russ.)].

9. Andersson M, Carlsson L, Persson M, Bergman B. Accuracy of machine milling and spark erosion with a CAD/ CAM system. The Journal of Prosthetic Dentistry. 1996; 76(2): 187-193. DOI: 10.1016/S0022-3913(96)90305-4

10. Buser D, Chappuis V, Belser UC, Chen S. Implant placement post extraction in esthetic single tooth sites: when immediate, when early, when late? Periodontology 2000. 2017; 73(1): 84–102. DOI: 10.1111/prd.12170

11. Загорский В.А., Робустова Т.Г. Протезирование зубов на имплантатах: руководство. – Москва: БИНОМ, 2011. – 352 с. [Zagorskij VA, Robustova TG. Protezirovanie zubov na implantatah: rukovodstvo [Dental prosthetics on implants: a guide]. Moskva: BINOM. [Moskow: BINOM]. 2011; 352 p. (In Russ.)].

12. Perez A, Valente NA, Trottet L, et al. Immediate implants in the esthetic area: Our perspective and clinical guidelines. J Oral Science Rehabilitation. 2018; 4(1): 16–23.

13. Pozzi A, Tallarico M, Marchetti M, et al. Computer-guided versus free-hand placement of immediately loaded dental implants: 1-year post-loading results of a multicentre randomised controlled trial. Eur J Oral Implantol. 2014; 7(3): 229–242.

14. Pozzi A, Mura P. Immediate Loading of Conical Connection Implants: Up-to-2-Year Retrospective Clinical and Radiologic Study. Int J Oral Maxillofac Implants. 2016; 31(1): 142–152. DOI: 10.11607/jomi.4061

15. Уникальная технология Procera от компании Nobel Biocare // Онлайн-журнал «Ваш Стоматолог». [Unikal’naya tekhnologiya Procera ot kompanii Nobel Biocare [Unique Procera technology from Nobel Biocare]. Online-zhurnal «Vash stomatolog» [Online journal «Your Dentist»] (In Russ.)]. http://www.vash-dentist.ru/ protezirovanie/nesemnyie-p/tehnologiya-procera.html

 

UDC: 616.728.3

DOI: 10.20969/VSKM.2022.15(5).58-65

PDF download ASSESSING OF PROPRIOCEPTIVE FUNCTION IN PATIENTS AFTER THE ANTERIOR CRUCIATE LIGAMENT REPAIR

ROMANOV DMITRIY A., ORCID ID: 0000-0002-5366-3735; Postgraduate Student of the Department of Trauma, Orthopedics and Disaster Surgery, First Moscow State Medical University named after I.M. Sechenov, Trubeckaya st., 8, building 2, Moscow, 119991, Russia, e-mail: Dr.romanov67@mail.ru

GARKAVI ANDREY V., ORCID ID: 0000-0003-4996-1657; Dr. Med. Sci., Prof. of the Department of Trauma, Orthopedics and Disaster Surgery, First Moscow State Medical University named after I.M. Sechenov, Trubeckaya st., 8, building 2, Moscow, 119991, Russia, e-mail: Avgar22@yandex.ru

DROGIN ANDREY R., ORCID ID: 0000-0003-4395-9425; C. Med. Sci., Associate Professor of the Department of Trauma, Orthopedics and Disaster Surgery, First Moscow State Medical University named after I.M. Sechenov, Trubeckaya st., 8, building 2, Moscow, 119991, Russia, e-mail: A.drogin@yandex.ru

SHISHOVA ANASTASIYA A., ORCID ID: 0000-0001-8520-2346; C. Med. Sci., Assistant Professor of the Department of Trauma, Orthopedics and Disaster Surgery, First Moscow State Medical University named after I.M. Sechenov, Trubeckaya st., 8, building 2, Moscow, 119991, Russia, e-mail n_a_s_t_y_a_@list.ru

KNELLER LEV O., ORCID ID: 0000-0003-4375-7495; C. Med. Sci., Trauma and orthopedic surgeon, State-funded health institution of the city of Moscow City clinical hospital No. 67 (named after L.A. Vorokhobov), Moscow, 123423, Russia, Salama Adilya st., 2/44, e-mail: Okneller90@gmail.com

MOLCHANOV IVAN S., ORCID ID: 0000-0002-8263-0617; physical therapy doctor, Clinic “K+31”, Moscow, 119415, Russia, Lobachevskogo st., 42, building 4, e-mail: Vanjamol@yahoo.com

Abstract. Introduction. Recently, interest has been revived in the primary repair of the anterior cruciate ligament, which is largely due to the potential possibility of preserving its proprioceptive function. Aim. The aim of the study was to evaluate the proprioceptive function of the knee joint in patients who underwent anterior cruciate ligament repair with additional augmentation and to compare the results with similar parameters in patients who underwent anterior cruciate ligament reconstruction using semitendinosus muscle tendon. Material and methods. 40 patients were evaluated, who were divided into two groups: in group 1 (n=20), due to damage to the anterior cruciate ligament, its repair with additional augmentation was performed; in group 2 (n=20), anterior cruciate ligament reconstruction using tendon of the semitendinosus muscle was performed. Proprioceptive function was tested no earlier than 12 months after surgery using the method of active reproduction of passive positioning and the force sense reproduction method. In addition, the functional state of the treated knee joint was compared using the Knee and Osteoarthritis Outcome Score and International Knee Documentation Committee questionnaire scales. The significance of differences between the study groups was assessed using the Mann-Whitney U-test (differences were considered statistically significant at p ≤ 0.05). Results and discussions. Despite the similar functional outcomes on the questionnaire scales (p>0.05), the patients of group 1 achieved statistically significant better results of the proprioception coefficient for all the methods used in comparison with group 2 (p<0.05). In addition, a comparative assessment of the treated and contralateral healthy joint within the groups showed similar data in group 1 patients (p>0.05) and statistically significant differences in group 2 (p<0.05) also for all methods used. Conclusion. The study demonstrated that the proprioception of the knee joint after anterior cruciate ligament repair is almost identical to that in the contralateral healthy joint and is significantly better than after anterior cruciate ligament reconstruction with a semitendinosus muscle tendon.

Keywords: proprioception, anterior cruciate ligament, repair, knee joint.

For reference: Romanov DA, Garkavi AV, Drogin AR, Shishova AA, Kneller LO, Molchanov IS. Assessing of proprioceptive function in patients after the anterior cruciate ligament repair // The Bulletin of Contemporary Clinical Medicine. 2022.15(5):58-65. DOI:10.20969/VSKM.2022.15(5).58-65.

References

1. Banios K, Raoulis V, Fyllos A, et al. Anterior and Posterior Cruciate Ligaments Mechanoreceptors: A Review of Basic Science. Diagnostics (Basel). 2022; 12 (2): 331. DOI: 10.3390/diagnostics12020331

2. Cabuk H, Kuşku Çabuk F. Mechanoreceptors of the ligaments and tendons around the knee. Clinical Anatomy. 2016; 29 (6): 789-795. DOI: 10.1002/ca.22743

3. Лисицын М.П. Артроскопическая реконструкция повреждений передней крестообразной связки коленного сустава с использованием компьютерной навигации и перспективы ее морфо-функционального восстановления: специальность 14.01.15 «Травматология и ортопедия»: диссертация на соискание ученой степени доктора медицинских наук / Лисицын Михаил Петрович; Московский государственный медико-стоматологический университет им. А. И. Евдокимова. – Москва, 2012. – 238 с. [Lisitsyn MP. Artroskopicheskaya rekonstrukciya povrezhdenij perednej krestoobraznoj svyazki kolennogo sustava s ispol’zovaniem komp’yuternoj navigacii i perspektivy ee morfo-funkcional’nogo vosstanovleniya [Arthroscopic reconstruction of injuries of the anterior cruciate ligament of the knee joint using computer navigation and the prospects for its morphofunctional restoration] : special’nost’ [speciality] 14.01.15 «Travmatologiya i ortopediya» [Traumatology and Orthopedics]: dissertaciya na soiskanie uchenoj stepeni doktora medicinskih nauk [Dissertation for the degree of doctor of medical sciences] / Lisicyn Mihail Petrovich; Moskovskij gosudarstvennyj mediko-stomatologicheskij universitet im. A. I. Evdokimova [Moscow State University of Medicine and Dentistry named after A. I. Evdokimov]. - Moskva [Moscow], 2012. - 239 p. (in Russ.)].

4. Dhillon MS, Bali K, Prabhakar S. Proprioception in anterior cruciate ligament deficient knees and its relevance in anterior cruciate ligament reconstruction. Indian J Orthop. 2011; 45 (4): 294-300. DOI: 10.4103/0019-5413.80320

5. Fleming JD, Ritzmann R, Centner C. Effect of an Anterior Cruciate Ligament Rupture on Knee Proprioception Within 2 Years After Conservative and Operative Treatment: A Systematic Review with Meta-Analysis. Sports Medicine. 2021: 1-12. DOI: 10.1007/s40279-021-01600-z

6. Kim HJ, Lee JH, Lee DH. Proprioception in patients with anterior cruciate ligament tears: a meta-analysis comparing injured and uninjured limbs. The American journal of sports medicine. 2017; 45 (12): 2916-2922. DOI: 10.1177/0363546516682231

7. Rahbari A, Rahimi A, Kalantari KK, Baghban AA. Changes of Knee Proprioception in Athletes With an Isolated Unilateral Complete Anterior Cruciate Ligament Rupture in a Six-Month Follow-up. Crescent Journal of Medical and Biological Sciences. 2021; 8 (4): 303-308. https://www.cjmb.org/uploads/pdf/pdf_CJMB_539.pdf

8. Relph N, Herrington L, Tyson S. The effects of ACL injury on knee proprioception: a meta-analysis. Physiotherapy. 2014; 100 (3): 187-95. DOI: 10.1016/j.physio.2013.11.002 (б. д.)

9. Gee MSM, Peterson CDR, Zhou ML, Bottoni CR. Anterior Cruciate Ligament Repair: Historical Perspective, Indications, Techniques, and Outcomes. J Am Acad Orthop Surg. 2020; 28 (23): 963-971. DOI: 10.5435/JAAOS-D-20-00077

10. Houck DA, Kraeutler MJ, Belk JW, et al. Primary Arthroscopic Repair of the Anterior Cruciate Ligament: A Systematic Review of Clinical Outcomes. Arthroscopy. 2019; 35 (12): 3318-3327. DOI: 10.1016/j.arthro.2019.06.034

11. Mahapatra P, Horriat S, Anand BS. Anterior cruciate ligament repair - past, present and future. J Exp Orthop. 2018; 5 (1): 20. DOI: 10.1186/s40634-018-0136-6

12. van der List JP, DiFelice GS. Primary repair of the anterior cruciate ligament: A paradigm shift. Surgeon. 2017; 15 (3): 161-168. DOI: 10.1016/j.surge.2016.09.006

13. Li B, Wang YT, Bai LH, Wen Y. Changes of mechanoreceptors in different-state remnants of ruptured anterior cruciate ligament. Int Orthop. 2018; 42 (11): 2613-2618. DOI: 10.1007/s00264-018-3933-8

14. Kosy JD, Mandalia VI. Anterior Cruciate Ligament Mechanoreceptors and their Potential Importance in Remnant-Preserving Reconstruction: A Review of Basic Science and Clinical Findings. J Knee Surg. 2018; 31 (8): 736-746. DOI: 10.1055/s-0037-1608941

15. Rebmann D, Mayr HO, Schmal H, et al. Immunohistochemical analysis of sensory corpuscles in human transplants of the anterior cruciate ligament. J Orthop Surg Res. 2020; 15 (1): 270. DOI: 10.1186/s13018-020-01785-5

16. Sha L, Xie G, Zhao S, Zhao J. A morphologic and quantitative comparison of mechanoreceptors in the tibial remnants of the ruptured human anterior cruciate ligament. Medicine (Baltimore). 2017; 96 (5): e6081. DOI:10.1097/MD.0000000000006081

17. Busch A, Blasimann A, Mayer F, Baur H. Alterations in sensorimotor function after ACL reconstruction during active joint position sense testing. A systematic review. PLoS One. 2021; 16(6): e0253503. DOI: 10.1371/journal.pone.0253503

18. Relph N, Herrington L. Knee joint position sense ability in elite athletes who have returned to international level play following ACL reconstruction: A cross-sectional study. Knee. 2016; 23 (6): 1029-1034. DOI: 10.1016/j.knee.2016.09.005

19. Angoules AG, Mavrogenis AF, Dimitriou R, et al. Knee proprioception following ACL reconstruction; a prospective trial comparing hamstrings with bone-patellar tendon-bone autograft. Knee. 2011; 18 (2): 76-82. DOI:10.1016/j.knee.2010.01.009

20. San Martín-Mohr C, Cristi-Sánchez I, Pincheira PA, et al. Knee sensorimotor control following anterior cruciate ligament reconstruction: A comparison between reconstruction techniques. PLoS One. 2018; 13 (11): e0205658. DOI: 10.1371/journal.pone.0205658

21. Li L, Ji ZQ, Li YX, Liu WT. Correlation study of knee joint proprioception test results using common test methods. J Phys Ther Sci. 2016; 28 (2): 478-82. DOI: 10.1589/jpts.28.478

22. Assimakopoulos AP, Katonis PG, Agapitos MV, Exarchou EI. The innervation of the human meniscus. Clin Orthop Relat Res. 1992; 275: 232-236.

23. Jerosch J, Prymka M. Proprioception and joint stability. Knee Surg Sports Traumatol Arthrosc. 1996; 4 (3): 171-179. DOI: 10.1007/BF01577413

 

UDC: 616.12-008.46-036.12:616.155.194.8-08

DOI: 10.20969/VSKM.2022.15(5).66-72

PDF download EFFECTIVENESS OF INTRAVENOUS ADMINISTRATION OF IRON (III) SUCROSE COMPLEX HYDROXIDE IN PATIENTS WITH CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION AND IRON DEFFICIENCY

ISMIRNOVA MARINA P., ORCID ID: 0000-0002-8988-998X, Scopus Author ID 55557722500, WOS Researcher ID CAG-1510-2022, RSCI Author ID 966593, C. Med. Sci., Associate Professor of Department of Internal Medicine of Yaroslavl State Medical University, Revolyutsionnaya St., 5, Yaroslavl, 150000, Russia, phone 8-910-975-48-72, e-mail: msm76-743@yandex.ru

CHIZHOV PETR A., ORCID ID 0000-0001-7969-6538, Scopus Author ID 57225743248, WOS Researcher ID ABD-2317-2021, RSCI Author ID 474084, D. Med. Sci., Professor, Head of the Department of Internal Medicine of Yaroslavl State Medical University, Revolyutsionnaya St., 5, Yaroslavl, 150000, Russia, e-mail: p.chizhov63@gmail.com

BARANOV ANDREY A., ORCID ID 0000-0001-7847-1679, Scopus Author ID: 7201565006, WOS Researcher ID CAG-3815-2022, RSCI Author ID 701166, D. Med. Sci., Professor, Head of the Department of Outpatient Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry of Yaroslavl State Medical University, Revolyutsionnaya St., 5, Yaroslavl, 150000, Russia, e-mail: bara_aa@mail.ru

Abstract. Introduction. Iron deficiency is diagnosed in 59% of patients with chronic heart failure with preserved ejection fraction. The efficacy of iron therapy in these patients has not been studied. Aim. The purpose of the study is to study the effectiveness of intravenous administration of iron (III) hydroxide sucrose complex in patients with chronic heart failure with preserved ejection fraction and iron deficiency. Material and methods. A study was conducted on 55 patients with ischemic heart disease and/or hypertension complicated by chronic heart failure with preserved ejection fraction with iron deficiency (14 men and 41 women), mean age 71.88±6.90 years. Patients of the main group (30 people) in addition to traditional therapy received iron (III) hydroxide-sucrose complex, patients of the control group (25 people) received only traditional therapy. In all patients, functional activity, the severity of clinical manifestations, asthenia, anxiety, depression, quality of life were assessed, echocardioscopy, complete blood count, and iron metabolism were determined. All examinations in the main and control groups were performed before the start of the study, after 2 weeks of therapy, 2 and 6 months after the end of treatment. Statistical analysis of the results at different observation times was performed using Stata/MP version 14.0 and MedCalc Statistical Software version 18.2.1. Results and discussion.The inclusion of iron (III) hydroxide sucrose complex in the complex therapy of iron-deficient patients with chronic heart failure with preserved ejection fraction increases the level of iron, ferritin, hemoglobin and transferrin iron saturation and reduces clinical manifestations of heart failure, severity of asthenia, anxiety, depression and increases physical performance and quality of life. The positive effect of the iron preparation appears by the end of the course of treatment, reaches a maximum after 2 months and lasts for 6 months. Conclusion. To increase the effectiveness of the treatment of patients with chronic heart failure with preserved ejection fraction and iron deficiency, it is recommended to conduct complex therapy, including, in addition to traditional treatment the administration of iron (III) sucrose hydroxide complex.

Keywords: heart failure with preserved ejection fraction, iron deficiency, iron (III) hydroxide sucrose complex.

For reference: Smirnova MP, Chizhov PA, Baranov AA. / Effectiveness of intravenous administration of iron (III) sucrose complex hydroxide in patients with chronic heart failure with preserved ejection fraction and iron deficiency. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):66-72. DOI: 10.20969/VSKM.2022.15(5).66-72.

References

1. Beattie JM, Khatib R, Phillips CJ, Williams SJ. Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study. Open Heart. 2020 Mar 11; 7(1): e001153. DOI: 10.1136/openhrt-2019-001153

2. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure Current Concepts and Emerging Therapies. Circulation. 2018; 138: 80–98. DOI: 10.1161/CIRCULATIONAHA.118.030099

3. Beale AL, Warren JL, Roberts N et al. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart. 2019; 6: e001012. DOI: 10.1136/openhrt-2019-001012

4. von Haeling S, Ebner N, Everts R et al. Iron deficiency in heart failure. JACC:Heart Failure. 2019; 7(1):36-46. DOI: 10.1016/j.jchf.2018.07.015

5. Anker DS, Comin-Colet J, Filippatos G et al. Rationale and design of ferinject assessment in patients with iron deficiency and chronic heart failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anemia. Eur J Heart Fail. 2009; 11: 1084-1091. DOI:10.1093/eurjhf/hfp140

6. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal. 2015; 36(11):657–668. DOI: 10.1093 / eurheartj / ehu385

7. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. - 2021; 42: 3599-3726. DOI: 10.1093/eurheartj/ehab368

8. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. -2020. - №25(11). - C. 311-374. [Chronicheskaya serdechnaya nedostatochnost’. Klinicheskie rekomendacii 2020 [Chronic heart failure. Clinical guidelines 2020]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2020; 25(11):311-374. (in Russ.)]. DOI: 10.15829/1560-4071-2020-4083

9. van Veldhuisen DJ, Ponikowski P, van der Meer P et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation.2017;136:1374–1383. DOI: 10.1161/CIRCULATIONAHA.117.0 27497

10. Edwards GC, Amaral N, Sleigh A et al. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency FERRIC-HF II Randomized Mechanistic Trial. Circulation.2019; 139: 2386–2398. DOI: 10.1161/CIRCULATIONAHA.118.038516

11. Ponikowski P, Kirwan B-A, Anker SD et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. LANCET. 2020; 396(10266):1895-1904. DOI: org/10.1016/S0140-6736(20)32339-4

12. Rizzo C, Carbonara R, Ruggieri R et al. Iron deficiency: a new target for patients with heart failure. Front. Cardiovasc. Med.2021;.8:709872. DOI: 10.3389/fcvm.2021.709872

13. Hoes MF, Grote BN, Kijlstra JD et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail.2018;.20: 910-919. DOI: 10.1002 / ejhf.1154

 

UDC: 616.13-004.6

DOI: 10.20969/VSKM.2022.15(5).73-80

PDF download COMPUTER SIMULATION OF ATHEROSCLEROTIC PROCESS INFLUENCE IN THE INTERNAL CAROTID ARTERY ON THE HEMODYNAMICS OF BRACHIOCEPHAL ARTERIES AND THE CIRCLE OF WILLISIAN

TSVETKOVA NADEZHDA V., ORCID ID: Resident Physician, Department of Radiation Diagnostics and Medical Imaging, V.A. Almazov National Medical Research Center, Assistant Professor of the Department of Fundamental Medicine and Biochemistry, Pskov State University, Russia, 180007, Pskov, Krasnoarmeyskaya st., 1, tel.: +7-911-396-04-69, e-mail: nadya.cvetkova@mail.ru

SLUCHANKO EVGENIA I., ORCID ID: Dr. Med. Sci., Professor, Head of the Department of Fundamental Medicine and Biochemistry, Pskov State University, 1 Krasnoarmeyskaya st., Pskov, 180007, Russia, tel.: +7-911-629-60-37, e-mail: evgenija-sluchanko@rambler.ru

Abstract. Introduction. The wide prevalence of atherosclerosis, as the main cause of the pathology of the cardiovascular system, determines its medical and social significance. Currently, the diagnosis of atherosclerosis is carried out by Doppler ultrasound and radiopaque CT-angiography. However, the most promising direction in the diagnosis of atherosclerosis is the creation and implementation in clinical practice of simulation computer models of the atherosclerotic process. Aim.The aim is to develop a simulation computer model of brachiocephalic arteries with the circle of Willis in normal conditions and with atherosclerotic changes in the vascular wall for the diagnosis and early prediction of the development of vascular complications. Material and methods. Data of X-ray contrast CT angiography of brachiocephalic arteries and ultrasound Dopplerography of neck vessels 4 patients with varying degrees of stenosis were used in the work. A computer model of the atherosclerotic process in the brachiocephalic arteries and arteries of the circle of Willis was built in the Comsol Multiphysics program using the finite element method to calculate the quantitative characteristics of blood. A mathematical model has been developed for the movement of fluids in blood vessel (Navier-Stokes equation, continuity equation, equilibrium equation). Results and discussion. Based on the developed simulation model of the atherosclerotic process, an application focused on medical workers has been created. The functionality of this application allows the user to adjust the geometry parameters (size, number and location of atherosclerotic plaques in the vessels) and the blood flow rate in accordance with the requirements of the study. With this application, the user can create a personalized model for the study of patients with cardiovascular pathology. Conclusion. The created computer model of brachiocephalic arteries with the circle of Willis and the application developed on its basis can be used in clinical practice as an additional in support of other imaging methods method for diagnosing atherosclerosis and early prediction of its complications, as well as for studying the pathogenetic role of the atherosclerotic process in patients with cardiovascular pathology.

Key words: Computer simulation, atherosclerosis, circle of Willis, atherosclerotic plaques, brachiocephalic arteries.

For reference: Tsvetkova NV, Sluchanko EI. Сomputer simulation of atherosclerotic process influence in the internal carotid artery on the hemodynamics of brachiocephal arteries and the circle of willisian. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):73-80. DOI: 10.20969/VSKM.2022.15(5).73-80.

References

1. Окороков А.Н. Лечение болезней внутренних органов. Лечение болезней сердца и сосудов. Лечение болезней системы крови // Москва: Медицинская литература, 2021. — Т.3, Кн.1. - 474 c. [Okorokov AN. Lechenie boleznej vnutrennih organov. Lechenie boleznej serdca i sosudov. Lechenie boleznej sistemy krovi [Treatment of diseases of internal organs. Treatment of diseases of the heart and blood vessels. Treatment of diseases of the blood system]. Moskva: Medicinskaya literature [Moscow: Medical Literature]. 2021; 3(1): 474р. (In Russ.)] https//znanium.com/catalog/product/1360835.pdf

2. Дроздов А.А., Дроздова М.В. Болезни сердца и сосудов: полный справочник // Саратов: Научная книга, 2019. — 668 c. [Drozdov AA, Drozdova MV. Bolezni serdca i sosudov: рolnyj spravochnik [Diseases of the heart and blood vessels: сomplete reference book]. Saratov: Nauchnaya kniga [Saratov: Scientific book]. 2019; 668 р. (In Russ.)]. https//profspo.ru/books/80194

3. Уайт П.Д. Ключи к диагностике и лечению болезней сердца: монография // Москва: Медицинская литература, 2021. — 191 c. [Uajt PD. Klyuchi k diagnostike i lecheniyu boleznej serdca monografiya [Keys to the diagnosis and treatment of heart disease: monograph]. Moskva: Medicinskaya literatura [Moscow: Medical Literature]. 2021; 191 р. (In Russ.)]. URL:https://znanium.com/catalog/product/1360843

4. Верещагин Н.В., Моргунов В.А., Гулевская Е.С. Патология головного мозга при атеросклерозе и артериальной гипертонии: монография // Москва: Медицина, 1997. - 287 с. [Vereshchagin NV, Morgunov VA, Gulevskay TS. Patologiya golovnogo mozga pri ateroskleroze i arterial’noj gipertonii: monografiya [Pathology of the brain in atherosclerosis and arterial hypertension: monograph]. Moskva: Medicina [Moscow: Medicine]. 1997; 287 р. (In Russ.)]. https://bookree.org/reader?file=562450

5. Белов Ю.В., Комаров Р.Н. Тактика хирургического лечения мультифокальных стенотических поражений артериальных бассейнов // Хирургия. Журнал им. Н.И. Пирогова. — 2007. — No3. — С. 60 64. [Belov YuV, Komarov RN. Taktika hirurgicheskogo lecheniya mul’tifokal’nyh stenoticheskih porazhenij arterial’nyh bassejnov [Tactics of surgical treatment of multifocal stenotic lesions of arterial basins] Hirurgiya. Zhurnal im. Pirogova NI [Surgery. Journal them Pirogov NI]. 2007; (3); 60 64 р. (In Russ.)]. https://www.elibrary.ru/item.asp?id=13285761

6. Акопов А. С. Имитационное моделирование: учебник и практикум для вузов // Москва: Юрайт, 2020. — 389 с. [Akopov AS. Imitacionnoe modelirovanie: uchebnik i praktikum dlya vuzov [Simulation modeling: textbook and workshop for universities]. Moskva: Yurajt [Moscow: Yurayt]. 2020; 389 р. (In Russ.)]. http://simulation.su/uploads/files/default/2014-uch-prakt-akopov.pdf

7. Скобцов Ю.А., Родин Ю.В., Оверко В.С. Моделирование и визуализация поведения потоков крови при патологических процессах // Донецк: Издатель Заславский А.Ю., 2008. - 212 c. [Skobcov YuA, Rodin YuV, Overko VS. Modelirovanie i vizualizaciya povedeniya potokov krovi pri patologicheskih processah [Modeling and visualization of the behavior of blood flows in pathological processes]. Doneck: Izdatel’ Zaslavskij AYu [Donetsk: Publisher Zaslavskiy AYu]. 2008; 212 р. (In Russ.)]. http://www.mif-ua.com/media/uploads/reading_book_full_texts/skobtsov.pdf

8. Бегун П.И., Афонин П.Н. Моделирование в биомеханике: учебное пособие // Москва: Высш. шк., 2004. — 390 с. [Begun PI, Afonin PN. Modelirovanie v biomekhanike: uchebnoe posobie [Modeling in Biomechanics: Tutorial]. Moskva: Vyssh. shk. [Moscow: Graduate School]. 2004; 390 р. (In Russ.)].

9. Djordjevic Vladan D. On the fluid flow over a compliant wall. Facta Univ. Ser. Mech., Autom. Contr. and Rob. Univ. Nis. 2000; 2, (10): 1219-1232. http://facta.junis.ni.ac.rs/macar/macar2000/macar2000-17.pdf

10. Cassot F. Hemodynamic role of the circle of Willis in stenoses of internal carotid arteries. An analytical solution of a linear model. Journal of biomechanics.1999; 6:395-405. https://pubmed.ncbi.nlm.nih.gov/10768388

11. Белоцерквская М.А., Родин Ю.В., Михайличенко В.Ю., и др. Моделирования кровотока в сонной артерии в области атеросклеротической бляшки в двумерной и трёхмерной постановке // Таврический медико-биологический вестник - 2014. - No 2. - С. 13 - 16. [Belocerkvskaya MA, Rodin YuV, Mihajlichenko VYu, et nl. Modelirovaniya krovotoka v sonnoj arterii v oblasti ateroskleroticheskoj blyashki v dvumernoj i tryohmernoj postanovke [Modeling of blood flow in the carotid artery in the area of atherosclerotic plaque in two and three dimensions]. Tavricheskij mediko-biologicheskij vestnik [Tauride Medical and Biological Bulletin]. 2014: 2 (66): 13 - 16. (In Russ.)]. https://www.elibrary.ru/download/elibrary2283354932119271.pdf

12. Педли Т. Гидродинамика крупных кровеносных сосудов: монография // Москва: Мир, 1983. - 400 с. [Pedli T. Gidrodinamika krupnyh krovenosnyh sosudov: monografiya [Hydrodynamics of large blood vessels: monograph]. Moskva: Mir [Moscow: World]. 1983; 400 р. (In Russ.)]. https://bookree.org/reader?file=469538

13. Zabielski L. Unsteady blood flow in a helically symmetric pipe. Journal of Fluid Mechanics Cambridge University Press. 1998; 370: 297-320. DOI: 10.1017/S0022112098001992

14. Борисюк А.О. Экспериментальное исследование пристенного давления в трубе за стенозом // Акустический вестник. — 2003. — No5. - С.19-26. [Borisyuk AO. Eksperimental’noe issledovanie pristennogo davleniya v trube za stenozom [Experimental study of near-wall pressure in a pipe behind a stenosis]. Akusticheskij vestnik [Acoustic messenger]. 2003; 5: 19-26. (In Russ.)]. http://hydromech.org.ua/content/ru/av/05-1_13-21.html

15. Taylor CA, Hughes TJR, Zarins CR. Finite Element Modeling of Blood Flow in Arteries. Comput. Methods Appl. Mech. Engrg. 1998; 158: 155-196. DOI: 10.1016/S0045-7825(98)80008-X

 

UDC: 616.717.8-002.42

DOI:10.20969/VSKM.2022.15(5).81-85

PDF download MSCT OF OSTEOMYELITIS OF THE UPPER JAW IN PATIENTS WHO HAD COVID-19

YUNUSOVA LALITA R., ORCID ID: 0000-0002-7807-9463, PhD, Associate Professor of the Department of Oncology and Medical Radiology, Tashkent State Dental Institute, Uzbekistan, 100047, Tashkent, Yashnabad district, 103 Taraqqiyot Street, tel. +99-871-2302073, e-mail: lolita_yunusova@mail.com

IKRAMOV GAYRAT O., ORCID ID: 0000-0002-5772-8938, Candidate of Medical Sciences, Associate Professor of the Department of Pediatric Maxillofacial Surgery, Tashkent State Dental Institute, Uzbekistan, 100047, Tashkent, Yashnabad district, 103 Taraqqiyot Street, tel. +99-871-2302073, e-mail: gayrat_ikromov@mail.com

KHALMANOV BAHODIR A., ORCID ID: 0000-0003-4282-7308, Candidate of Medical Sciences, Associate Professor of the Department of Implantology, Tashkent State Dental Institute, Uzbekistan, 100047, Tashkent, Yashnabad district, 103 Taraqqiyot Street, tel. +99-871-2302073, e-mail: bakhodir_kholmanov@mail.com

SUVONOV KAIM J., ORCID ID: 0000-0001-6849-1326, Doctor of Medical Sciences, Associate Professor of the Department of Implantology, Tashkent State Dental Institute, Uzbekistan, 100047, Tashkent, Yashnabad district, 103 Taraqqiyot Street, tel. +99-871-2302073, e-mail: kayim_suvonov@mail.com

Abstract. Introduction. COVID-19 is widely known as a disease that causes respiratory dysfunction, however, it is also associated with a mass of extrapulmonary manifestations and complications, gastrointestinal, hepatocellular complications, neurological diseases, as well as complications in the maxillofacial region. Aim. The aim of this study was to diagnose osteomyelitis of the upper jaw in post COVID-19 patients using multispiral computed tomography. Material and methods. We retrospectively evaluated radiation imaging and clinical data of 37 patients, aged 28 to 52 years with osteomyelitis of the upper jaw, who underwent COVID-19. The male sex prevailed among the patients. Results and discussion. All patients had sinusitis and ophthalmic symptoms. The pattern of anatomical lesions of the upper jaw, nasal cavity, maxillary sinus, orbit, and lattice cells was consistently observed in all patients. Conclusion. Progressive and rapid course, involvement of the cavernous sinus, vascular structures, and further upward spread (intracranial) complications may be the usual evolution of rhinophthalmocerebral mucormycosis. Multiplanar tomographic imaging shows the localization, nature, as well as relationship of the surrounding structures, helping in turn to plan the operation. However, the prognosis remains difficult, despite radical surgery and, in particular, antifungal treatment.

Keywords: COVID-19, MSCT, osteomyelitis, upper jaw, mucormycosis.

For reference: Yunusova LT, Ikramov GO, Khalmanov BA, Suvonov KJ. MSCT of osteomyelitis of the upper jaw in patients who had COVID-19. Bulletin of Modern Clinical Medicine. 2022.15(5):81-85. DOI: 10.20969/VSKM.2022.15(5).81-85.

References

1. Yunusova LR, Khodjibekova YuM, et al. Visualizationof complications of the middle zone of the person who underwent Covid-19. Pediatrics scientific and practical journal. 2021; 6: 25-31. DOI:10.37988/1811-153X_2022_2_94

2. Kaye AD, Cornett EM, Brondeel KC, et al. Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. Best Pract. Res. Clin.Anaesthesiol. 2020; 35: 269–292. DOI: 10.1016/j. bpa.2020.12.003

3. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review. Ann. Intern. Med. 2021;174: 655–662. DOI: 10.7326/ M20-6976

4. Raveendran AV; Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab. Syndr. 2021;15, 869–875. DOI: 10.1016/j.dsx.2021.04.007

5. Prasad KC, Prasad SC, Mouli N, Agarwal S. Osteomyelitis in the head and neck. Acta Oto-Laryngol. 2007; 127: 194– 205. DOI: 10.1080/00016480600818054

6. Leitner C, Hoffmann J, Zerfowski M, Reinert S. Mucormycosis: Necrotizing soft tissue lesion of the face. J. Oral Maxillofac. Surg. 2003, 61: 1354–1358. DOI: 10.1016/s0278-2391(03)00740-7

7. Yun S, Kim C, Kwon T-G, et al. Mucormycosis of the Maxilla: A Case Report. Korean J. Oral Maxillofac. Pathol. 2015, 39: 637–642. DOI: 10.17779/KAOMP.2015.39.5.637

8. Cordeiro PG, Disa JJ. Challenges in midface reconstruction. In Seminars in Surgical Oncology; JohnWiley & Sons, Inc.: New York, NY, USA, 2000;19: 218– 225. DOI: 10.1002/1098-2388(200010/11)19:3<218::aid-ssu3>3.0.co;2-l

9. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am. J. Emerg. Med. 2021; 42: 264.e265–264.e268. DOI: 10.1016/j.ajem.2020.09.032

10. Hingad N, Kumar G, Deshmukh R. Oral Mucormycosis Causing Necrotizing Lesion in a Diabetic Patient: A Case Report. Int. J. Oral Maxillofac. Pathol. 2012; 3: 8–13. DOI: 10.4103/jomfp.JOMFP_77_18

11. Jones AC, Bentsen TY, Freedman PD. Mucormycosis of the oral cavity. Oral Surg. Oral Med. Oral Pathol. 1993; 75: 455–460 DOI: 10.1016/0030-4220(93)90170-9

12. Ibrahim AS. Host cell invasion in mucormycosis: Role of iron. Curr. Opin. Microbiol. 2011; 14: 406–411. DOI: 10.1016/j.mib.2011.07.004

13. Li T, Zhang Y, Gong C, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur. J. Clin. Nutr. 2020; 74: 871–875. DOI: 10.1038/s41430-020-0642-3

14. Zhang S, Liu Y, Wang X, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. 2020; 13: 120. DOI: 10.1186/s13045-020-00954-7

15. Roberts J, Pritchard AL, Treweeke AT, et al. Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. Front. Cardiovasc. Med. 2020; 7: 629933. DOI: 10.3389/ fcvm.2020.629933

16. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, et al. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J. Diabetes 2015; 6: 1073–1081. DOI: 10.4239/wjd.v6.i8.1073

17. Dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, et al. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv. Rheumatol. 2020; 60: 32. DOI: 10.1186/s42358-020-00134-8

18. Azevedo MM, Teixeira-Santos R, Silva AP, et al. The effect of antibacterial and non-antibacterial compounds alone or associated with antifugals upon fungi. Front. Microbiol. 2015; 6: 669. DOI.org/10.3389/fmicb.2015.00669

 

UDC: 616.24-008.444-06:616.12-008.46

DOI: 10.20969/VSKM.2022.15(2).86-92

PDF download PROGNOSTIC VALUE OF GENETIC POLYMORPHISMS OF MATRIX METALLOPROTEINASES IN PATIENTS WITH CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA SYNDROME

YAKOVLEV ALEXEY V., ORCID ID: 0000-0002-4763-0961; C. Med. Sci., associate professor of the Department of Internal Medicine, Hematology and Transfusiology of Novosibirsk State Medical University, Russia, 630091, Novosibirsk, Red prospect, 52, e-mail: alex-yak-card@mail.ru

TEPLYAKOV ALEXANDER T., ORCID ID: 0000-0003-0721-0038; D. Med. Sci., professor, Honored Scientist of the Russian Federation, Chief Researcher of Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russia, 634012, Tomsk, Kievskaya str., 111a, e-mail: vgelen1970@gmail.ru

MAYANSKAYA SVETLANA D., ORCID ID: 0000-0001-6701-5395; D. Med. Sci., professor, Department of Advanced Internal Medicine of Kazan State Medical University, Russia, 420012, Kazan, Butlerova str., 49, e-mail: smayanskaya@mail.ru

GRAKOVA ELENA V., ORCID ID 0000-0003-4019-3735; D. Med. Sci., Leading Researcher, Department of Myocardial Pathology of Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russia, 634012, Tomsk, Kievskaya str., 111a, e-mail: gev@cardio-tomsk.ru

SHILOV SERGEY N., ORCID ID: 0000-0002-7777-6419; D. Med. Sci., associate professor of the Department of Pathological Physiology and Clinical Pathophysiology of Novosibirsk State Medical University, Russia, 630091, Novosibirsk, Red prospect, 52, e-mail: newsib54@gmail.com

KOPYEVA KRISTINA V., ORCID ID: 0000-0002-2285-6438; C. Med. Sci., researcher, Department of Myocardial Pathology of Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russia, 634012, Tomsk, Kievskaya str., 111a, e-mail: kristin-kop@inbox.ru

EFREMOV IVAN A., ORCID ID: 0000-0002-1704-2528; postgraduate student of the Department of Internal Medicine, Hematology and Transfusiology of Novosibirsk State Medical University, Russia, 630091, Novosibirsk, Red prospect, 52, e-mail: mr.and1997@inbox.ru

Abstract. Introduction. The relevance of the issues of diagnosis and treatment of chronic heart failure with preserved ejection fraction associated with obstructive sleep apnea is determined by the high prevalence of this comorbidity and a significant increase in cardiovascular risks. Promising in clinical practice is the study of the relationship between various genetic polymorphisms of matrix metalloproteinases and the clinical course of chronic heart failure with obstructive sleep apnea. Aim. The aim is to study the associations of various genetic polymorphisms of matrix metalloproteinases with variants of the clinical course of chronic heart failure with preserved ejection fraction in patients with obstructive sleep apnea. Material and methods. The study included 76 patients – men, who were found to have moderate-to-severe obstructive sleep apnea, arterial hypertension and were overweight. Then all the patients underwent polysomnography, echocardiography and N-terminal fragment of precursor protein brain-type natriuretic peptide level was determined. Polymerase chain reaction was used to assess gene polymorphisms: matrix metalloproteinase-2 (rs243865) and matrix metalloproteinase-9 (rs3918242), as well as a six-minute walk test. After 12 months of prospective observation, all patients underwent repeated the six-minute walk test and the variant of the clinical course of the disease was assessed.Results and discussion. According to the results of the analysis, the G/A genotype of the matrix metalloproteinase-9 gene (rs3918242) was associated with an increase in the risk of unfavorable cardiovascular events by 3.73 times (odds ratio 3.73 (2.18-11.76), p=0.012) and risk of chronic heart failure progression by 5.34 times (odds ratio 5.34 (1.81-23.12), p=0.001). No reliable associations of genetic polymorphisms of matrix metalloproteinase-2 with the clinical course of chronic heart failure were found which is consistent with the data of previous studies. Conclusion. The results obtained may indicate a genetically determined predisposition to the progression of heart failure in patients with obstructive sleep apnea with a certain genotype. The data obtained can be useful for stratification of cardiovascular risks and the construction of a personalized treatment strategy in patients with obstructive sleep apnea.

Key words: obstructive sleep apnea syndrome, chronic heart failure with preserved left ventricular ejection fraction, genetic polymorphism, matrix metalloproteinases, oxidative stress.

For reference: Yakovlev AV, Teplyakov AT, Mayanskaya SD, Grakova EV, Shilov SN, Kopyeva KV, Efremov IA. Prognostic value of genetic polymorphisms of matrix metalloproteinases in patients with chronic heart failure with preserved ejection fraction associated with obstructive sleep apnea syndrome. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):86-92. DOI: 10.20969 / VSKM.2022.15(5).86-92.

References

  1. Deursen V, Urso R, Laroche C, et al. Comorbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014; 16: 103–111. doi: 10.1002/ejhf.30
  2. Tobias M, Otto S, Marc B, et al. Obstructive sleep apnoea and heart failure. Cardiovascular medicine. 2017; 20: 9–16. doi: 10.4414/cvm.2017.00452
  3. Mentz R, Fiuzat M. Sleep-disordered breathing in patients with heart failure. Heart Fail Clin. 2014; 10: 243–250. doi: 10.1016/j.hfc.2013.10.001
  4. Медведева Е.А., Коростовцева Л.С., Сазонова Ю.В. и др. Синдром обструктивного апноэ во сне при хронической сердечной недостаточности: взгляд кардиолога // Российский кардиологический журнал. – 2018. – No 1. – С.78-82. [Medvedeva EA, Korostovceva LS, Sazonova YuV, et al. Sindrom obstruktivnogo apnoe vo sne pri hronicheskoj serdechnoj nedostatochnosti: vzglyad kardiologa [Obstructive Sleep Apnea Syndrome in Chronic Heart Failure: A Cardiologist’s Perspective]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2018; 1: 78-82. (In Russ.)]. doi: 10.15829/1560-4071-2018-1-78-82
  5. Sozer V, Kutnu M, Atahan E. Changes in inflammatory mediators as a result of intermittent hypoxia in obstructive sleep apnea syndrome. Clin Respir J. 2018; 12: 1615– 1622. doi: 10.1111/crj.12718
  6. Chirinos J, Orlenko A, Zhao L, et al. Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2020; 75: 1281–1295. DOI: 10.1016 / j.jacc.2019.12.069
  7. Pan W, Yang D, Yu P, et al. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions. BMC Cardiovasc Disord. 2020; 20: 208–219. DOI: 10.1186 / s12872-020-01493-2
  8. Юлдашев C., Ахмедова Г., Ибрагимова Э. и др. Роль матриксных металлопротеиназ в развитии хронической сердечной недостаточности // Вопросы науки и образования. – 2019. – No 35 (4). – С.175-185. [Yuldashev S, Ahmedova G, Ibragimova E, et al. Rol’ matriksnyh metalloproteinaz v razvitii hronicheskoj serdechnoj nedostatochnosti [The role of matrix metalloproteinases in the development of chronic heart failure]. Voprosy nauki i obrazovaniya [Questions of science and education]. 2019; 35 (4): 175-185. (In Russ.)].
  9. Ahmed S, Clark L, Pennington W, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006; 113: 2089–2096. DOI: 10.1161/ CIRCULATIONAHA.105.573865

  1. Шумаков Д.В., Зыбин Д.И., Попов М.А. Роль матриксной металлопротеиназы 9 в ремоделировании миокарда левого желудочка // Российский медицинский журнал. – 2020. – No 10. – С.17-19. [Shumakov DV, Zybin DI, Popov MA. Rol’ matriksnoj metalloproteinazy 9 v remodelirovanii miokarda levogo zheludochka [Role of matrix metalloproteinase 9 in left ventricular myocardial remodeling]. Rossijskij medicinskij zhurnal [Russian medical journal]. 2020; 10: 17-19. (In Russ.)].

  2. Yalcınkaya M, Erbek S, Babakurban S, et al. Lack of association of matrix metalloproteinase-9 promoter gene polymorphism in obstructive sleep apnea syndrome. J Craniomaxillofac Surg. 2015; 43; 1099–1103. DOI: 10.1016/j.jcms.2015.06.014

  3. Шадрина А., Плиева Я., Кушлинский Д. и др. Классификация, регуляция активности, генетический полиморфизм матриксных металлопротеиназ в норме и при патологии // Альманах клинической медицины. – 2017. – No 45 (4). – С. 266-279. [Shadrina A, Plieva Ya, Kushlinskij D, et al. Klassifikaciya, regulyaciya aktivnosti, geneticheskij polimorfizm matriksnyh metalloproteinaz v norme i pri patologii [Classification, regulation of activity, genetic polymorphism of matrix metalloproteinases in health and disease] Al’manah klinicheskoj mediciny [Almanac of Clinical Medicine]. 2017; 45 (4): 266-279. (In Russ.)]. DOI:10.18786/2072-0505-2017-45-4-266-279

  4. Franczak A, Skomro R, Bil-Lula I, et al. Activity of serum matrix metalloproteinase 9 in patients with obstructive sleep apnea. Pol Arch Intern Med.. 2021; 90: P.131–136. DOI: 10.20452/pamw.16014

  5. Wang S, Li S, Wang B, et al. Matrix Metalloproteinase-9 Is a Predictive Factor for Systematic Hypertension and Heart Dysfunction in Patients with Obstructive Sleep Apnea Syndrome. Biomed Res Int. 2018; 2018: 8–19. DOI: 10.1155 / 2018/1569701

  6. Ramos P, Rubies C, Torres M, et al. Atrial fibrosis in a chronic murine model of obstructive sleep apnea: mechanisms and prevention by mesenchymal stem cells. Respir Res. 2014; 15: 141–148. DOI: 10.1186/1465-9921-15-54

  7. Fang X, Chen J, Wang W, et al. Matrix metalloproteinase 9 (MMP9) level and MMP9 -1562C>T in patients with obstructive sleep apnea: a systematic review and meta-analysis of case-control studies. Sleep Med. 2020; 67: 110–119. DOI: 10.1016 / j.sleep.2019.11.1247

  8. Watson C, Spiers J, Waterstone M, et al. Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up programme. BMC Cardiovasc Disord. 2021; 21: 87–97. DOI: 10.1186/s12872-021-01860-7

  9. Yukse M, Kuzu-Okur H, Velioglu-Ogunç A, et al. Matrix Metalloproteinase-9 Level and Gene Polymorphism in Sleep Disordered Breathing Patients with or without Cardiovascular Disorders. Balkan Med J. 2013; 30: 8–12. DOI: 10.5152/balkanmedj.2012.068

  10. Galis Z, Johnson C, Godin D, et al. Targeted Disruption of the Matrix Metalloproteinase-9 Gene Impairs Smooth Muscle Cell Migration and Geometrical Arterial Remodeling. Circ Res. 2002; 91: 852–859. DOI: 10.1161/01.res.0000041036.86977.14

  11. Cao C, Wu B, Wu Y, et al. Functional polymorphisms in the promoter region of MMP-2 and MMP-9 and susceptibility to obstructive sleep apnea. Sci Rep. 2015; 5: 152–159. DOI: 10.1038/srep08966

  12. Franczak A, Skomro R, Sawicka J, et al. Serum matrix metalloproteinase-2 as a predictor of level of hypoxemia and severity of obstructive sleep apnea. Sleep Breath. 2021; 25: 877–886. DOI: 10.1007/s11325-020-02200-3

  13. Wang W, Sawicki G, Schulz R, et al. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 2002; 53: 165– 174. DOI: 10.1016/s0008-6363(01)00445-x

  14. Chuang L, Chen N, Lin S, et al. Increased matrix metalloproteinases-9 after sleep in plasma and in monocytes of obstructive sleep apnea patients. Life Sci. 2013; 93: 220–225. DOI: 10.1016/j.lfs.2013.06.009

  15. Ben-Yosef Y, Miller A, Shapiro S, et al. Hypoxia of endothelial cells leads to MMP-2-dependent survival and death. Am J Physiol Cell Physiol. 2005; 289: 1321–1331. DOI: 10.1152/ajpcell.00079.2005

 

REVIEWS

UDC:616.322-089.87-053.2

DOI: 10.20969/VSKM.2022.15(5).93-99

PDF download LONG - TERM IMPACTS OF TONSILLECTOMY IN CHILDREN

BOIKO NATALIA V., ORCID ID: 0000-0002-1316-5061, Scopus Author ID: 16681053200, Researcher ID: I-9086-2017; D. Med. Sci, professor of Department of Otorhinolaryngology of Rostov State Medical University, 344022, Russia, Rostov-on-Don, Nakchichevanskiy, 29, tel. +7-903-433-41-13, e-mail: nvboiko@gmail.com

STAGNIEVA IRINA V., ORCID ID: 0000-0002-2894-2062, Scopus Author ID: 37008481700; D. Med. Sci, associate professor, head of Department of Otorhinolaryngology of Rostov State Medical University, 344022, Russia, Rostov-on-Don, Nakchichevanskiy, 29, e-mail: irinastagnieva@yandex.ru

KIM ANASTASIYA S., ORCID ID: 0000-0001-7358-7912, Scopus Author ID: 57203241125; postgraduate student of Department of Otorhinolaryngology of Rostov State Medical University, 344022, Russia, Rostov-on-Don, Nakchichevanskiy, 29, e-mail: anastasiya.bachurina@inbox.ru

GUKASYAN ELENA L., ORCID ID: 0000-0001-7401-0680, Scopus Author ID: 57384421800, C. Med. Sci, assistant professor of Department of Otorhinolaryngology of Rostov State Medical University, 344022, Russia, Rostov-on-Don, Nakchichevanskiy, 29, e-mail: elena.guckasyan@yandex.ru

ZATULIVETROVA DARIA O., ORCID ID: 0000-0002-4841-2712, postgraduate student of Department of Otorhinolaryngology of Rostov State Medical University, 344022, Russia, Rostov-on-Don, Nakchichevanskiy, 29, e-mail: emuviz@yandex.ru

STATESHNAYA PAULA A., ORCID ID: 0000-0002-7035-4344, Scopus Author ID: 57384660800, postgraduate student of Department of Otorhinolaryngology of Rostov State Medical University, 344022, Russia, Rostov-on-Don, Nakchichevanskiy, 29, e-mail: lula14@rambler.ru

Abstract. Introduction. Tonsillectomy is the most common surgical procedure in the practice of pediatric otorhinolaryngology. Over the past 100 years views on the indications and utility of this surgery in childhood have been changed many times. Aim. The aim is to summarize the available studies of the long-term effects of tonsillectomy in children. Material and methods. A search was carried out in the SCOPUS, Science Direct, MEDLINE, COCHRANE, RSCI databases using the keywords: chronic tonsillitis, recurrent tonsillitis, tonsillectomy in children, long-term results, quality of life, immune system. A selection of meta-analyses, systematic reviews, cohort, prospective and controlled studies for the period from 2002 to 2021 was performed for further analysis. Results and discussion. Analysis of the literature demonstrates an unequivocal positive assessment of the long-term results of tonsillectomy in such diseases and pathological conditions as obstructive sleep apnea (OSA), Marshall’s syndrome (PFAPA syndrome), pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS), recurrent tonsillitis. However, cohort studies carried out in Denmark and Sweden found an increased relative risk of upper respiratory and autoimmune diseases in the long-term period. Conclusion. The ambiguity in assessing the long-term results of tonsillectomy performed in childhood indicates the need for strict selection of children for surgical treatment, taking into account all the risks in the early and late postoperative period.

Key words: chronic tonsillitis, recurrent tonsillitis, tonsillectomy in children, long-term results, quality of life.

For reference: Boiko NV, Stagnieva IV, Kim AS, Gukasyan EL, Zatulivetrova DO, Stateshnaya DA. Long-term impacts of tonsillectomy in children. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):93-99. DOI:10/20969/VSKM.2022.15(5).93-99.

References

  1. Chinnadurai S, Jordan AK, Sathe NA, et al. Tonsillectomy for obstructive sleep-disordered breathing: a meta-analysis. Pediatrics. 2017; 139(2): e20163491. DOI:10.1542/peds.2016-3491

  2. Wetmore RF. Surgical management of the tonsillectomy and adenoidectomy patient. World J Otorhinolar Head Neck Surg. 2017; 3(3): 176-182. DOI:10.1016/j. wjorl.2017.01.001

  3. Шабалдина Е.В., Ахтямов Д.Р., Гривцова С.В., и др. Эффективность растительного лекарственного препарата в лечении и иммунореабилитации детей раннего и дошкольного возраста с повторяющимися острыми назофарингитами // Вопросы практической пелиатрии. – 2020. – Т. 15, No 5. - С. 57-67. [Shabaldina EV, Akhtyamov DR, Grivtsova SV, et al. Effektivnost’ rastitel’nogo lekarstvennogo preparata v lechenii i immunoreabilitatsii dete rannego i doshkol’nogo vozrasta s povtoryayushchimisya ostrymi nazofaringitami [Efficacy of herbal medicine in the treatment and immunorehabilitation of preschool children with recurrent acute nasopharyngitis]. Voprosy prakticheskoy peliatrii [Issues of practical pediatrics]. 2020; 15(5): 57-67. (In Russ.)]. DOI: 10.20953/1817-7646-2020-5-57-66

  4. Ким А.С., Бойко Н.В., Стагниева И.В., Панченко С.Н. Малые слюнные железы в паратонзиллярном пространстве у детей // Вестник оториноларингологии. –2021.–Т.86.-No1.–С.41-45.[KimAS,BoykoNV, Stagnieva IV, Panchenko SN. Malye slyunnye zhelezy v paratonzillyarnom prostranstve u detei [Small salivary glands in the paratonsillar space in children]. Vestnik otorinolaringologii [Bulletin of Otorhinolaryngology]. 2021; 86(1): 41–45. (In Russ.)]. DOI:10.17116/ otorino20218601141

  5. Douglas CM, Altmyer U, Cottom L, et al. A 20-year observational cohort of a 5 million patient population - Tonsillectomy rates in the context of two national policy changes. Clin Otolaryngol. 2019; 44(1): 7-13. DOI:10.1111/ coa.13233

  6. Пальчун В.Т., Гуров А.В., Дубовая Т.К., Ермолаев А.Г. Гистологический анализ состояния небным миндалин при хроническом тонзиллите // Медицинский совет. – 2019. – No 20. – С. 68-71. [Pal’chun VT, Gurov AV, Dubovaya TK, Ermolaev AG. Gistologicheskii analiz sostoyaniya nebnym mindalin pri khronicheskom tonzillite [Histological exam of the palatine tonsils in chronic tonsillitis]. Meditsinskiy sovet [Medical Council]. 2019; (20): 68-71. (In Russ.)]. DOI: 10.21518/2079-701X-2019-20-68-71

  7. Пальчун В.Т., Крюков А.И., Гуров А.В., и др. Морфофункциональное состояние небных миндалин при различных формах хронического тонзиллита // Медицинский совет. – 2020. - No 16. – С. 150–159. [Pal’chun VT, Kriukov AI, Gurov AV, et al. Morfofunktsional’noe sostoyanie nebnykh mindalin pri razlichnykh formakh khronicheskogo tonzillita [Morphofunctional condition of palatine tonsils in various forms of chronic tonsillitis]. Meditsinskiy sovet [Medical Council]. 2020; (16): 150–159. (In Russ.)]. DOI: 10.21518/2079-701X-2020-16-150-159

  8. Cooper CM, Checketts JX, Brame L, et al. An analysis of the literature addressing tonsillectomy knowledge gaps. Int J Pediatr Otorhinolaryngol. 2018; 115: 89-93. DOI:10.1016/j.ijporl.2018.09.027

  9. Keltie K, Donne A, Daniel M, et al. Paediatric tonsillectomy in England: A cohort study of clinical practice and outcomes using Hospital Episode Statistics data (2008-2019). Clinical Otolaryngology. 2021;46:552–561. DOI:10.1111/coa.13707

  10. Bitar MA, Dowli A, Mourad M. The effect of tonsillectomy on the immune system: A systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol. 2015;79(8):1184-1191. DOI:10.1016/j.ijporl.2015.05.016

  11. Kaygusuz I, Alpay HC, Goderkmerdan A, et al. Evaluation of long-term impacts of tonsillectomy on immune functions of children: A follow-up study. Int J Pediatr Otorhinolaryngol. 2009. 73(3):445-449. DOI:10.1016/j. ijporl.2008.11.014

12. Бойко Н.В., Бачурина А.С., Оксенюк О.С., Колмакова Т.С. Лечение послеоперационного воспаления после тонзиллэктомии у детей // Педиатрия. Журнал им. Г.Н. Сперанского. – 2016. – Т. 95. - No 1. – С. 93-97. [Boiko NV, Bachurina AS, Oksenyuk OS, Kolmakova TS. Lechenie posleoperatsionnogo vospaleniya posle tonzillektomii u detei [Postoperative inflammation treatment after tonsillectomy in children]. Pediatriya - Zhurnal im. G.N. Speranskogo [Pediatrics. Journal named after G.N. Speransky]. 2016; 95(1): 93-97. (In Russ.)]. DOI:10.24110/0031-403X-2018-97-4-168-172

13. Бойко Н.В., Ким А.С., Стагниева И.В., Симбирцев А.С. Содержание провоспалительных цитокинов в слюне детей с хроническим тонзиллитом // Вестник оториноларингологии. – 2019. – Т. 84. - No 3. – С. 26-31. [Boiko NV, Stagnieva IV, Kim AS, Simbirtsev AS. Soderzhanie provospalitel’nykh tsitokinov v slyune detei s khronicheskim tonzillitom [Proinflammatory cytokine content in the saliva of children suffering from chronic tonsillitis]. Vestnik оtorinolaringologii [Bulletin of Otorhinolaryngology]. 2019; 84(3): 26-31. (In Russ.)]. DOI:10.17116/otorino20198403126

14. Yan Y, Song Y, Liu Y, et al. Short- and long-term impacts of adenoidectomy with/without tonsillectomy on immune function of young children <3 years of age. A cohort study. Medicine. 2019; 98(19): e15530. DOI:10.1097/ MD.0000000000015530

15. Funakoshi U, Jonekura S, Iinuma T, et al. The influence of tonsillectomy on allergic diseases in pediatric patients. Int J Pediatr Otorhinolaryngol. 2021; 140: 110503. DOI:10/1016/j.ijporl.2020.110503

16. Byars SG, Stearns SC, Boomsma JJ. Association of Long-term Risk of Respiratory, Allergic, and Infectious Diseases With Removal of Adenoids and Tonsils in Childhood. JAMA Otolaryngol. Head Neck Surg. 2018; 144(7): 294-603. DOI:10.1001/jamaoto.2018.0614

17. Ovesen T, Kamarauskas A, Hlidarsdottir T, et al. Good long-term results after tonsillectomy in ear, nose and throat practice. Dan Med J. 2013; 60(5): e4637. PMID: 23673266

  1. Nakso-Koivisto J, Blomgren K, Roine RP, et al. Impact of tonsillectomy on health-related quality of life and healthcare costs in children and adolescents. Int J Pediatr Otorhinolaryngol. 2014; 78: 1508-1512. DOI:10.1016/j. ijporl.2014.06.021

  2. Schwentner I, Schmutzhard J, Schwentner C, et al. The impact of adenotonsillectomy on children’s quality of life. Clin Otolaryngol. 2008; 33(1): 56-59. DOI:10.1111/j.1749-4486.2007.01578.x

  3. Kubba H, Swan IR, Gatehouse S. The Glasgow Children’s Benefit Inventory: a new instrument for assessing health-related benefit after an intervention. Ann. Otol. Rhinol. Laryngol. 2004; 113(12): 980–986. DOI:10.1177/000348940411301208

  4. Konieczny KM, Pitts-Tucker TN, Biggs TC, Pringle MB. A five-year follow-up observational study of the T-14 paediatric throat disorders outcome measure in tonsillectomy and adenotonsillectomy. Ann R Coll Surg Engl. 2019; 101(1): 40-43. DOI:10.1308/rcsann.2018.0133

  5. Hopkins C, Fairley J, Yung M, et al. The 14-item Paediatric Throat Disorders Outcome Test: a valid, sensitive, reliable, parent-reported outcome measure for paediatric throat disorders. J Laryngol Otol. 2010; 124(3): 306–314. DOI:10.1017/S0022215109992386

  6. Lee C-H, Kang K-T, Weng W-C, et al. Quality of life after adenotonsillectomy for children with sleep-disordered breathing: A linear mixed model analysis. Int J Pediatr Otorhinolaryngol. 2014; 78: 1374-1380. DOI:10.1016/j. ijporl.2014.05.038

  7. Todd CA, Bareiss AK, Mc Coul ED, et al. Adenotonsillectomy for Obstructive Sleep Apnea and Quality of Life: Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2017; 157(5): 767–773. DOI:10.1177/0194599817717480

  8. Косяков С.Я., Анготоева И.Б., Поляков Д.П., Мулдашева А.А. Противоречивые аспекты современных представлений о проблеме хронического тонзилита // Consilium Medicum. – 2016. – Т. 18. - No 11. – С. 55–58. [Kosyakov SYa, Angotoeva IB, Polyakov DP, Muldasheva AA. Protivorechivye aspekty sovremennykh predstavlenii o probleme khronicheskogo tonzilita [Сontroversial aspects of modern ideas about the problem of chronic tonsillitis]. Consilium Medicum. [Consilium Medicum]. 2016; 18(11): 55–58. (In Russ.)]. DOI: 10.26442/2075-1753_2016.11.55-58.

  9. Бойко Н.В., Летифов Г.М., Ким А.С., Стагниева И.В. Оценка эффективности лечения острого тонзиллофарингита при острых респираторных вирусных инфекциях у детей // Педиатрия. Журнал им. Г.Н. Сперанского. – 2018. – Т. 97. - No 4. – С. 168-172. [Boyko NV, Letifov GM, Kim AS, Stagnieva IV. Otsenka effektivnosti lecheniya ostrogo tonzillofaringita pri ostrykh respiratornykh virusnykh infektsiyakh u detei [Evaluation of efficacy of treatment of acute tonsillopharyngitis associated with acute respiratory viral infections in children]. Pediatriya. Zhurnal im G.N. Speranskogo [Pediatrics. Journal named after G.N. Speransky]. 2018; 97(4): 168-172. (In Russ.)]. DOI:10.24110/0031-403x-2018-97-4-168-172

  10. Clark ST, Johnston J, Biswas K, et al. Effect of tonsillectomy on antibiotic prescribing in children. Int J Pediatr Otorhinolaryngol. 2020; 138: 110338. DOI:10.1016/j.ijporl.2020.110338

28. Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr. 1987; 110(1): 43-46. DOI:10.1016/s0022-3476(87)80285-8

29. Marshall GS, Edwards KM, Lawton AR. PFAPA syndrome. Pediatr Infect Dis J. 1989; 8(9): 658-659. DOI:10.1097/00006454-198909000-00026

30. Lantto U, Koivunen P, Tapianen T, Renko M. Long-Term Outcome of Classic and Incomplete PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis) Syndrome after Tonsillectomy. J Pediatr. 2016; 179: 172-177. e1. DOI:10.1016/j.jpeds.2016.08.097

31. Burton MJ, Pollard AJ, Ramsden JD, et al. Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). Cochrane Database of Systematic Reviews 2019, 12(12): CD008669. DOI: 10.1002/14651858.CD008669.pub3

32. Aktas O, Aytuluk HG, Caliskan SK, et al. Long-term follow-up of tonsillectomy efficacy in children with PFAPA syndrome. Braz J Otorhinolaryngol. 2019; 85(1): 78-82. DOI:10.1016/j.bjorl.2017.10.012

33. Щербина А.Ю. Аутовоспалительные заболевания – взгляд иммунолога // Современная ревматология. – 2015. - No 1. – С. 48–54. [Shcherbina AYu. Autovospalitel’nye zabolevaniya – vzglyad immunologa [Autoinflammatory diseases: An immunologist’s view]. Sovremennaya Revmatologiya [Modern Rheumatology Journal]. 2015; (1): 48–54. (In Russ.)]. DOI:10.14412/1996-7012-2015-1-48-54

34. Thomas KT, Feder H M Jr, Lawton AR, Edwards KM. Periodic fever syndrome in children. J Pediatr. 1999; 135(1): 15-21. DOI:10.1016/s0022-3476(99)70321-5

35. Galanakis E, Papadakis CE, Giannoussi E, et al. PFAPA syndrome in children evaluated for tonsillectomy. Arch Dis Child. 2002; 86(6): 434-435. DOI:10.1136/adc.86.6.434

36. Berlucchi M, Meini A, Plebani A, et al. Update on treatment of marshall’s syndrome (PFAPA syndrome): report of five cases with review of the literature. Ann Otol Rhinol Laryngol. 2003; 112(4): 365-369. DOI:10.1177/000348940311200412

37. Renko M, Salo E, Putto-Laurila A, et al. A randomized, controlled trial of tonsillectomy in periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome. J Pediatr. 2007; 151(3): 289-92. DOI: 10.1016/j.jpeds.2007.03.015

38. Garavello W, Romagnoli M, Gaini RM. Effectiveness of adenotonsillectomy in PFAPA syndrome: a randomized study. J Pediatr. 2009; 155(2): 250-253. DOI:10.1016/j. jpeds.2009.02.038

39. Prasad N, Johng S, Powel D, et al. Role of tonsillectomy and adenoidectomy in parental satisfaction of treatments for PANDAS. Am J Otolaryngol. 2021; 42(4): 102963. DOI:10.1016/j.amjoto.2021.102963

40. Jianguang Ji, Sundquist J, Sundquist K. Tonsillectomy associated with an increased risk of autoimmune diseases: A national cohort study. J Autoimmun. 2016; 72: 1-7. DOI:10.1016/j.jaut.2016.06.007

41. Jakimovski D, Ahmed MK, Vaughn CB, et el. Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. Mult Scler Relat Disord. 2020; 42: 102131. DOI:10.1016/j.msard.2020.102131

42. Sawahata M, Nakamura Y, Sugiyama Y. Appendectomy, tonsillectomy, and risk for sarcoidosis – A hospital-based case-control study in Japan. Respir Investig. 2017; 55(3): 196-202. DOI:10.1016/j.resinv.2016.12.004

43. Chung S-D, Lin H-C, Wu C-S, et al. A tonsillectomy increased the risk of chronic rhinosinusitis among children: A three-year follow-up study. Int J Pediatr Otorhinolaryngol. 2016; 91: 82-85. DOI:10.1016/j.ijporl.2016.09.038

44. Бойко Н.В., Ким А.С., Стагниева И.В. и др. Значение показателей антистрептолизина O при определении показаний к тонзиллэктомии у детей // Вестник оторинолар. – 2018. – Т. 83. - No 4. - 73-77. [Boiko NV., Kim AS, Stagnieva IV, et al. Znachenie pokazatelei antistreptolizina O pri opredelenii pokazanii k tonzillektomii u detei [The significance of antistreptolysin O characteristics for the determination of indications for tonsillectomy in the children]. Vestnik Otorinolaringologii [Bulletin of Otorhinolaryngology]. 2018; 83(4): 73-77. (In Russ.)]. DOI:10.17116/otorino201883473

45. Sumilo D, Nichols L, Ryan R, Marshall T. Incidence of indications for tonsillectomy and frequency of evidence-based surgery: a 12-year retrospective cohort study of primary care electronic records. Br J Gen Pract. 2019; 69(678): 33-41. DOI:10.3399/bjg-p18X699833

46. Mandavia R, Schilder AGM, Dimitriadis PA, Mossialos E. Addressing the challenges in tonsillectomy research to inform health care policy: a review. JAMA Otolaryngol. Head Neck Surg. 2017; 143(9): 943–947. DOI:10.1001/ jamaoto.2017.0964

 

UDC

DOI:10.20969/VSKM.2022.15(5).100-106

PDF download REPRODUCTIVE HEALTH OF THE RUSSIAN POPULATION AS A KEY FACTOR OF DEMOGRAPHIC DYNAMICS

KADYROV ZIYORATSHO A., ORCID ID: 0000-0002-1108-8138, professor, Doctor of Medical Sciences, head of the Department of Endoscopic Urology, Department of Continuing Education for Medical Professionals at the Medical Institute of the Russian University of the People’s Friendship, 117198, Russia, Moscow, Miklukho-Maklaya st. 6, tel: +7-925-743-98-22, e-mail: zieratsho@yandex.ru

FANIEV MIKHAIL V., ORCID ID: 0000-0002-7323-3126, Doctor of Medical Sciences, associate professor of the Department of Endoscopic Urology, Department of Continuing Education for Medical Professionals at the Medical Institute of the Russian University of the People’s Friendship, 117198, Russia, Moscow, Miklukho-Maklaya, st. 6, phone: +7-988-246-55-14, e-mail: faniev.mv@gmail.com

PROKOPIEV YAROSLAV V., ORCID ID: 0000-0002-4345-127X, C. Med. Sci., associate professor of the Department of Urology and Nephrology, Kazan State Medical Academy - branch of the Russian Medical Academy of Continues Professional Education, 420012, Russia, Privolzhsky Federal District, Republic of Tatarstan, Kazan, Mushtari st. 11, e-mail: androhelp@rambler.ru

FAUSTOVA KARINA V., ORCID ID: 0000-0001-8702-0159, clinical resident, Department of Obstetrics and Gynecology, Kazan State Medical Academy - branch of the Russian Medical Academy of Continues Professional Education, 420012, Russia, Privolzhsky Federal District, Republic of Tatarstan, Kazan, Mushtari st. 11.

SEVRYUKOV FYODOR A., ORCID ID: 0000-0001-5120-2620, professor of the Department of Urology, Volga Medical Research University, 603950, Russia, Nizhny Novgorod, Minin and Pozharsky sq., 10/1, e-mail: fedor_ sevryukov@mail.ru

VODOLAZHSKY DMITRY I., ORCID ID: 0000-0003-1114-8732, Scopus Author ID: 6506507156, Web of Science Researcher ID: AAF-7800-2020, C. Bio. Sci., head of the Laboratory of Cellular Technologies, Central Scientific Research Laboratory of the Medical Academy named after S.I. Georgievsky at the Crimean Federal University named after V.I. Vernadsky, 295006, Russia, Republic of Crimea, Simferopol, Lenin Boulevard, 5/7, e-mail - dvodolazhsky@gmail.com

KRUPIN VALENTIN N., ORCID ID: 0000-0002-4887-4888, head of the Department of Urology, Volga Medical Research University, 603950, Russia, Nizhny Novgorod, Minin and Pozharsky sq., 10/1, e-mail: vn.krupin@mail.ru

Abstract. Introduction. The trends in birth and death rates over the last 25 years determine the negative demographic picture in the Russian Federation. The key factor influencing the birth rate increase is the reproductive health of the population. The low level is largely due not only to socio-economic factors, but also due to medical and biological factors. Aim. In order to preserve men and women reproductive health, it is extremely important to improve ways of preventive diagnosis of diseases and conditions that can lead to infertility, as well as to expand the methods of treatment in case when infertility is already identified. Material and methods. The analytical research of Russian and foreign publications to find mentioned problem solutions was conducted. Results and discussion. A large number of federal programs have been adopted and successfully carried out in recent decades because of the disappointing indicators of natural growth and also for overcoming the country’s birth rate crisis. These measures have led to some rise in statistical indicators but not enough to solve the problem. Large number of both social and medical factors affecting the reproductive health of the population and leading to infertility. In vitro fertilization procedures bring a significant meaning in this fight against infertility. But the matter is that nowadays clinicians and researchers from all over the world do not have an unambiguous attitude to this method. The reason is the large number of both positive and negative effects of the in vitro fertilization procedure, as well as the lack of information and study in this area. The question of raising the birth rate in Russia and preserving the reproductive health of its citizens remains open.Conclusion. One of the possible ways to solve this problem could be the creation of reproductive health centers that provide the population with narrow-profile diagnostics and qualified assistance from specialists, as well as implementing programs for the prevention of reproductive disorders in men and women. Lack of highly specialized doctors in this sphere is also the reason of inadequate diagnosis and treatment of infertility, it is necessary to expand programs for their education and training. It is also important to ensure access of relevant theoretical sources of information about the evidence-based medicine principles in reproduction - clinical recommendations, manuals for doctors.

Key words: reproductive health, male and female health centers, infertility, fertility, mortality, natural growth.

For reference: Kadyrov ZA, Faniev MV, Prokopiev YV, Faustova KV, Sevryukov FA, Vodolazhsky DI, Krupin VN. Reproductive health of the Russian population as a key factor of demographic dynamics // The Bulletin of Contemporary Clinical Medicine. 2022.15(5):100-106. DOI: 10.20969/VSKM.2022.15(5). 100-106.

References

  1. Федеральная служба государственной статистики (Росстат). [Federal’naya sluzhba gosudarstvennoj statistiki (Rosstat) [Federal State Statistics Service (Rosstat)] (In Russ.)]. https://rosstat.gov.ru/folder/12781
  2. Ковыршина М.Н., Попов Н.В. Демографическое развитие России: проблемы и пути решения // Пробелы в российском законодательстве. – 2015. – вып. 1. – С.1-4. [Kovyrshina MN, Popov NV. Demograficheskoe razvitie Rossii: problemy i puti resheniya [Demographic development of Russia: problems and solutions] Probely v rossijskom zakonodatel’stve [Gaps in Russian legislation]. 2015; 1: 1-4. (In Russ.)]. https://cyberleninka. ru/article/n/demograficheskoe-razvitie-rossii-problemy-i-puti-resheniya
  3. Паспорт Национальной программы демографического развития России. – 2006. – C.1-44. [Pasport Nacional’noj programmy demograficheskogo razvitiya Rossii [Passport of the National Program for the Demographic Development of Russia]. 2006. (In Russ.)]. https://rg.ru/i/spec/tabl.pdf
  4. Клеева Л.П. Динамика естественного прироста населения Российской Федерации // Компетентность. – 2020. – вып. 4. – С. 46-51. [Kleeva LP. Dinamika estestvennogo prirosta naseleniya Rossijskoj Federacii [Dynamics of natural increase in the population of the Russian Federation] Kompetentnost’ [Competence]. 2020; 4: 46-51. (In Russ.)]. https://cyberleninka.ru/ article/n/dinamika-estestvennogo-prirosta-naseleniya-rossiyskoy-federatsii
  5. НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «НМИРЦ» МЗ РФ, ФГБУ «Государственный научно-исследовательский центр профилактической медицины» МЗ РФ - Мужское репродуктивное здоровье и активное социальное долголетие. Пилотная межрегиональная программа. – 2016. – С. 1-11. [NII urologii i intervencionnoj radioogii im. N.A. Lopatkina – filial FGBU «NMIRC» MZ RF [Research Institute of Urology and Interventional Radiology named after Lopatkin N.A. - branch of the Federal State Budgetary Institution “NMIRC” of the Ministry of Health of the Russian Federation], FGBU «Gosudarstvennyj nauchno-issledovatel’skij centr profilakticheskoj mediciny» MZ RF [Federal State Budgetary Institution «State Research Center for Preventive Medicine» of the Ministry of Health of the Russian Federation]. Muzhskoe reproduktivnoe zdorov’e i aktivnoe social’noe dolgoletie. Pilotnaya mezhregional’naya programma [Male reproductive health and active social longevity. Pilot interregional program]. 2016; 1-11. (In Russ.)].
  6. Роув П.Дж. и др. Руководство ВОЗ по стандартизованному обследованию и диагностике бесплодных супружеских пар. Пер. с англ. 4-е изд. // Мед-Пресс. — 1997. — 91 с. [Rowe PJ et all. Rukovodstvo VOZ po standartizovannomu obsledovaniyu i diagnostike besplodnyh supruzheskih par. Per. s angl. 4-e izd. [WHO Guidelines for the standardized examination and diagnosis of infertile couples. Trans. From Eng. 4 edit.]. MedPress [MedPress]. 1997; 91 p. (In Russ.)].
  7. Всемирная организация здравоохранения (ВОЗ). Международная классификация болезней, 11-й пересмотр (МКБ-11). – 2018 г. [Vsemirnaya organizaciya zdravoohraneniya (VOZ) [World Health Organization (WHO)]. Mezhdunarodnaya klassifikaciya boleznej, 11-j peresmotr (MKB-11) [International Classification of Diseases, 11th Revision (ICD-11)]. 2018; (In Russ.)].
  8. Петров Ю.А., Кулина А.Д. Отношение студентов медицинского вуза к проблеме охраны репродуктивного здоровья // Репродуктивное здоровье детей и подростков. – 2020. – Т. 16, вып. 2. – С. 22-31. [Petrov YuA, Kulina AD. Otnoshenie studentov medicinskogo vuza k probleme ohrany reproduktivnogo zdorov’ya [The attitude of medical students to the problem of reproductive health]. Reproduktivnoe zdorov’e detej i podrostkov [Reproductive health of children and adolescents]. 2020; 16 (2): 22-31. (In Russ.)]. DOI: 10.33029/1816-2134-2020-16-1-22-31

  1. Пахомова Ж.В. Уровень информированности студентов в вопросах охраны репродуктивного здоровья // Здоровье и образование в XXI веке. – 2011. – вып. 4. – С. 13-15. [Pahomova ZhV. Uroven’ informirovannosti studentov v voprosah ohrany reproduktivnogo zdorov’ya [The level of students’ awareness of reproductive health issues]. Zdorov’e i obrazovanie v XXI veke [Health and Education in the 21st Century]. 2011; 4: 13-15. (In Russ.)]. https://cyberleninka.ru/article/n/uroven-informirovannosti- studentov-v-voprosah-ohrany-reproduktivnogo-zdorovya

  2. Обоскалова Т.А., Прохорова О.В. Репродуктивное поведение студентов медицинского вуза: реалии контрацептивного выбора // Гинекология. – 2018. – вып. 3. – С. 16-20. [Oboskalova TA, Prohorova OV. Reproduktivnoe povedenie studentov medicinskogo vuza: realii kontraceptivnogo vybora [Reproductive behavior of medical students: realities of contraceptive choice]. Ginekologiya [Gynecology]. 2018; 3: 16-20. (In Russ.)]. DOI: 10.26442/2079-5696_2018.3.16-20

  3. Аполихин О.И., Москалева Н.Г., Комарова В.А. Современная демографическая ситуация и проблемы улучшения репродуктивного здоровья населения России // Экспериментальная и клиническая урология. – 2015. – No 4. – С. 4-14. [Apolihin OI, Moskaleva NG, Komarova VA. Sovremennaya demograficheskaya situaciya i problemy uluchsheniya reproduktivnogo zdorov’ya naseleniya Rossii [Modern demographic situation and problems of improving the reproductive health of the Russian population]. Eksperimental’naya i klinicheskaya urologiya [Experimental and clinical urology]. 2015; 4: 4-14. (In Russ.)]. https://cyberleninka.ru/article/n/sovremennaya- demograficheskaya-situatsiya-i-problemy-uluchsheniya-reproduktivnogo-zdorovya-naseleniya-rossii

  4. Кулаков В.И., Долженко И.С. Основные тенденции изменения репродуктивного здоровья девочек в современных условиях // Репродукт. здоровье детей и подростков. 2005. – вып. 1. – С. 22–26. [Kulakov VI, Dolzhenko IS. Osnovnye tendencii izmeneniya reproduktivnogo zdorov’ya devochek v sovremennyh usloviyah [The main trends in the reproductive health of girls in modern conditions]. Reprodukt. zdorov’e deteĭ i podrostkov [Reproduction. child and adolescent health]. 2005; 1: 22–26. (In Russ.)].

  5. Буралкина H.A., Уварова Е.В. Современные представления о репродуктивном здоровье девочек (обзор литературы) // Репродукт. здоровье детей и подростков. –2010. – вып. 2. – С. 12-31. [Buralkina HA, Uvarova EV. Sovremennye predstavleniya o reproduktivnom zdorov’e devochek (obzor literatury) [Modern ideas about the reproductive health of girls (literature review)]. Reproduktivnoe zdorov’e deteĭ i podrostkov [Reproductive health of children and adolescents]. 2010; 2: 12–31. (In Russ.)].

  6. Чечулина О.В., Давлятшина Л.Р. Влияние соматической патологии на репродуктивное здоровье девочек-подростков // Репродуктивное здоровье детей и подростков. – 2020. – Т. 16, вып. 1. – С. 116–127. [Chechulina OV, Davlyatshina LR. Vliyanie somaticheskoĭ patologii na reproduktivnoe zdorov’e devochek-podrostkov [Influence of somatic pathology on the reproductive health of adolescent girls]. Reproduktivnoe zdorov’e deteĭ i podrostkov [Reproductive health of children and adolescents]. 2020; 16 (1): 16–127. (In Russ.)]. DOI: 10.33029/1816-2134-2020-16-1-116-127

  7. Уварова Е.В., Гайнова И.Г. Дисменорея: современный взгляд на этиологию, патогенез и обоснование лечебного воздействия // Гинекология. – 2005. – Т.6, вып. 3. – С. 114–120. [Uvarova EV, Gaĭnova IG. Dismenoreya: sovremennyĭ vzglyad na etiologiyu, patogenez i obosnovanie lechebnogo vozdeĭstviya [Dysmenorrhea: a modern view on the etiology, pathogenesis and rationale for therapeutic effects]. Ginekologiya [Gynecology]. 2005; 6 (3): 114-120. (In Russ.)].

  8.  Стенограмма заседания «круглого» стола Комитета Госдумы ФС РФ по охране здоровья. Проблемы правоприменения Федерального закона «Об основах охраны здоровья граждан в Российской Федерации» в сфере правового регулирования репродуктивной деятельности. – 2014, – с.7-8. [Stenogramma zasedaniya «kruglogo» stola Komiteta Gosdumy FS RF po ohrane zdorov’ya [Transcript of the meeting of the “round” table of the Committee of the State Duma of the Federal Assembly of the Russian Federation on health protection]. Problemy pravo primeneniya Federal’nogo zakona «Ob osnovah ohrany zdorov’ya grazhdan v Rossijskoj Federacii» v sfere pravovogo regulirovaniya reproduktivnoj deyatel’nosti [Problems of the right to apply the Federal Law “On the basics of protecting the health of citizens in the Russian Federation” in the field of legal regulation of reproductive activity]. 2014; 7-8. (In Russ.)].

  9.  Бобровская А.В. Ищенко О.Ю. Профилактические мероприятия по абортам в Краснодарском крае // Датский научный журнал: сб. статей. – 2020. – Т. 2, вып. 42. – С. 22-24. [Bobrovskaya AV, Ishchenko OYu. Profilakticheskie meropriyatiya po abortam v Krasnodarskom krae [Preventive measures for abortion in the Krasnodar Territory]. Datskij nauchnyj zhurnal: sb. stateĭ [Danish scientific journal: Sat. articles]. 2020; 2 (42): 22-24. (In Russ.)].

  10.  Капто А.А. и др. (ред.). Руководство по клинической андрологии // Медпрактика-М. – 2008. – 272 с. [Kapto AA et all (ed.) Rukovodstvo po klinicheskoĭ andrologii [Guide to clinical andrology]. Medpraktika-M [Medpractice-M]. 2008; 272 p. (In Russ.)].

  11.  Кулаков В.И., Савельева Г.М., Манухин И.Б. Гинекология – национальное руководство // Гоэтар-медиа, 2009. – 1088 с. [Kulakov VI, Savel’eva GM, Manuhin IB. Ginekologiya – nacional’noe rukovodstvo [Gynecology - national leadership]. Goetar-media [Goetar-media]. 2009; 1088 p. (In Russ.)].

  12.  Collins JA, Crosignani PG. Unexplained infertility: a review of diagnosis, prognosis, treatment efficacy and management. 1992; 39 (4): 267-275. DOI: 10.1016/0020-7292(92)90257-J

  13.  Malik S. Genital tuberculosis and implantation in assisted reproduction. Reviews in Gynaecological Practice. 2003; 3 (3): 160-164. DOI: 10.1016/S1471-7697(03)00059-5

  14.  Sills ES, Palermo GD. Intrauterine pregnancy following low-dose gonadotropin ovulation induction and direct intraperitoneal insemination for severe cervical stenosis. BMC Pregnancy Childbirth. 2002; 2 (9). DOI: 10.1186/1471-2393-2-9

  15.  Falcone T, Hurd WW edit. Clinical reproductive medicine and surgery: a practical guide. Third edition. 2017.

  16.  WHO Scientific Group on Recent Advances in Medically Assisted Conception & World Health Organization. Recent advances in medically assisted conception: report of a WHO scientific group. 1992. https://apps.who.int/iris/ handle/10665/38679

  17.  Нишлага Э., Бере Г.М. (ред.). Андрология. Мужское здоровье и дисфункция репродуктивной системы: Пер. с англ. // МИА. – 2005. [Nishlaga Е, Bere GM (ed.) Andrologiya. Muzhskoe zdorov’e i disfunkciya reproduktivnoj sistemy: Per. s angl. [Andrology. Men’s health and dysfunction of the reproductive system: Trans. from English]. MIA [MIA]. 2005. (In Russ.)].

  18. Петров Ю.А., Алехина А.Г., Блесманович А.Е. Синдром гиперстимуляции яичников в программах экстракорпорального оплодотворения // Главный врач юга России. – 2019. – Т. 2, вып. 66 – С. 41-44. [Petrov YuA, Alekhina AG, Blesmanovich AE. Sindrom giperstimulyacii yaichnikov v programmah ekstrakorporal’nogo oplodotvoreniya [Ovarian hyperstimulation syndrome in in vitro fertilization programs]. Glavnyĭ vrach yuga Rossii [Chief physician of the south of Russia]. 2019; 2(66): 41–44. (In Russ.)].

  19. Здановский В. М., Витязева И. И. Течение и исход беременностей после лечения бесплодия методами вспомогательной репродукции // Проблемы репродукции. – 2000. – Т. 6, вып. 3 – С. 55–56. [Zdanovskij VM, Vityazeva II. Techenie i iskhod beremennostej posle lecheniya besplodiya metodami vspomogatel’noj reprodukcii [The course and outcome of pregnancies after infertility treatment using assisted reproduction]. Problemy reprodukcii [Problems of reproduction]. 2000; 6 (3): 55–56. (In Russ.)].

  20. Витязева И.И. Инновационные технологии в лечении бесплодия у пациентов с эндокринопатиями // Доктор.Ру. – 2009. – Т. 6, вып. 2. [Vityazeva II. Innovacionnye tekhnologii v lechenii besplodiya u pacientov s endokrinopatiyami [Innovative technologies in the treatment of infertility in patients with endocrinopathies]. Doktor.Ru [Doctor.Ru]. 2009; 6 (2). (In Russ.)].

  21. Митрофанова И.В., Луцай Е.Д., Сирик Е.Н. Эффективность экстракорпорального оплодотворения у женщин разных периодов зрелого возраста в Оренбургской области// Вятский медицинский вестник. – 2021. – Т. 1, вып. 69 – С. 56-59. [Mitrofanova IV, Lucaj ED, Sirik EN. Effektivnost’ ekstrakorporal’nogo oplodotvoreniya u zhenshchin raznyh periodov zrelogo vozrasta v Orenburgskoj oblasti [The effectiveness of in vitro fertilization in women of different periods of adulthood in the Orenburg region]. Vyatskij medicinskij vestnik [Vyatka Medical Bulletin]. 2021; 1 (69): 56-59. (In Russ.)].

  22. Оразов М.Р. и др. Эффективность альтернативных методов лечения бесплодия маточного генеза // Гинекология. – 2021. – вып. 1 – С. 92-94. [Orazov MR et all. Effektivnost’ al’ternativnyh metodov lecheniya besplodiya matochnogo geneza [The effectiveness of alternative methods of treatment of uterine infertility]. Ginekologiya [Gynecology]. 2021; 23 (1): 92-94. (In Russ.)].

  23. Каширская Е.И. и др. Состояние здоровья детей, зачатых путем экстракорпорального оплодотворения // Астраханский медицинский журнал. – 2020. – Т. 15, вып. 4, – С. 108-115. [Kashirskaya EI et all. Sostoyanie zdorov’ya detej, zachatyh putem ekstrakorporal’nogo oplodotvoreniya [The state of health of children conceived by in vitro fertilization]. Astrahanskij medicinskij zhurnal [Astrakhan Medical Journal]. 2020; 15 (4): 108-115. (In Russ.)].

  24. Министерствo здравоохранения Российской Федерации (Минздрав России). Приказ No 1183н «Об утверждении номенклатуры должностей медицинских работников и фармацевтических работников». – 2012 – с.3-10. [Ministerstvo zdravoohraneniya Rossijskoj Federacii (Minzdrav Rossii) [Ministry of Health of the Russian Federation]. Prikaz No 1183n «Ob utverzhdenii nomenklatury dolzhnostej medicinskih rabotnikov i farmacevticheskih rabotnikov» [Order No 1183n “On approval of the nomenclature of positions of medical workers and pharmaceutical workers”]. 2012; 3-10. (In Russ.)]. http://www.rg.ru/2013/03/27/ nomenklatura-dok.html

  25. Segal TR, Giudice LC. Before the beginning: environmental exposures and reproductive and obstetrical outcomes. Fertility and Sterility 2019;112(4):613-21.

  26. Mascarenhas MN et all. National, Regional, and Global Trends in Infertility Prevalence Since 1990: A Systematic Analysis of 277 Health Surveys. PloS Med. 2012; 9 (12). DOI: 10.1371/journal.pmed.1001356

  27. Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007; 22 (6): 1506-1512. DOI: 10.1093/ humrep/dem046

  28. Общероссийская общественная организация «Российская Ассоциация Репродукции Человека». 25-й ежегодный отчет Регистра ВРТ. – 2021. – С. 33,48. [Obshcherossijskaya obshchestvennaya organizaciya «Rossijskaya Associaciya Reprodukcii Cheloveka» [Russian Public Organization «Russian Association of Human Reproduction»]. 25-j ezhegodnyj otchet Registra VRT [The 25th annual report of the ART Register]. 2021; 33,48. (In Russ.)].

 

UDC: 616-039.11

DOI: 10.20969/VSKM.2022.15(5).107-115

PDF download DRUG-INDUCED LIVER INJURY - MODERN VIEW ON THE CORRECT PROBLEM

MOLOSTVOVA ALSU F., ORCID ID: 0000-0001-6996-9985; Assistant of professor of the Department of Internal medicine, Kazan State Medical University, 420012, Russia, Kazan, Butlerov str., 49, tel.: +7-904-672-81-19, e-mail: alsuvesna@mail.ru

KHABIROVA GUZEL I., ORCID ID: 0000-0002-5355-9372; student, Kazan State Medical University, 420012, Russia, Kazan, Butlerov str., 49, tel.: +7-987-219-94-81, e-mail: guzelkah24@gmail.com

KHARISOVA YULIA I., ORCID ID: 0000-0002-1053-5100; student, Kazan State Medical University, 420012, Russia, Kazan, Butlerov str., 49, tel.: +7-958-279-57-95, e-mail: femirayan@gmail.com

SALIMOVA LILIYA M., ORCID ID: 0000-0003-4186-6049; assistant of professor of the Department of Internal Medicine, Kazan State Medical University, 420012, Russia, Kazan, Butlerov str., 49, tel.: +7-927-246-40-59, e-mail: сalimova.lili@gmail.сom

Abstract. Introduction. The high prevalence, variability of clinical manifestations, limited knowledge about the mechanisms of toxicity, the complexity of diagnosis makes drug-induced liver injury one of the unsolved problems in clinical medicine. The expansion of the pharmaceutical market, the growth in the number of uncontrolled medications put forward drug-induced liver damage in a number of urgent problems not only for hepatologists, but also for doctors of other specialties. Aim. Review of current scientific publications devoted to the study of drug-induced liver damage. Material and methods. A search and subsequent analysis of scientific publications devoted to the study of the issue of diagnosis and treatment of drug-induced liver lesions, published on the databases: Unpaywall, PubMed, eLibrary, CyberLeninka, MedLine, was carried out. Results and discussion. The article presents up-to-date data on the pathogenesis of occurrence, classification features, principles of diagnosis and treatment of drug-induced liver lesions. Pharmaceuticals that most commonly cause drug-induced liver injury are listed. Conclusion. Drug-induced liver injury covers a wide range of clinical conditions, ranging from mild abnormalities in biochemical parameters to acute liver failure. The vast majority of adverse liver reactions occur from 5-90 days after the last dose of inducer drugs. Many scientific papers have been devoted to the study of drug-induced liver injury, but clinical practitioners still have many unresolved issues related to the correct diagnosis and treatment of drug-induced liver injury. This is facilitated primarily by the uncontrolled prescription and intake of pharmaceuticals, the «fashion» for biologically active additives, which in its outcome forms the development of polypharmacy and, accordingly, the potentiation of hepatotoxicity of drugs.

Key words: drug-induced liver injury, hepatotoxicity, idiosyncrosis, hepatotropism, idiosyncrasy.

For reference: Molostova AF, Khabirova GI, Kharisova YI, Salimova LM. / Drug-induced liver injury - modern view on the correct problem. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):107-115. DOI: 10.20969/ VSKM.2022.15(5).107-115.

References

1. Ивашкин В.Т., Барановский А.Ю., Райхельсон К.Л., и др. Лекарственные поражения печени (клинические рекомендации для врачей) // Российский журнал гастроэнтерологов, гепатологов и колопроктологов. – 2019. – Т.29, вып.1. - С.101–131. [Ivashkin VT, Baranovskij AYu, Rajhel’son KL et al. Lekarstvennye porazheniya pecheni (klinicheskie rekomendacii dlya vrachej) [Drug-induced liver injury (clinical recommendations for physicians)]. Rossijskij zhurnal gastroenterologov, gepatologov i koloproktologov [Russian journal of gastroenterologists, hepatologists and coloproctologists]. 2019; 29(1): 101–131. (in Russ)] DOI:10.22416/1382-4376-2019-29-1-101-13

2. Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3): 221-241. DOI:10.1007/ s12072-017-9793-2

3. Остроумова О.Д., Борисова Е.В., Пиксина Г.Ф., Павлеева Е.Е. Лекарственные поражения печени в практике врача первичного звена (обзор клинических рекомендаций) // Медицинский алфавит. – 2020. – No21 – С.58–68. [Ostroumova OD, Borisova EV, Piksina GF, Pavleeva EE. Lekarstvennye porazheniya pecheni v praktike vracha pervichnogo zvena (obzor klinicheskih rekomendacij) [Drug-induced liver injury in the practice of a primary care physician (review of clinical guidelines)]. Medicinskij alfavit [Мedical alphabet]. 2020; 21: 58-68. (In Russ.)] DOI: 10.33667/2078-5631-2020-21-58-68

4. Губергриц Н.Б., Беляева Н.В., Клочков А.Ю., и др. Лекарственное поражение печени: от патогенеза к лечению // Вестник панкреатического клуба. – 2020. – Т. 46, вып.1. – С.72-80. [Gubergric NB, Belyaeva NV, Klochkov AYU, et al. Lekarstvennoe porazhenie pecheni: ot patogeneza k lecheniyu [Drug-induced liver injury: from pathogenesis to treatment] Vestnik pankreaticheskogo kluba [Herald of Pancreatic Club]. 2020;46(1): 72-80. (In Russ.)] DOI: 10.33149/vkp.2020.01.1

5. World Health Organization (WHO). The Use of the WHO-UMC System for Standardised Case Causality Assessment. WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database 2000. https://www. who-umc.org/media/2768/ standardised-case-causality-assessment.pdf

6. Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013; 144(7): 1419-1425. DOI: 10.1053/j. gastro.2013.02.006

7. Leone A, Nie A, Brandon Parker J. et al. Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants. Toxicol Appl Pharmacol. 2014; 275(3): 189–97. DOI:10.1016/j. taap.2014.01.017

8. Lo Re V 3rd, Haynes K, Forde KA. et al. Risk of acute liver failure inpatients with drug-induced liver injury: evaluation of Hy’s Law and a new prognostic model. Clin Gastroenterol Hepatol. 2015; 13 (13): 2360-2368. DOI:10.1016/j.cgh.2015.06.020

9. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013; 37 (1): 3–17. DOI:10.1111/apt.12109

10. Буеверов А.О., Буеверова Е.Л. Эволюция представлений о лекарственных поражениях печени. // Экспериментальная и клиническая гастроэнтерология. - 2019 – Вып.163, No3 – С. 89–96. [Bueverov AO, Bueverova EL. Evolyuciya predstavlenij o lekarstvennyh porazheniyah pecheni [The evolution of ideas about medicinal liver damage] Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2019; 163(3): 89-96. (In Russ.)] DOI: 10.31146/1682-8658-ecg-163-3-89-96

11. Grattagliano I, Bonfrate L, Diogo CV, et al. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J Gastroenterol. 2009; 15(39): 4865-4876. DOI:10.3748/wjg.15.4865

12. Галимова С.Ф. Лекарственные поражения печени (часть1) // Трансплантология. 2011-No1 - С.13-21. [Galimova SF. Lekarstvennye porazheniya pecheni (chast’1) [Drug-induced lesions of the liver (part 1)] Transplantologiya [Transplantology]. 2011; 1: 13-21. (in Russ)]. DOI:10.23873/2074-0506-2011-0-1-13-21

13. Галимова С.Ф. Лекарственные поражения печени (Часть 2-я) // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014 –No1 – С.21–28. [Galimova SF. Lekarstvennye porazheniia pecheni (Chast’ 2-ia) [Drug-induced lesions of the liver (part 2)] Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2014; 1: 21–28 (in Russ).] https://www.elibrary.ru/item.asp?id=21593432

14. Логинов А.Ф., Буторова Л.И., Логинов В.А. Лекарственные поражения печени: диагностика, лечение // РМЖ. Гастроэнтерология. 2016 – 11 - С.721–727. [Loginov AF, Butorova LI, Loginov VA. Lekarstvennye porazheniya pecheni: diagnostika, lechenie [Drug-induced liver injury: diagnosis, treatment]. RMZh. Gastroenterologiya [BC. Gastroenterology]. 2016; 11: 721–727. (in Russ)]. https:// www.elibrary.ru/item.asp?id=26376307

15. Aithal GP, Watkins PB, Andrade RJ et al. Review. Case definition andphenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011; 89(6): 806–815. DOI:10.1038/clpt.2011.58

16. Delemos AS, Foureau DM, Jacobs C et al. Drug-induced liver injurywith autoimmune features. Semin Liver Dis. 2014; 34(2): 194–204. DOI:10.1055/s-0034-1375959

17. Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015; 63 (2):503–514. DOI:10.1016/j. jhep.2015.04.016

18. Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-inducedliver injury. Curr Opin Allergy Clin Immunol. 2014; 14 (4): 286–292. DOI:10.1097/ACI.0000000000000070

19. Lucena MI, Andrade RJ, Kaplowitz N et al. Spanish Group for the Study of Drug-Induced Liver Disease. Phenotypic characterization of idiosyncraticdrug-induced liver injury: The influence of age and sex. Hepatology. 2009; 49 (6): 2001–2009. DOI: 10.1002/hep.22895

20. Reuben A, Koch DG, Lee WM; Group ALFS. Druginduced acute liver failure: Results of a U. S. multicenter, prospective study. Hepatology. 2010; 52 (6): 2065–2076. DOI:10.1002/hep.23937

21. Fontana RJ, Hayashi PH, Gu J et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014; 147 (1): 96–108. DOI:10.1053/j. gastro.2014.03.045

22. Байкова И.Е., Никитин И.Г. Лекарственное поражение печени // РМЖ. 2009 – 1 – С. 4–10. [Bajkova IE, Nikitin IG. Lekarstvennoe porazhenie pecheni [Drug-induced liver injuries]. RMZh [RMJ]. 2009; 1: 4–10 (In Russ.)]. https:// www.rmj.ru/articles/bolezni_organov_pishchevareniya/ Lekarstvennoe_poraghenie_pecheni

23. Andrade RJ, Lopez-Ortega S, Lopez-Vega MC et al. Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Rev Clin Pharmacol. 2008; 1 (2): 261–76. DOI:10.1586/17512433.1.2.261

24. Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case character-ization, clinical features and risk factors in drug-induced liver injury. Int Mol Sci. 2016; 17 (5): 714. DOI:10.3390/ijms17050714

25. Sim SC, Ingelman-Sundberg M. Update on allele nomenclature for humancytochromes P450 and the human cytochrome P450 allele (CYP-allele) nomenclature database. Methods Mol Biol. 2013; 987: 251–259. DOI:10.1007/978-1-62703-321-3_21

26. Abajo FJ de, Montero D, Madurga M, Garcia Rodríguez LA. Acute andclinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004; 58 (1): 71–80. DOI:10.1111/j.1365-2125.2004.02133.x

27. Lemasters JJ, Qian T, Bradham CA et al. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J Bioenerg Biomembr. 1999; 31 (4): 305–319. DOI:10.1023/a:1005419617371

28. Dara L, Liu Z, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016; 36 (2): 158–65. DOI:10.1111/liv.12988

  1. Grattagliano I, Bonfrate L, Diogo CV et al. Biochemical mechanisms in drug-induced liver injury: Certainties and doubts. World J Gastroenterol 2009; 15(39): 4865-4876. DOI: 10.3748/wjg.15.4865
  2. Лазебник Л.Б., Голованова Е.В., Хлынова О.В., и др. Лекарственные поражения печени (ЛПП) у взрослых // Экспериментальная и клиническая гастроэнтерология. – 2020. –No2 (174) – С.24-59. [Lazebnik LB, Golovanova EV, Hlynova OV, et al. Lekarstvennye porazheniya pecheni (LPP) u vzroslyh [Drug-induced liver injury (DILI) in adults]. Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2020; 2 (174): 29–54. (in Russ)]. DOI: 10.31146/1682-8658-ecg-174-2-29-54
  3. Полунина Т.Е. Лекарственные поражения печени // РМЖ. Медицинское обозрение. -2018. - No7 (I). С.7-12. [Polunina TE. Lekarstvennye porazheniya pecheni [Drug-induced liver injury]. RMZh. Meditsinskoye obozreniye [RMJ. Medical Review]. 2018; 7 (1): 7-12. (In Russ.)]. https://www.rmj.ru/articles/gastroenterologiya/ Lekarstvennye_povreghdeniya_pecheni
  4. Aithal GP, Watkins PB, Andrade RJ et al. Case definition and phenotype standardization in drug-induced liver injury. Review. Clin.Pharmacol. Ther. 2011; 89 (6): 806– 815. DOI:10.1038/clpt.2011.58
  5. Chalasani NP, Hayashi PH, Bonkovsky HL et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109 (7): 950–66. DOI:10.1038/ajg.2014.131
  6. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015; 17 (1): 14. DOI:10.3390/ijms17010014
  7. Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221-241. DOI:10.1007/ s12072-017-9793-2
  8. Food and Drug Administration. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. July 2009. http://www.fda.gov/downloads/Drugs/.../ Guidances/ UCM174090.pdf. Accessed by May 08, 2016
  9. Krenzelok EP. The FDA Acetaminophen Advisory Committee Meeting — what is the future of acetaminophen in the United States: the perspective of a committee member. Clin Toxicol (Phila). 2009; 47 (8): 784–789. DOI: 10.1080/15563650903232345
  10. Zhu SS, Dong Y, Gan Y et al. Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010; 24 (2): 136–138.
  11. Leone A, Nie A, Brandon Parker J et al. Oxidative stress/ reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants. Toxicol Appl Pharmacol. 2014; 275 (3): 189–197. DOI:10.1016/j. taap.2014.01.017
  12. Лазебник Л. Б., Голованова Е. В., Алексеенко С.А. и др. Российский консенсус «Гипераммониемии у взрослых» // Экспериментальная и клиническая гастроэнтерология. – 2019. - №12.- С. 3–23. [Lazebnik LB, Golovanova EV, Alekseenko SA et al. Rossijskij konsensus «Giperammoniemii u vzroslyh» [Russian Consensus “Hyperammonemia in Adults”]. Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2019; 12: 3–23. (In Russ.)]. DOI: 10.31146/1682–8658-ecg-172–12–3–23
  13. Горецкая М. В., Шейбак В. М. Гепатопротекторные свойства таурина при интоксикации парацетамолом // Известия Национальной академии наук Белоруссии.  - 2013. - № 3. - С. 96–101. [Goretskaya MV, Sheybak VM. Gepatoprotektornye svojstva taurina pri intoksikacii paracetamolom [Hepatoprotective properties of taurine in paracetamol intoxication]. Izvestiya Nacional’noj akademii nauk Belorussii [News of the National Academy of Sciences of Belarus]. 2013; 3: 96–101(In Russ.)]. https://www.elibrary.ru/item.asp?id=23923904
  14. Королева М. В. Фармакоэпидемиологическая и клинико-лабораторная характеристика лекарственно-индуцированного поражения печени при туберкулезе // Журнал Инфектологии. - 2015 - Т. 7, №4. – С.44-50. [Koroleva MV. Farmakoepidemiologicheskaya i kliniko-laboratornaya harakteristika lekarstvennoinducirovannogo porazheniya pecheni pri tuberkuleze [Pharmaco-epidemiological, clinical and laboratory characteristics of drug-induced liver injury in tuberculosis]. Zhurnal Infektologii [Journal Infectology].2015; 7(4):44-50 (In Russ.)]. DOI:10.22625/2072-6732-2015-7-4-44-50
  15. Пальцев А. И. и др. Гепатозащитная роль гидролизата плаценты лаеннека в лечении больных с вирусно-паразитарными заболеваниями печени // Экспериментальная и клиническая гастроэнтерология. – 2016. - № 11. – С. 94–99. [Pal’cev AI i dr. Gepatozashchitnaya rol’ gidrolizata placenty laenneka v lechenii bol’nyh s virusnoparazitarnymi zabolevaniyami pecheni [Hepatoprotective role of Laennec placenta hydrolyzate in the treatment of patients with viral and parasitic liver diseases] Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2016; (11): 94–99. (In Russ.)]. https://www.nogr.org/jour/article/view/330
  16. Минушкин О.Н., Максимов В.А., Пальцев А.И., и др. Рекомендации по применению гидролизата человеческой плаценты при заболеваниях печени // Экспериментальная и клиническая гастроэнтерология. – 2016. - № 12. – С. 75–77. [Minushkin ON, Maksimov VA, Pal’cev AI et al. Rekomendacii po primeneniyu gidrolizata chelovecheskoj placenty pri zabolevaniyah pecheni [Recommendations for the use of human placenta hydrolyzate in liver disease]. Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2016; 12: 75–77. (In Russ.)]. https://www.nogr.org/jour/article/view/349
  17. Минушкин О. Н., Масловский Л. В., Зверков И. В. и др. «Лаеннек» в лечении некоторых заболеваний печени // Эффективная фармакотерапия. – 2008. - № 1. – С. 30–34. [Minushkin ON, Maslovskij LV, Zverkov IV et al. «Laennek» v lechenii nekotoryh zabolevanij pecheni [«Laennec» in the treatment of certain liver diseases]. Effektivnaya farmakoterapiya [Effective pharmacotherapy]. 2008; 1: 30–34. (In Russ.)]. https://elibrary.ru/item.asp?id=22778552
  18. Громова О. А., Торшин И. Ю., Минушкин О. Н., и др. Об эффективности и молекулярных механизмах действия препарата «Лаеннек» в лечении патологических состояний печени, связанных с отложением железа в печени // Медицинский журнал Дело Жизни. - 2015. – № 1(1). – С. 44–51. [Gromova OA, Torshin IYu, Minushkin ON et al. Ob effektivnosti i molekulyarnyh mekhanizmah dejstviya preparata «Laennek» v lechenii patologicheskih sostoyanij pecheni, svyazannyh s otlozheniem zheleza v pecheni [On the effectiveness and molecular mechanisms of action of the drug «Laennec»
    in the treatment of pathological conditions of the liver associated with iron deposition in the liver]. Medicinskij zhurnal Delo Zhizni [The Medical Journal of Life]. 2015; 1 (1): 44–51. (In Russ.)]. https://rhana.ru/upload/iblock/b7c/b7cadd4784b7389ee35d754cbb18b299.pdf

 

UDC:616:[578.28HIV+578.834.1](048.8)

DOI:10.20969/VSKM.2022.15(5).116-121

PDF download CLINICAL OUTCOMES OF COVID-19 IN PEOPLE LIVING WITH HIV

OVSYANNIKOV NIKOLAY V., ORCID ID: 0000-0002-9945-7881; D. Med. Sci, Associate Professor, Head of Internal Diseases Department of Omsk State Medical University, Russia, 644099, Omsk, Lenin Str., 12; tel. +7-913-965-05-24, e-mail: niklajjovs@rambler.ru

BILEVICH OLGA A., ORCID ID: 0000-0003-2583-5648; C. Med. Sci., Associate Professor of Internal Diseases Department of Omsk State Medical University, Russia, 644099, Omsk, Lenin Str., 12; tel. +7-983-114-64-58, e-mail: bilewich@mail.ru

PYANNIKOVA VALERIA A., ORCID ID: 0000-0002-9961-5747, 4th year student of the General Medicine Faculty, Internal Diseases Department of Omsk State Medical University, Russia, 644099, Omsk, Lenin Str., 12; tel. +7-950-795-12-76, e-mail: lera_pyannikova@mail.ru

Abstract. Introduction. Since the early 1980s, the world has experienced an epidemic of human immunodeficiency virus infection. After that, in 2019 healthcare system faced a pandemic of infection caused by the emergence of a new coronavirus SARS-CoV-2, which caused high morbidity and mortality worldwide. Data on the incidence, course, and outcomes of COVID-19 in people living with human immunodeficiency virus are limited. Aim. The aim of the study is to examine data from publications on clinical outcomes of COVID-19 in people living with human immunodeficiency virus.Material and methods. A thorough literature search was carried out using the MEDLINE, Embase, Scopus databases, 21 sources were selected and analyzed. Results and discussion. Publication data do not indicate that people living with human immunodeficiency virus are more susceptible to COVID-19 than the general population. As in the general population, older age and the presence of comorbidities worsen the prognosis in patients with human immunodeficiency virus and COVID-19. A number of authors note higher mortality rates from COVID-19 infection in HIV-infected patients of African and Asian descent. Well-controlled human immunodeficiency virus infection does not change the clinical presentation or worsen the clinical outcome of hospitalization for COVID-19 infection in HIV-infected patients. Patients with human immunodeficiency virus in the advanced stages of the disease may show less severe symptoms of COVID-19 infection due to a reduction in the severity of immune responses. Conclusion. Clinical outcomes of COVID-19 in patients with and without human immunodeficiency virus coinfection are comparable. The high-risk group for COVID-19 includes human immunodeficiency virus patients with pre-existing comorbidities and individuals in older age groups. Controlled human immunodeficiency virus patients with an undetectable viral load have a better prognosis than uncontrolled patients.

Key words: COVID-19, HIV, coinfection, clinical outcomes.

For reference: Ovsyannikov NV, Bilevich OA, Pyannikova VA. Clinical outcomes of COVID-19 in people living with HIV. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):116-121. DOI: 10.20969/VSKM.2022.15(5).116-121.

References

1. Бартлетт Дж., Редфилд Р., Фам П., Мазус А.И. Клинические аспекты ВИЧ-инфекции. – Москва: Гранат, 2013. – 696 с. [Bartlett Dzh, Redfild R, Fam P, Mazus AI. Klinicheskie aspekty VICh-infekcii [Clinical manifestations of HIV infection]. Moskva: Granat [Moscow: Granat]. 2013; 696 p. (In Russ.)]. ISBN 978-5-93439-298-8

2. Либман Г., Макадон Х. Дж. ВИЧ-инфекция. – Москва: ГЭОТАР-Медиа, 2013. – 560 с. [Libman G, Makadon KDh. VICh-infekcziya [HIV infection]. Moskva: GEOTAR-Media [Moscow: GEOTAR-Media]. 2013; 560 p. (In Russ.)]. ISBN 978-5-9704-1761-4

3. Покровский В.В. (ред.). ВИЧ-инфекция и СПИД. Национальное руководство. – Москва: ГЭОТАР-Медиа, 2020. – 696 с. [Pokrovskij VV (ed.). VICh-infekcija i SPID. Nacional’noe rukovodstvo [HIV infection and AIDS. National guidelines]. Moskva: GEOTAR-Media [Moscow: GEOTAR-Media]. 2020; 696 p. (In Russ.)]. ISBN 978-5-9704-5421-3

4. ВИЧ-инфекция у взрослых. Клинические рекомендации [VICh-infekcija u vzroslyh. Klinicheskie rekomendacii [HIV infection in adults. Clinical guidelines]. Moskva [Moscow]. 2020; 230 с. (In Russ.)]. http:// rushiv.ru/klinicheskie-rekomendatsii-vich-infektsiya-u-vzroslyh-2020

5. Костинов М.П., Чучалин А.Г. (ред.). Руководство по клинической иммунологии в респираторной медицине. – Москва: Атмосфера, 2016. – 128 с. [Kostinov MP, Chuchalin AG (eds.). Rukovodstvo po klinicheskoj immunologii v respiratornoj medicine [Guidelines for clinical immunology in respiratory medicine]. Moskva: Atmosfera [Moscow: Atmosfera]. 2016; 128 p. (In Russ.)]. ISBN 978-5-902123-70-5

6. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395 (10224): 565-574. DOI: 10.1016/s0140-6736(20)30251-8

7. Tan W, Zhao X, Ma X, et al. A novel coronavirus genome identified in a cluster of pneumonia cases – Wuhan, China 2019−2020. China CDC Weekly. 2020; 2 (4): 61–62. DOI: 10.46234/ccdcw2020.017

8. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24 (6): 490–502. DOI: 10.1016/j. tim.2016.03.003.

9. Zhou P, Yang X-L, Wang X-G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020. Published online Jan 23. DOI: 10.1101/2020.01.22.914952

10. WHO Coronavirus (COVID-19) Dashboard. World Health Organization: official site. https://covid19.who.int (access date: 23.03.2022)

11. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. World Health Organization: official site. https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/situation-reports (access date: 02.05.2022)

12. Dawei W, Bo H, Chang H, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061-1069. DOI:10.1001/jama.2020.1585

13. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584 (7821): 430-436. DOI:10.1038/s41586-020-2521-4

14. COVID-19 Daily Deaths. NHS England: official site. https://www.england.nhs.uk/statistics/statistical-work- areas/covid-19-daily-deaths/ (access date: 02.05.2022)

15. COVID-19 Report. ICNARC. Intensive Care National Audit & Research Centre: site. https://web.archive.org/ web/20200425133758/https:/www.icnarc.org/Our-Audit/ Audits/Cmp/Reports (access date: 02.05.2022)

16. Coronavirus (COVID-19) in the UK. GOV.uk. Coronavirus (COVID-19) cases in the UK: site. https://web.archive. org/web/20200502045059/https://coronavirus.data.gov. uk/ (access date: 02.05.2022)

17. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020; 24 (1): 179. DOI: 10.1186/s13054-020-02902-w

18. Public Health England. Disparities in the risk and outcomes from COVID-19. London. 2020; 92 p. https://assets. publishing.service.gov.uk/government/uploads/system/ uploads/attachment_data/file/908434/Disparities_in_the_ risk_and_outcomes_of_COVID_August_2020_update. pdf (access date: 02.05.2022)

19. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020; 8 (5): 436-438. DOI: 10.1016/S2213-2600(20)30167-3

20. Massarvva T. Clinical outcomes of COVID-19 amongst HIV patients: a systematic literature review. Epidemiol Health. 2021; 43: e2021036. Published online May 17. DOI: 10.4178/epih.e2021036

21. Woodward WC. Can you explain AIDS and how it affects the immune system? How does HIV become AIDS? Scientific American: site. Published 1999 Nov 28. URL: https://www.scientificamerican.com/article/can-you- explain-aids-and/ (access date: 02.05.2022)

22. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med. 2020; 21 (9): 567–577. DOI: 10.1111/hiv.12911

23. COVID-19 and HIV. IAPAC: site. URL: https://www.iapac. org/education/hiv-covid-19/ (access date: 02.05.2022)

24. HIV and COVID-19 Basics. CDC. Centers for Disease Control and Prevention: site. https:// www.cdc.gov/hiv/basics/covid-19.html?CDC_AA_ refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus %2F2019-ncov%2Fneed-extra-precautions%2Fhiv.html (access date: 02.05.2022)

25. Dong Y, Li Zh, Ding Sh, et al. HIV infection and risk of COVID-19 mortality: A meta-analysis. Medicine (Baltimore). 2021; 100 (26): e26573. DOI: 10.1097/ MD.0000000000026573

26. Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: summary of the data and responses to date. Curr Opin HIV AIDS. 2021; 16 (1): 63-73. DOI: 10.1097/COH.0000000000000659

27. Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020; 7 (5): e314-e316. DOI:10.1016/S2352-3018(20)30111-9

28. Inciarte A, Gonzalez-Cordon A, Rojas J, et al. Clinical characteristics, risk factors, and incidence of symptomatic COVID-19 in adults living with HIV: a single-center, prospective observational study. AIDS. 2020; 34 (12): 1775-1780. DOI: 10.1097/QAD.0000000000002643

29. Etienne N, Karmochkine M, Slama L, et al. HIV infection and COVID-19: risk factors for severe disease. AIDS. 2020; 34 (12): 1771–1774. DOI: 10.1097/ QAD.0000000000002651

30. Diez C, Del Romero-Raposo J, Mican R, et al. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. HIV Medicine. 2021; 22 (9): 867-876. DOI: 10.1111/hiv.13145

31. Berenguer J, Ryan P, Rodriguez-Bano J, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020; 26 (11): 1525-1536. DOI: 10.1016/j.cmi.2020.07.024

32. Boulle A, Davies MA, Hussey H, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis 2021; 73 (7): e2005-2015. DOI: 10.1093/cid/ciaa1198

33. Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020; 71 (11): 2933-2938. DOI: 10.1093/cid/ ciaa880

34. Brown AE, Croxford SE, Sara E, et al. COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in England. HIV Medicine. 2022; 23 (1): 90-102. DOI: 10.1111/hiv.13167

35. Alinaghi S, Karimi A, Mohsseni PM, et al. The clinical outcomes of COVID-19 in HIV-positive patients: A systematic review of current evidence. Immun Inflamm Dis. 2021; 9 (4): 1160-1185. DOI: 10.1002/iid3.497

  1. Cooper TJ, Woodward B, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med. 2020; 21(9): 567-577. DOI: 10.1111/hiv.12911

  2. Laurence J. Why aren’t people living with HIV at higher risk for developing severe coronavirus disease 2019 (COVID-19)? AIDS Patient Care STDS. 2020; 34 (6): 247-248. DOI: 10.1089/apc.2020.29005

  3. Cabello A, Zamarro B, Nistal S, et al. COVID-19 in people living with HIV: A multicenter case-series study. Int J Infect Dis. 2021; 102: 310-315. DOI: 10.1016/j.ijid.2020.10.060

  4. Braunstein SL, Lazar R, Wahnich A, et al. Coronavirus disease 2019 (COVID-19) infection among people with human immunodeficiency virus in New York City: A population-level analysis of linked surveillance data. Clin Infect Dis. 2021; 72 (12): e1021-e1029. DOI: 10.1093/cid/ ciaa1793

  5. Meyerowitz EA, Kim AY, Ard KL, et al. Disproportionate burden of COVID-19 among racial minorities and those in congregate settings among a large cohort of people with HIV. AIDS. 2020; 34 (12): 1781-1787. DOI: 10.1097/ QAD.0000000000002607

  6. Petrilli CM, Jones SA, Yang J, et al. Factors Associated with Hospital Admission and Critical Illness Among 5279 People With Coronavirus Disease 2019 in New York City: Prospective Cohort Study. BMJ. 2020; 369: m1966. DOI: 10.1136/bmj.m1966

  7. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan). 2021; 13 (1): 5. DOI: 10.1186/ s41479-021-00083-w

  8. McIntosh K. Coronaviruses. https://www.uptodate.com/ contents/coronaviruses/print (access date: 12.03.2020)

44. Zhu X, Ge Y, Wu T, et al. Co-infection with respiratory pathogens among COVID-19 cases. Virus Res. 2020; 285: 198005. DOI: 10.1016/j.virusres.2020.198005

45. Verduyn M, Allou N, Gazaille V, et al. Co-infection of dengue and COVID-19: a case report. PLoS Negl Trop Dis. 2020; 14 (8): e0008476. DOI: 10.1371/journal. pntd.0008476

46. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Inf Secur. 2020; 81 (2): 266–275. DOI: 10.1016/j.jinf.2020.05.046

47. Gudipati S, Brar I, Murray S, et al. Descriptive analysis of patients living with HIV affected by COVID-19. J Acquir Immune Defic Syndr. 2020; 85 (2): 123–126. DOI: 10.1097/QAI.0000000000002450

48. Chen XP, Cao Y. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome. Clin Infect Dis. 2004; 38 (7): 1030-1032. DOI: 10.1086/386340

49. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020; 253: 117592. DOI: 10.1016/j. lfs.2020.117592

50. Ford N, Vitoria M, Rangaraj A, et al. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc. 2020; 23 (4): e25489. DOI: 10.1002/ jia2.25489

51. Mendoza P, Lorenzi JCC, Gaebler C. СOVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. Curr Opin HIV AIDS. 2021; 16 (1): 25-35. DOI: 10.1097/COH.0000000000000657

 

EXPERIENCE EXCHANGE

UDC: 614.446.1

DOI: 10.20969/VSKM.2022.15(5).122-128

PDF download RISK ASSESSMENT OF THE SEVERE COURSE OF COVID-19 AND CASES OF IRRATIONAL PRESCRIBING OF MEDICATIONS

CHERESHNEVA NATALIA DMITRIEVNA, ORCID ID: 0000-0003-4821-6890, AUTHOR ID: 6975-2356, C. Med. Sci., Pharmacy Director, Republican Clinical Hospital of War Veterans, Russian Federation, 424037, Yoshkar-Ola, 24 Osipenko Str.; Assistant Professor, Mari State University, Russian Federation, 424031, Yoshkar-Ola, 60 Osipenko Str., cell 8-927-88-33-221, e-mail: Natapharm@mail.ru

Abstract. Introduction. The coronavirus infection pandemic has caused a significant increase in hospitalizations worldwide. Hospital mortality among patients aged 70 to 79 years was as high as 35%, and for patients older than 80 years more than 60%. The severity of COVID-19 is closely related to comorbidities. The COVID-19 outbreak necessitated the development of drugs to combat the pandemic, and known off-label drugs were used as an alternative treatment. The use of drugs with unproven efficacy is especially dangerous in individuals with serious heart disease and can be fatal. Aim. To reveal the dependence of severity of the disease on age and body weight on the analysis of COVID-19 patient charts, to compare the obtained results with the literature data and to identify cases of irrational prescribing of drugs. Material and methods. Case reports of 334 patients treated at a reassigned infectious disease hospital with COVID-19 were analyzed. Patients were divided into 2 groups: those aged 60 years and older (group 1) and those younger than 60 years (group 2). Statistics were calculated: for indicators having normal distribution the results were calculated as arithmetic mean, for the rest as median and interquartile range, categorical variables were presented as number or percentage. For nonparametric variables, we calculated the χ2 criterion for 2x2 tables (Pearson’s goodness-of-fit test). The maximum significance value was χ2 = 3.84 (with degree of freedom d.f.=1; p<0.05). Results and discussion. Analysis showed that individuals under 60 years of age were less likely to have a severe course of the disease (33.8%) than those aged 60 years or older (45.6%). The duration of hospital stay in older patients was 10.7±2.58 bed/days, in younger patients 9.8±2.21. Statistically significant dependence of disease severity on body weight was not revealed. It was found that almost all patients were prescribed 5 drugs: omeprazole, paracetamol, ambroxol, heparin and acetylsalicylic acid. There were cases of irrational prescription of the following drugs: favipiravir, paracetamol, interferon-α, acetylsalicylic acid, baricitinib. Conclusion.COVID-19 management should be performed with careful evaluation of the prescribed medications for potential drug interactions and/or additional side effects.

Keywords: Elderly patient, new coronavirus infection, COVID-19, pandemic, hospitalization, morbidity, irrational drug therapy.

For reference: Chereshneva N.D. Risk assessment of the severe course of COVID-19 and cases of irrational prescribing of medications. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):122-128. DOI: 10.20969/VSKM.2022.15(5).122-128.

References

1. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324 (8): 782-793. DOI: 10.1001/ jama.2020.12839

2. Richardson S, Hirsch JS, Narasimhan M, et al. The Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323 (20): 2052-2059. DOI:10.1001/ jama.2020.6775

3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3

4. Arachchillage DR, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18: 1233–1234. DOI: 10.1111/jth.14768

5. Liu Y, Sun W, Guo Y, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020; 31: 490–496. DOI: 10.1080/09537104.2020.1754383

6. Gao L, Jiang D, Wen XS, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020; 21: 83. DOI: 10.1186/s12931-020-01352-w

7. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55 (5): 2000524. DOI: 10.1183/13993003.00524-2020

8. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020; 12 (10): 9959-9981. DOI: 10.18632/aging.103344

9. Stefan N, Birkenfeld AL, Schulze MB, et al. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020; 16 (7): 341-342. DOI: 10.1038/ s41574-020-0364-6

10. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation. 2020; 142 (1): 4-6. DOI: 10.1161/CIRCULATIONAHA.120.047659

11. Hamer M, Kivimäki M, Gale CR, et al. Lifetyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. Brain Behav Immun. 2020; 87: 184-187. DOI: 10.1016/j. bbi.2020.05.059

12. Paumgartten FJR, Oliveira ACAX. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Cien Saude Colet. 2020; 25 (9): 3413-3419. DOI: 10.1590/1413-81232020259.16792020

13. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol. 2019; 43 (6): 101300. DOI: 10.1016/j.smim.2019.101300

14. Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020; 11: 1061. DOI: 10.3389/fimmu.2020.01061

  1. Pereda R, González D, Rivero HB, et al. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. J Interferon Cytokine Res. 2020; 40 (9): 438-442. DOI: 10.1089/jir.2020.0124

  2. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844-847. DOI: 10.1111/jth.14768

  3. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18 (5): 1023–1026. DOI: 10.1111/jth.14810

  4. Bianconi V, Violi F, Fallarino F, et al. Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19? Drugs. 2020; 80 (14): 1383-1396. DOI: 10.1007/s40265-020-01365-1

  5. Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021; 397 (10291): 2253-2263. DOI: 10.1016/S0140-6736(21)01203-4

  6. Marconi VC, Ramanan AV, de Bono S, et al. COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021; 9 (12): 1407-1418. DOI: 10.1016/S2213-2600(21)00331-3

21. Zippi M, Fiorino S, Budriesi R, et al. Paradoxical relationship between proton pump inhibitors and COVID-19: A systematic review and meta-analysis. World J Clin Cases. 2021; 9 (12): 2763-2777. DOI: 10.12998/ wjcc.v9.i12.2763

22. Luxenburger H, Sturm L, Biever P, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? J Intern Med. 2021; 289 (1): 121-124. DOI: 10.1111/ joim.13121

23. Price E, Treacher DF. Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections. Crit Care. 2021; 25 (1): 73. DOI: 10.1186/ s13054-021-03497-6

24. Yozgat A, Kasapoğlu B, Can G, et al. Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turk J Med Sci. 2021; 51 (3): 1675-1681. DOI: 10.3906/sag-2103-80

25. Ramachandran P, Perisetti A, Gajendran M, et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. Eur J Gastroenterol Hepatol. 2022; 34 (2): 137-141. DOI: 10.1097/MEG.0000000000002013

 

HEALTHCARE ORGANIZATION

UDC 614.2 : 616-08.6

DOI: 10.20969/VSKM.2022.15(5).129-136

PDF download APPLICATION OF FUZZY MATHEMATICS TO MANAGE MEDICAL AND SOCIAL DECISIONS DURING A PANDEMIC

LYAPIN VITALY A., ORCID ID: 0000-0002-9034-1727; D. Med. Sci., Professor, Professor of the Department of Management, Politics and Law, Omsk Humanitarian Academy, Russia, 644050, Omsk, st. 4th Chelyuskintsev, 2A, tel: 8-381-229-00-87, e-mail: upp@omga.su

MARENKO VALENTINA A., ORCID ID: 0000-0001-7288-9353; С. Tech. Sci., аssociate professor, Senior researcher. Laboratory of methods for representation and transformation of information of the Sobolev Institute of mathematics, Siberian Branch of the Russian Academy of Sciences, Russia, 630090, Novosibirsk, Ac. Koptyuga, 4. tel: 8-902-677-39-13, e-mail: marenko@ofim.oscsbras.ru

NESTEROVA KLIMENTINA I., ORCID ID: 0000-0002-9793-7179; Scopus Author ID: 8555826800; D. Med. Sci., Professor of the Department of ENT, Omsk State Medical University, Russia, 644099 Omsk, st. Lenina, 12, tel. 8-381-295-70-01, е-mail: klnesterova@gmail.com

NESTEROVA ANNA A., ORCID ID: 0000-0002-2637-855X; C. Med. Sci., ENT doctor, Deputy for medical and scientific part of “ENT Center. Head and Neck Surgery”. Russia, 119034, Moscow, ul. Novosushchevskaya, d. 21. tel. 8-495-477-45-34, e-mail: annamedical@gmail.com

MIRAKYAN RUBEN G., ORCID ID:0000-0003-3563-2308, Cand. medical Sci., ENT doctor, head of the “ENT Center. Head and Neck Surgery”. Russia, 119034, Moscow, ul. Novosushchevskaya, 21. tel. 8-495-477-45-34, e-mail: rgmirakyan@lormedcentr.ru

YELOKHOVA YULIA A., ORCID ID: 0000-0003-3455-6878, С. Biol. Sci., Associate Professor of the Department of Physical Culture and Sports, Omsk State Agrarian University. Russia, 644008, Omsk, Institutskaya Square, 1. tel.: +7-903-926-4424, e-mail: yua.elokhova@omgau.org

Abstract. Introduction. The Covid-19 pandemic, which began in early 2020, has changed the organizational foundations of outpatient care and the psychological mindset of patients. Insufficiently informed medical and social decisions led to increasing citizen dissatisfaction with the level of medical care. Mathematical modeling plays a major role in understanding pandemic processes and supporting management decision making. Aim. The aim is substantiation of the choice of the optimal solution for managing the quality of outpatient medical care during a pandemic using mathematical modeling. Material and methods. The material was information about various aspects of the work of polyclinics from 871 questionnaires of a survey of citizens of the city of Omsk of different age categories: group 1 up to 25 years old (n=145), group 2 - 25-55 years old (n=540), group 3 - over 55 years old (n=186). The study protocol was approved by the center’s local ethics committee. Written informed consent was obtained from each participant to participate in the study. The research methodology is based on the theory of fuzzy sets, mathematical modeling, the use of a cognitive approach and simplicial analysis. Results and discussion. Factors influencing the degree of dissatisfaction with medical care have been identified. Possible causal relationships between them are constructed in the form of a cognitive map. A simplicial analysis of the formed cognitive structure and a computational experiment were carried out to observe trends in the development of dissatisfaction with medical care during a pandemic. Gender and age differences were revealed, showing, in particular, that young men have a higher degree of dissatisfaction with medical care (0.6) than women (0.48), but these differences smooth out with age. It was revealed, among other things, that with the improvement of the factor «work schedule of the polyclinic», the factor «dissatisfaction with medical care» is reduced by 2 times. It has been proven that the more significant for the satisfaction of the patient with medical care in the outpatient clinic will be its competent routing at the level of the registry and the general reception room. Conclusion. The use of cognitive technologies and mathematical modeling makes it possible to predict trends in the development of dissatisfaction with medical care when its individual factors change. This is the rationale for the rapid choice of a medical and social solution to eliminate deficiencies, which is extremely important during a pandemic.

Key words: healthcare, organization of medical care, pandemic, fuzzy set, cognitive model.

For reference: Lyapin V.A., Marenko V.A., Nesterova K.I., Nesterova A.A., Mirakyan R.G., Yelokhova Yu.A. Application of fuzzy mathematics to manage medical and social decisions during a pandemic. The Bulletin of Contemporary Clinical Medicine. 2022.15(5):129-136. DOI: 10.20969/VSKM.2022.15(5).129-136.

References

1. Суходолов А.П., Маренко В.А. К вопросу использования математического моделирования в разработке теории медиасферы // Вопросы теории и практики журналистики. – 2018. – Т.7, №1. – С. 5-23. [Sukhodolov AP, Marenko VA. K voprosu ispol’zovaniya matematicheskogo modelirovaniya v razrabotke teorii mediasfery [On the issue of mathematical modelling and developing a theory of the media sphere]. Voprosy teorii i praktiki zhurnalistiki [Questions of theory and practice of journalism]. 2018; 7(1): 5-23. (In Russ.)]. DOI: 10.17150/2308-6203.2018.7(1).5-23

2. Dąbrowska E, Divjak D. Cognitive Linguistics - A Survey of Linguistic Subfields. Berlin, Boston: De Gruyter Mouton; 2019; 248. DOI: 10.1515/9783110626452 

3. Langacker R.W. Discourse in Cognitive Grammar. Cognitive Linguistics. 2001; 12(2): 143-188. DOI: 10.1515/cogl.12.2.143 

4. Багишева Н.В., Моисеева М.В., Викторова И.А. и др. Качество жизни как интегральный показатель эффективности терапии: в фокусе пациенты с хронической обструктивной болезнью легких, туберкулезом легких и артериальной гипертензией // Медицинский альянс. – 2020 – Т.8, №3. – С. 37-45. [Bagisheva NV, Moiseyeva MV, Viktorova IA. et al. Kachestvo zhizni kak integral’nyy pokazatel’ effektivnosti terapii: v fokuse patsiyenty s khronicheskoy obstruktivnoy bolezn’yu legkikh, tuberkulezom legkikh i arterial’noy gipertenziyey [Quality of life as an integral indicator of the effectiveness of therapy: in focus are patients with chronic obstructive pulmonary disease, pulmonary tuberculosis and arterial hypertension]. Meditsinskiy al’yans [Medical Alliance]. 2020; 8(3): 37-45. (In Russ.)]. DOI: 10.36422/23076348-2020-8-3-37-45

5. Маренко В.А., Лучко О.Н., Ляпин В.А. и др. Анализ когнитивных моделей «Артериальная гипертензия» // Математические структуры и моделирование. – 2015. – №2 (34). – С. 64-74. [Marenko VA, Luchko ON, Lyapin VA, et al. Analiz kognitivnykh modeley «Arterial’naya gipertenziya» [Analysis of cognitive models “Hypertension”]. Matematicheskiye struktury i modelirovaniye [Mathematical structures and modeling.]. 2015; 2(34): 64-74. (In Russ.)]. https://elibrary.ru/download/elibrary_25339520_34679086.pdf

6. Brandt P, Cronquist U. Diagrams and mental figuration: A semio-cognitive analysis. // Semiotica. - 2019(229), 253-272.

7. Дмитриева В.Д. Экономическая модель социальной изоляции в условиях пандемии COVID-2019 // Интеллектуальные ресурсы – региональному развитию. – 2020. – №2. – С. 292-296. [Dmitriyeva VD. Ekonomicheskaya model’ sotsial’noy izolyatsii v usloviyakh pandemii COVID 2019 [The economic model of social isolation in the context of COVID-2019 pandemic]. Intellektual’nyye resursy - regional’nomu razvitiyu [Intellectual resources for regional development]. 2020; 2: 292-296. (In Russ.)]. https://elibrary.ru/download/elibrary_43033240_ 29449593.pdf

8. Левкова Е.А., Сепиашвили Р.И., Савин С.З. Проблемы создания прогностических моделей пандемии короновирусной инфекции COVID-19 // Вестник Российского университета дружбы народов. – 2021. – Т.25, №1. – С. 31-38. [Levkova YeA, Sepiashvili RI, Savin SZ. Problemy sozdaniya prognosticheskikh modeley pandemii koronovirusnoy infektsii COVID-19 [Problems of creating predictive models for the pandemic of coronovirus infection COVID-19]. Vestnik Rossiyskogo universiteta druzhby narodov. [Bulletin of the Peoples’ Friendship University of Russia]. 2021; 25(1): 31-38. (In Russ.)]. DOI: 10.22363/2313-0245-2021-25-1-31-38

9. Багишева Н.В., Мордык А.В., Нестерова К.И. и др. Факторный анализ социально-демографических предпосылок формирования туберкулеза у пациентов с хронической обструктивной болезнью легких // Вестник современной клинической медицины. – 2021. – Т. 14, вып. 1. – С.7–15. [Bagisheva NV, Mordyk AV, Nesterova KI, et al. Faktornyy analiz sotsial’no-demograficheskikh predposylok formirovaniya tuberkuleza u patsiyentov s khronicheskoy obstruktivnoy bolezn’yu legkikh [Factor analysis of socio-demographic prerequisites for the formation of tuberculosis in patients with chronic obstructive pulmonary disease]. Vestnik sovremennoy klinicheskoy meditsiny [Bulletin of modern clinical medicine]. 2021; 14(1): 7–15. (In Russ.)]. DOI:10.20969/VSKM.2021.14(1).7-15

10. Удалова Т.Ю., Багишева Н.В., Мордык А.В. и др. Особенности межличностного взаимодействия пациентов с социально значимым заболеванием // Лечащий врач. – 2020. – №1. – С. 55-57. [Udalova TYu, Bagisheva NV, Mordyk АV, et al. Osobennosti mezhlichnostnogo vzaimodeystviya patsiyentov s sotsial’no znachimym zabolevaniyem [Features of interpersonal interaction of patients with socially significant disease]. Lechashchiy vrach [Attending physician]. 2020;1: 55-57. (In Russ.)]. DOI: 10.26295/OS.2019.45.65.012

11. Васильева А.В. Эволюционная модель депрессии в период пандемии. Альянс психо- и фармакотерапии // Обозрение психотерапии и медицинской психологии. – 2021. – №1. – С. 91-101. [Vasil’yeva AV. Evolyutsionnaya model’ depressii v period pandemii. Al’yans psikho- i farmakoterapii [An evolutionary model of depression during a pandemic. Alliance of Psychoand Pharmacotherapy]. Obozreniye psikhoterapii i meditsinskoy psikhologii [Review of Psychotherapy and Medical Psychology]. 2021; 1: 91-101. (In Russ.)]. DOI: 10.31363/2313-7053-2021-1-91-101

12. Stein ML, Rudge JW, Coker R, et al. Development of a resource modelling tool to support decision makers in pandemic influenza preparedness: The AsiaFluCap Simulator. BMC Public Health. – 2012; 12: 870. DOI: 10.1186/1471-2458-12-870

13. Rhodes T, Lancaster K, Lees S, Parker M. Modelling the pandemic: attuning models to their contexts. BMJ Global Health 2020; 5: e002914. DOI:10.1136/bmjgh-2020-002914

14. Шулаев А.В., Хисамиев Р.Ш., Зиновьев П.В. Оценка эффективности и степени зависимости показателей медицинской организации от уровня управленческих компетенций руководителя // Вестник современной клинической медицины. – 2021. – Т.14, №5. – С. 68-73. [Shulayev AV, Khisamiyev RSH, Zinov’yev PV. Otsenka effektivnosti i stepeni zavisimosti pokazateley meditsinskoy organizatsii ot urovnya upravlencheskikh kompetentsiy rukovoditelya [Evaluation of the effectiveness and degree of dependence of the indicators of a medical organization on the level of managerial competencies of the leader]. Vestnik sovremennoy klinicheskoy meditsiny [Bulletin of modern clinical medicine]. 2021; 14(5): 68-73. (In Russ.)]. DOI: 10.20969/VSKM.2021.14(5).68-73

15. Суслин С.А., Вавилов А.В., Гиннятулина Р.И. Удовлетворенность пациентов городской многопрофильной больницы медицинским обслуживанием // Исследования и практика в медицине. – 2018. – Т.5, №4. – С. 118-125. [Suslin SA, Vavilov AV, Ginnyatulina RI. Udovletvorennost’ patsiyentov gorodskoy mnogoprofil’noy bol’nitsy meditsinskim obsluzhivaniyem [Satisfaction of patients of the city multidisciplinary hospital with medical care]. Issledovaniya i praktika v meditsine [Research and practice in medicine]. 2018; 5(4): 118-125. (In Russ.)]. DOI: 10.17709/2409-2231-2018-5-4-12

16. Маренко В.А., Лучко О.Н. Когнитивное моделирование как инструмент поддержки принятия решений. Новосибирск, 2014. – 118 с. [Marenko VA, Luchko ON. Kognitivnoye modelirovaniye kak instrument podderzhki prinyatiya resheniy [Cognitive modeling as a decision support tool]. Novosibirsk, 2014:118. (In Russ.)]. https://www.iprbookshop.ru/32787

17. Билалов Ф.С., Сквирская Г.П., Шарафутдинова Н.Х. Доступность медицинской диагностической помощи на примере медицинских организаций Республики Башкортостан //Менеджер здравоохранения. - 2018. - №1. - С. 42-51. [Bilalov FS, Skvirskaya GP, Sharafutdinova NH. Dostupnost’ meditsinskoy diagnosticheskoy pomoshchi na primere meditsinskikh organizatsiy Respubliki Bashkortostan [Availability of the medical diagnostic care and continuity in its organization at various stages of exercise of medical and diagnostic process] Menedzher zdravookhraneniya [Manager zdravoohranenia] 2018; 1: 42-51. (In Russ.)]. https://www. elibrary.ru/download/elibrary_32716518_70504128.pdf

18. Roberts FS. Discrete Mathematical Models, with Applications to Social, Biological and Environmental Problems, Prentice-Hall, Englewood Cliffs, NJ, 1976. https://archive.org/details/discretemathemat0000robe

19. Lozhnikov V, Marenko V. Software for the computational experiment “Synthesis of the topological structure of the cognitive model” // Journal of Physics: Conference Series. XIII International Scientific and Technical Conference “Applied Mechanics and Systems Dynamics”. 2020; 012148. DOI: 10.1088/1742-6596/1441/1/012148